Skip to main content
Journal of Arrhythmia logoLink to Journal of Arrhythmia
. 2026 Oct 21;42(5):e70491. doi: 10.1002/joa3.70491

2026 Asia Pacific Heart Rhythm Society (APHRS) Guidelines (Part II) on Stroke Prevention in Atrial Fibrillation

Tze‐Fan Chao 1,✉, Gregory Y H Lip 2,3,4,✉, Yi‐Hsin Chan 5, So‐Ryoung Lee 6,7, Mingfang Li 8, Daehoon Kim 9, Ling Kuo 1,10, Ken Okumura 11, Hung‐Fat Tse 12, Eue‐Keun Choi 6,7, Minglong Chen 8, Boyoung Joung 9, Rungroj Krittayaphong 13, Melissa E Middeldorp 14, Kyoko Soejima 15, Hui‐Nam Pak 9
PMCID: PMC13687583  PMID: 42923502

ABSTRACT

The 2026 Asia Pacific Heart Rhythm Society (APHRS) Guidelines represent the first comprehensive APHRS guidelines dedicated to the management of atrial fibrillation (AF) and comprise four parts covering epidemiology, detection/screening and integrated care; stroke prevention; rate and rhythm control; and lifestyle risk factor and comorbidity management. Part II focuses on stroke prevention in AF, integrating contemporary global evidence with data and clinical considerations specific to the Asia‐Pacific region. It provides evidence‐based and practical recommendations for stroke and bleeding risk assessment, oral anticoagulation, selection and appropriate dosing of direct oral anticoagulants, management of patients with special or complex clinical characteristics, and left atrial appendage occlusion. Particular attention is given to issues (and evidence) highly relevant to Asia‐Pacific populations, including the evolving risk of ischemic stroke, appropriate anticoagulant dosing, renal function assessment, and balancing thromboembolic and bleeding risks. These recommendations aim to support individualized clinical decision‐making, promote appropriate use of stroke‐prevention strategies, and improve outcomes for patients with AF across the Asia‐Pacific region.

Keywords: Asia Pacific Heart Rhythm Society, atrial fibrillation, guidelines, oral anticoagulation, stroke prevention

1. Introduction

The 2026 Asia Pacific Heart Rhythm Society (APHRS) Guidelines represent the first comprehensive APHRS guidelines dedicated to the management of atrial fibrillation (AF) and comprise four parts covering epidemiology, detection/screening and integrated care; stroke prevention; rate and rhythm control; and lifestyle risk factor and comorbidity management.

Part II focuses on stroke prevention in Asia‐Pacific patients with AF. We summarize contemporary trends in oral anticoagulant (OAC) prescription across the Asia‐Pacific region, review stroke and bleeding risk assessment as dynamic rather than static processes, and propose a practical three‐step approach to anticoagulation. We further address dosing of direct oral anticoagulants (DOACs), device‐detected AF (DDAF), left atrial appendage occlusion (LAAO), management in special populations, and the recognition and management of bleeding.

This is important since stroke prevention remains the cornerstone of AF management, yet Asian patients differ from Western populations in their stroke and bleeding profiles, in their response to vitamin K antagonists, and in access to DOACs [1, 2, 3].

These recommendations are intended to provide clinical guidance rather than to replace clinical judgment. We fully realize that there are gaps, unaddressed questions, and many areas of uncertainty and debate in the current knowledge of AF. The decision of the treating physician, based on the best available evidence, individualized to the characteristics and preferences of each patient, and reached through shared decision‐making with the patient, remains the most important factor in the management of AF.

2. Trends of OACs

2.1. Two Major Changes About Prescriptions of Oral Anticoagulants for Stroke Prevention in Atrial Fibrillation in Asia

There were two major changes in stroke prevention in AF following the increased availability of DOACs [4]: (1) Change 1: from non‐anticoagulation to DOACs; and (2) Change 2: from “lower‐dose” to “higher‐dose” of DOACs [5, 6, 7]. Table 1 summarizes these two important changes in different regions of Asia [4].

TABLE 1.

Changes about stroke prevention in AF in Asia.

China Hong Kong Japan South Korea Taiwan Thailand

Change 1

From non‐anticoagulation to OACs

Moving from Warfarin to DOACs

GLORIA‐AF in China:

Phase II (2013–2014): OACs 21% (15.2% warfarin and 5.8% DOACs)

=> Phase III (2015–2016): 40.7% (23.5% warfarin and 17.2% DOACs)

Shanghai, China 2015–2020: The prescription rate of OACs increased from 19.46% in 2015 to 56.57% in 2020

(warfarin: 18.52% => 24.44%; DOACs: 0.94% => 32.13%)

The prescription rate of OACs (warfarin or DOACs) for newly‐diagnosed AF patients increased from 31.9% in 2002, to 33.1% in 2012, and 67.2% in 2022.

The prescription rate of DOACs for newly‐diagnosed AF patients increased from 10.8% in 2012, to 60.7% in 2022.

Fushimi AF registry: OACs in 53% (51% warfarin and 2% DOACs) of patients in year 2011 => 70% (18% warfarin and 52% DOACs) in year 2021 Nationwide cohort: OACs in 44.6% of newly‐diagnosed AF patients in 2013 => 77.5% in 2022

Nationwide cohort:

The prescription rate of OACs for newly‐diagnosed AF patients increased from 13.6% (2008 Q1) to 35.6% (2015 Q3) and further increased to 57.7% in 2020 (DOACs accounts for 91% of overall OAC prescriptions)

COOL AF registry (27 hospitals involved in Phase 1, 33 hospitals participating in Phase 2):

Prescription rate of OACs in patients with a CHA2DS2‐VA ≥ 2:

82.4% (COOL‐AF 1; 2014–2017)

94.1% (COOL‐AF 2; from 2024)

DOACs accounts for 8.9% of overall OAC prescriptions in Phase 1 and 55.2% in Phase 2

Change 2

From “lower‐dose” to “higher‐dose” DOACs

No report No report The percentages of standard‐dose DOACs increased from 14% in year 2012 to 39% in year 2017 among DOAC users No report For DOAC users, higher dose use increased from 11.04% in 2012 to 44.29% in 2019–2020 temporally associated with a lower risk of ischemic stroke in the years 2015–2017 and 2018–2020 compared to 2012–2014 No report

Note: The table was adopted from the paper by Chao et al. [4] and based on the data of the papers by Liao et al. [5] and Krittayaphong et al. [6, 7]

Abbreviations: AF, atrial fibrillation; DOAC, direct oral anticoagulant; OAC, oral anticoagulant.

Overall, the prescription rate of OACs has increased substantially across Asia over the past decade. This increase has been driven predominantly by the uptake of DOACs. In Taiwan, for example, the OAC prescription rate increased from 13.6% in 2008 to 35.6% in 2015, and further rose to 57.7% in 2020 [5, 8]. Notably, DOACs accounted for 91% of all OAC prescriptions in 2020 [5]. The COOL‐AF registry from Thailand also demonstrated a marked increase in DOAC use over time, with the proportion of DOAC prescriptions among all OAC prescriptions rising from 8.9% in Phase I to 55.2% in Phase II.

Beyond the reduction in non‐anticoagulation (Change 1), a second major evolution in contemporary AF management has been the transition from lower‐dose to standard‐dose DOAC prescribing (Change 2) [5, 9]. Inappropriate DOAC underdosing is not uncommon in Asian populations and has been consistently associated with worse clinical outcomes [10, 11]. With the accumulation of real‐world evidence supporting the effectiveness and safety of DOAC therapy, as well as growing recognition of the importance of on‐label dosing, physicians have increasingly adopted standard‐dose DOAC regimens when indicated. In Taiwan, the proportion of DOAC users receiving higher/standard doses increased from 11.0% in 2012 to 44.3% in 2019–2020, a trend that was temporally associated with a progressive reduction in ischemic stroke risk compared with the 2012–2014 period [5].

2.2. Temporal Changes in Stroke Risk Among Asian Patients With AF

With improvements in both the underutilization of OACs and the underdosing of DOACs, a gradual decline in stroke risk among patients with AF has been observed. Despite substantial differences in clinical characteristics and healthcare systems across countries, a consistent reduction in stroke risk over time was evident in Japan, Taiwan, and South Korea (Figure 1) [4, 5, 9, 12]. These observations highlight the important role of DOACs in improving clinical outcomes among patients with AF.

FIGURE 1.

FIGURE 1

Temporal trends in stroke risk among patients with AF in Asia. AF, atrial fibrillation; HR, hazard ratio. The figure was redrawn and modified from the paper by Chao et al. [4], and based on the data adapted from papers by Akao et al. [9], Liao et al. [5], and Lee et al. [12]

2.3. Factors Associated With Non‐Anticoagulation in the Era of DOACs

Even in the DOAC era, a considerable proportion of patients with AF remain untreated with OACs for stroke prevention. Taking Taiwan as an example, several factors have been identified as being associated with non‐anticoagulation, including a high HAS‐BLED score, a history of cancer, impaired renal function, and anemia [5]. Collectively, these findings suggest that concerns about bleeding remain a major barrier to OAC prescription among physicians.

Indeed, a prior history of bleeding is more common among Asian than European patients with AF [13]. Furthermore, Asian patients appear to be more susceptible to the adverse impact of clinical complexity. Even with a similar burden of coexisting risk factors, clinical complexity is associated with a disproportionately greater risk of adverse clinical outcomes in Asian than in non‐Asian populations, highlighting their heightened vulnerability to both thromboembolic and bleeding events [14, 15]. Nevertheless, it should be emphasized that a perceived high bleeding risk should not, by itself, justify withholding OAC therapy.

Importantly, bleeding risk reflects the interaction of modifiable and non‐modifiable risk factors. In addition, bleeding risk scores have been shown to overestimate the actual bleeding risk in patients with AF, particularly among those classified as having a high bleeding risk [16].

3. Differences in AF Patients Across Asian Subregions

3.1. Differences in Patient Characteristics and Clinical Outcomes Across Asian Subregions

Asia is a vast region with substantial subregional differences in ethnicity, culture, and healthcare systems. Population‐based studies show ethnic differences in AF clinical epidemiology [17], as well as AF‐related complications, such as stroke and bleeding [2, 3, 18]. Differences in outcomes are also apparent. For example, following major bleeding, East Asian patients in the APHRS AF registry might be more susceptible to major adverse cardiovascular events (MACE) and thromboembolism when compared with Europeans in the EORP‐AF registry [13].

In the COMBINE AF dataset, which included 9943 Asian patients from East (n = 3388), Northeast (n = 2751), Southeast (n = 1673), and South Asia (n = 2131), significant differences in baseline characteristics across the four subregions were observed (Figure 2) [19]. Patients in East Asia were older, heavier and had a higher prevalence of prior stroke or transient ischemic attack (TIA) than those in other regions. Hypertension was most prevalent in Southeast Asia, whereas heart failure and myocardial infarction were most common in South Asia.

FIGURE 2.

FIGURE 2

Subregional differences of clinical characteristics and comorbidities of AF patients across Asia. AF, atrial fibrillation; CrCl, creatinine clearance; TIA, transient ischemic attack; VKA, vitamin K antagonist. The figure was redrawn based on the data of the abstract by Chao et al. [19]

For patients receiving warfarin, the median time in therapeutic range (TTR) varied substantially across Asian subregions (Northeast Asia 62.5%, Southeast Asia 60.1%, East Asia 57.1%, and South Asia 48.6%; p < 0.001). The clinical risks among patients treated with warfarin also differed significantly across Asian subregions, even after adjustment for TTR (Figure 3) [19]. For example, the risks of stroke/systemic embolic events and cardiovascular death were lower in Northeast Asia, whereas the risks of major bleeding and gastrointestinal bleeding were lower in South Asia.

FIGURE 3.

FIGURE 3

Risk of clinical outcomes across Asian subregions treated with warfarin. CV, cardiovascular; GI, gastrointestinal; ICH, intracranial hemorrhage; NCO, net clinical outcome (stroke/SEE/major bleeding/death); SEE, systemic embolic event. The figure was redrawn based on the data of the abstract by Chao et al. [19]

3.2. Differences in Clinical Characteristics and Adherence to the ABC Pathway Across Developed Asian Settings

Despite focusing on five developed Asian settings (Hong Kong, Japan, Singapore, South Korea, and Taiwan) participating in the APHRS AF registry, substantial differences in clinical characteristics were still observed (Figure 4) [4]. For example, the mean age of patients with AF was 73.59 years in Hong Kong, compared with 65.28 years in South Korea. The highest CHA2DS2‐VASc scores were observed in Hong Kong, whereas the lowest were reported in Japan. Similarly, the HAS‐BLED score showed significant variation, with the highest mean value in Hong Kong (1.81) and the lowest in Japan (1.08).

FIGURE 4.

FIGURE 4

Clinical characteristics of AF patients enrolled in APHRS AF registry. AF, atrial fibrillation; APHRS, Asia Pacific Heart Rhythm Society; EHRA, European Heart Rhythm Association; TIA, transient ischemic attack. The figure was redrawn and modified from the paper by Chao et al. [4]

Not only did the clinical characteristics differ across Asian settings, but there was heterogeneous adherence to holistic or integrated care management based on the Atrial Fibrillation Better Care (ABC) pathway [20]. Adherence to the ABC pathway has been associated with improved clinical outcomes [21]. Of note, the highest adherence rate to all three ABC domains was observed in South Korea (49.1%), whereas the lowest was reported in Hong Kong (26.3%) (Figure 5) [4]. Overall, adherence to the “A” and “B” domains was high, exceeding 80% and even 90% in some countries/regions. In contrast, adherence to the “C” domain was considerably lower, ranging from 31.9% in Hong Kong to 58.4% in South Korea, despite the latter representing the highest adherence rate among the five Asian settings (Figure 5) [4].

FIGURE 5.

FIGURE 5

Adherence to ABC pathway of AF patients enrolled in APHRS AF registry. ABC, Atrial fibrillation Better Care (A = Avoid stroke/anticoagulation; B = Better symptom management; C = Cardiovascular and comorbidity optimization); AF, atrial fibrillation; APHRS, Asia Pacific Heart Rhythm Society. The figure was redrawn and modified from the paper by Chao et al. [4]

Given the substantial subregional and country‐level differences in comorbidities, clinical outcomes, and adherence to integrated AF care, which likely reflect underlying variations in ethnicity, socioeconomic status, and healthcare systems, subregional and country‐specific investigations are warranted to identify local priorities and optimize AF management.

Recommendation Box 1. Recommendations for Subregional and Country‐Specific Management in AF.

Recommendation Class Level
Substantial subregional and country‐level differences in comorbidities, clinical outcomes, and adherence to integrated AF care were observed across Asia. Therefore, subregional and country‐specific investigations are recommended to identify local priorities, address regional challenges, and optimize AF management strategies [4, 19]. I C

Abbreviation: AF, atrial fibrillation.

4. Stroke Risk Assessment

AF is a major risk factor for ischemic stroke, contributing substantially to morbidity and mortality in Asia [22]. A pooled analysis of eight studies demonstrated that Asian patients with AF have an annual risk of ischemic stroke of approximately 3.0%, with reported rates ranging from 1.60% to 4.95% [22]. Over the past decades, considerable efforts have been made to improve the identification of patients at increased risk of stroke.

Stroke risk in patients with AF is heterogeneous and determined by the presence and accumulation of multiple risk factors (Table 2) [23, 24, 25, 26, 27, 28, 29, 30, 31, 32, 33, 34, 35, 36]. Evidence from randomized trials, large observational cohorts, and meta‐analyses has consistently identified prior stroke or TIA, older age, hypertension, diabetes mellitus, heart failure, and vascular disease as the major clinical risk factors [23, 24, 37]. Beyond established clinical risk factors, a range of imaging markers as well as blood and urinary biomarkers are associated with stroke risk in patients with AF [25, 27, 28, 29]. In addition, non‐paroxysmal AF and greater AF burden (and arrhythmia density) have also been found to be associated with a higher risk of stroke in patients with AF [33, 34, 35, 36].

TABLE 2.

Stroke risk factors in patients with AF.

Traditional clinical risk factors [23, 24] Age, prior stroke or TIA, CHF/LV dysfunction, hypertension, diabetes mellitus, vascular disease, sex category
Other clinical risk factors [25, 26] Impaired renal function/CKD, OSA, HCM, amyloidosis in degenerative cerebral and heart diseases, hyperlipidemia, smoking, metabolic syndrome, malignancy
Imaging markers [27, 28, 29, 30]

Echocardiography: Left atrial enlargement, spontaneous echo contrast, left atrial appendage thrombus, reduced LAA emptying velocity, complex aortic plaque

Cerebral imaging: small vessel disease

Blood/urinary biomarkers [31, 32] NT‐proBNP, troponin, cystatin C, proteinuria, CrCl/eGFR, CRP, IL‐6, GDF‐15, D‐dimer, von Willebrand factor
AF‐related factors [33, 34, 35, 36] Non‐paroxysmal AF, greater AF burden, arrhythmia density

Abbreviations: AF, atrial fibrillation; CHF, congestive heart failure; CKD, chronic kidney disease; CrCl, creatinine clearance; CRP, C‐reactive protein; eGFR, estimated glomerular filtration rate; GDF‐15, growth differentiation factor‐15; HCM, hypertrophic cardiomyopathy; IL‐6, interleukin 6; LAA, left atrial appendage; LV, left ventricular; NT‐proBNP, N‐terminal pro–B‐type natriuretic peptide; OSA, obstructive sleep apnea; TIA, transient ischemic attack.

Given the complexity of individual risk factors, various risk stratification schemes have been developed to facilitate stroke risk assessment in patients with AF, focused on the more common and validated risk factors. Among these, the clinical risk‐factor‐based CHA2DS2‐VASc score [38] (Table 3, Figure 6) is recommended as the preferred tool for stroke risk assessment in patients with AF in the Asia‐Pacific region. This recommendation is supported by extensive validation in Asian AF populations [39, 40, 41, 42, 43, 44].

TABLE 3.

CHA2DS2‐VASc score–risk factors and definitions.

Risk factors Definitions Point awarded
C Congestive heart failure Symptoms and signs of heart failure (irrespective of LVEF), or the presence of asymptomatic LVEF ≤ 40% or HCM 1
H Hypertension History of hypertension, uncontrolled blood pressure or on antihypertensive therapy 1
A Age 75 years or older 2
D Diabetes mellitus Diabetes mellitus (Type 1 or Type 2) 1
S Stroke Previous stroke, TIA, or thromboembolism 2
V Vascular disease (CAD, PAD or aortic plaque)

CAD: Prior myocardial infarction, angina, history of coronary revascularization (surgical or percutaneous), or significant CAD documented by coronary angiography or cardiac imaging.

PAD: Symptomatic PAD, prior peripheral arterial revascularization or amputation, or objectively documented PAD by vascular imaging or ABI ≤ 0.90.

Aortic plaque: Aortic plaque with mobility, ulceration, pedunculation, or thickness ≥ 4 mm on imaging.

1
A Age 65–74 years 1
Sc Sex category Female 1
Maximum score 9

Abbreviations: ABI, ankle‐brachial index; AF, atrial fibrillation; CAD, coronary artery disease; HCM, hypertrophic cardiomyopathy; LVEF, left ventricular ejection fraction; PAD, peripheral artery disease; TIA, transient ischemic attack.

FIGURE 6.

FIGURE 6

The incidence rate of ischemic stroke and major bleeding stratified by the CHA2DS2‐VASc and HAS‐BLED scores in Asian AF patients. AF, atrial fibrillation; NR, not reported. The figure was redrawn and data were adapted from the papers by Chao et al. [41, 45, 46]

Other, more complex scoring schemes incorporating additional (multiple) clinical variables or biomarkers (e.g., blood, urine, imaging [heart, brain], electrocardiographic [ECG] or retina) have been proposed [47, 48, 49, 50, 51, 52]. These approaches may show statistically significant improvements in discrimination; however, the incremental gain, as reflected by the C‐statistic, is generally modest [45]. Moreover, statistical significance is not equivalent to clinical significance and must be balanced against practical applicability in busy clinical settings [45].

Furthermore, some of the published studies included mixed anticoagulated and non‐anticoagulated cohorts, but anticoagulation status is not a simple yes/no adjustment on multivariate analysis but depends on the quality of anticoagulation control (if on warfarin) or appropriate label‐adherent DOAC dosing. More recently, the GLORIA‐AF stroke score provided risk refinement beyond the CHA2DS2‐VASc score, while retaining discrimination consistent with more complex risk models [53]. This stroke score is also agnostic to OAC use and has been externally validated in European and Asia‐Pacific registries, offering the possibility of residual stroke risk stratification.

In the 2024 European Society of Cardiology guidelines for management of AF, the CHA2DS2‐VA (excluding sex) is recommended (Level of Evidence C) [54]. This approach was apparently justified on the grounds that “the inclusion of gender complicates clinical practice both for healthcare professionals and patients” and “omits individuals who identify as non‐binary, transgender, or are undergoing sex hormone therapy.” However, the applicability of this approach to Asian populations requires support from region‐specific data.

Emerging evidence from large Asian cohorts, including the COOL‐AF registry in Thailand [55] and Taiwan's National Health Database [56], indicates that sex‐related differences in stroke risk are not uniform across risk strata. Specifically, women had higher rates of stroke or systemic embolism than men among patients with AF in higher CHA2DS2‐VA score categories (e.g., scores ≥ 2), whereas such differences are not evident among patients at lower risk. Appropriate methodology is also needed; for example, if the question is whether female sex adds to stroke risk, non‐anticoagulated cohorts with censoring at OAC initiation are required [57, 58]. In nationwide Swedish data, stroke risk reclassification improved when female sex was retained, even accounting for healthcare utilization and socio‐demographic factors [58].

The evidence from Asia‐Pacific studies supports the concept that female sex functions as a risk modifier, rather than an independent risk factor, in stroke risk stratification. In addition, comparative analyses from these two studies indicate that the discriminative performance of the CHA2DS2‐VASc score and CHA2DS2‐VA score was broadly similar, with evidence supporting improved stroke risk reclassification when female sex is retained [56]. Taken together, the routine omission of female sex from stroke risk assessment may be associated with underestimation of risk and under‐anticoagulation among females [59, 60], and may not be appropriate in the Asia‐Pacific context.

5. Bleeding Risk Assessment

Bleeding risk assessment is essential when initiating OAC therapy in patients with AF. Risk assessment should address modifiable (e.g., uncontrolled hypertension, excess alcohol intake, poor adherence), potentially modifiable (e.g., anemia, falls risk), and non‐modifiable factors (e.g., age, prior bleeding, or comorbidities) [61, 62]. These factors frequently coexist and contribute cumulatively to bleeding risk (Figure 7). The purpose of bleeding risk assessment is to facilitate modification of reversible risk factors and identify patients at high risk of bleeding for closer monitoring and earlier follow‐up, rather than to preclude anticoagulation [62, 63]. This is crucial because bleeding risk is not static but highly dynamic, reflecting the interplay of modifiable and non‐modifiable bleeding risk factors [64].

FIGURE 7.

FIGURE 7

Bleeding risk factors in AF patients treated with anticoagulation. AF, atrial fibrillation; CrCl, creatinine clearance; cTnT‐hs, high‐sensitivity cardiac troponin T; CYP2C9, cytochrome P450 2C9; GDF‐15, growth differentiation factor 15; INR, international normalized ratio; NSAID, nonsteroidal anti‐inflammatory drug; OAC, oral anticoagulant; SBP, systolic blood pressure; TTR, time in therapeutic range; VKA, vitamin K antagonist; vWF, von Willebrand factor. Adapted from the paper by Lip et al. [61]

Various bleeding risk scores have been developed incorporating validated clinical risk factors, with some also including biomarkers. Among them, the HAS‐BLED score (Table 4, Figure 6) is recommended for bleeding risk assessment in Asian patients with AF [65]. It has been consistently validated in Asian populations and demonstrates favorable predictive performance compared with other available approaches, including ATRIA, ORBIT, HEMORR2HAGES, and GARFIELD‐AF scores, and strategies based solely on modifiable risk factors [16, 46, 66, 67, 68]. Indeed, focusing only on modifiable risk factors is an inferior strategy for bleeding risk prediction [67]. The HAS‐BLED score also performs well in contemporary practice, including among Asian patients treated with DOACs [16].

TABLE 4.

HAS‐BLED score–risk factors and definitions.

Risk factors Definitions Point awarded
H Uncontrolled hypertension e.g., SBP > 160 mmHg 1
A Abnormal renal and/or hepatic function Dialysis, transplant, serum creatinine > 200 μmol/L, cirrhosis, bilirubin > 2 × upper limit of normal, AST/ALT/ALP > 3 × upper limit of normal 1 point for each
S Stroke Previous ischemic or hemorrhagic a stroke 1
B Bleeding history or predisposition Previous major hemorrhage or anemia or severe thrombocytopenia 1
L Labile INR b TTR < 60% in patients receiving VKA 1
E Elderly Aged > 65 years or extreme frailty 1
D Drugs or excessive alcohol drinking c Concomitant use of antiplatelet or NSAID; and/or excessive alcohol per week 1 point for each
Maximum score 9

Abbreviations: AF, atrial fibrillation; ALP, alkaline phosphatase; ALT, alanine aminotransferase; AST, aspartate aminotransferase; INR, international normalized ratio; NSAID, nonsteroidal anti‐inflammatory drug; SBP, systolic blood pressure; TTR, time in therapeutic range; VKA, vitamin K antagonist.

a

A history of hemorrhagic stroke is also assigned 1 point under the “B” (bleeding history) criterion.

b

This criterion applies only to patients receiving a VKA (scores “0” if on a DOAC).

c

Alcohol excess or abuse refers to a high level of intake (e.g., > 14 units per week), which is likely to adversely affect health or increase bleeding risk in the clinician's judgment.

Importantly, the HAS‐BLED score is the only bleeding risk score that has been prospectively demonstrated to be an effective tool for guiding proactive bleeding risk management in Asian patients with AF [69]. In the mAFA‐II cluster‐randomized trial, which compared mobile health‐supported integrated care with usual care, the HAS‐BLED score was used to guide bleeding risk modification in the intervention group. This strategy was associated with a lower rate of major bleeding (2.1% vs. 4.3% at 12 months) and increased use of OAC compared with usual care [70]. In contrast, use of the biomarker‐based ABC‐AF score did not improve clinical outcomes compared with usual guideline‐directed care in patients with AF [71]. More recently, the GLORIA‐AF bleeding risk score has been proposed, derived from the GLORIA‐AF population and validated in the European and APHRS AF registries [72]. Because this bleeding score does not rely on the use or type of OAC, it may potentially be used for assessing the residual risk of events that persists even in patients receiving OAC.

Therefore, balancing simplicity, practicality, and available evidence, the use of validated clinical risk scores, particularly HAS‐BLED, is recommended for routine bleeding risk assessment and management in Asian patients with AF.

6. Dynamic Nature of Risk Scoring Schemes

Stroke and bleeding risk in patients with AF is dynamic rather than static and evolves over time with aging, the development of new comorbidities, and changes in risk factor management [73]. Consequently, CHA2DS2‐VASc scores may increase during follow‐up. This phenomenon has been consistently demonstrated in Asian populations. In a large cohort study from Taiwan involving 31 039 patients with AF who had no CHA2DS2‐VASc risk factors other than age and sex and were not receiving antithrombotic therapy, approximately 11% of patients acquired at least one additional stroke risk factor within 6 months of AF diagnosis, resulting in a transition to a higher‐risk category and potential eligibility for OAC [74]. Similar findings were subsequently confirmed in the Korean nationwide AF registry [75].

Among the risk factors most commonly acquired after AF diagnosis, hypertension is the leading newly incident component, followed by age ≥ 65 years, heart failure, diabetes mellitus, and vascular disease (Figure 8) [76]. Given the dynamic nature of stroke risk, both the follow‐up CHA2DS2‐VASc score and the delta CHA2DS2‐VASc score (defined as the change between baseline and follow‐up scores) have been shown to predict ischemic stroke more accurately than the baseline score alone (Figure 8) [74, 77]. Furthermore, for initially low‐risk non‐anticoagulated AF patients, timely initiation of OAC therapy following the acquisition of new stroke risk factors was associated with a reduction in adverse clinical outcomes [76]. These findings support the need for regular assessment of stroke risk throughout follow‐up.

FIGURE 8.

FIGURE 8

Dynamic stroke risk assessment in patients with atrial fibrillation. Left panel: Cumulative incidence of newly acquired stroke risk factors among patients with a baseline CHA2DS2‐VASc score of 0 (male) or 1 (female) during follow‐up. Right panel: Predictive performance of baseline, follow‐up, and delta CHA2DS2‐VASc scores for ischemic stroke. Follow‐up and delta CHA2DS2‐VASc scores demonstrated better discrimination than the baseline CHA2DS2‐VASc score. AUC, area under the curve; F, female; M, male. The figure was redrawn and data were adapted from papers by Chao et al. [74, 76]

The optimal time interval for reassessing stroke risk in patients with AF has not been definitively established. Nevertheless, evidence suggests that new stroke risk factors may develop within 4–5 months after AF diagnosis, and ischemic stroke often occurs shortly thereafter [76]. In the present guideline, we endorse regular reassessment of stroke risk, with evaluation performed at least once yearly and preferably every 4 months. Importantly, stroke risk reassessment is relevant not only for patients initially classified as low risk, in whom newly acquired risk factors may prompt initiation of OAC therapy, but also for those already receiving anticoagulation, as a rising stroke risk underscores the importance of treatment adherence, appropriate dosing, and optimization of modifiable risk factors.

A similar dynamic pattern has also been observed for bleeding risk, which is dependent on modifiable and non‐modifiable risk factors [64]. Indeed, the HAS‐BLED score is not static and may change over time with aging, the development of new comorbidities, and changes in clinical status. In a contemporary cohort, approximately 22% of patients receiving OACs with a baseline HAS‐BLED score of 0–2 developed a HAS‐BLED score ≥ 3 within 1 year [78]. Among the individual HAS‐BLED components, (uncontrolled) hypertension represents the most frequently acquired bleeding risk factor during follow‐up (Figure 9) [78]. Importantly, both the follow‐up HAS‐BLED score and the delta HAS‐BLED score have been shown to predict major bleeding more accurately than the baseline HAS‐BLED score alone (Figure 9) [79]. This dynamic nature of bleeding risk is particularly relevant in patients with a baseline HAS‐BLED score of 0–2. Among those whose HAS‐BLED score increased to ≥ 3 during follow‐up, continuation of OAC therapy was associated with lower risks of ischemic stroke, major bleeding, all‐cause mortality, and overall adverse clinical outcomes compared with OAC discontinuation [78].

FIGURE 9.

FIGURE 9

Dynamic bleeding risk assessment in patients with atrial fibrillation. Left panel: Cumulative incidence of newly acquired bleeding risk factors among patients with a baseline HAS‐BLED score of 0–2 during follow‐up. Right panel: Predictive performance of baseline, follow‐up, and delta HAS‐BLED scores for major bleeding. Follow‐up and delta HAS‐BLED scores demonstrated better discrimination than the baseline HAS‐BLED score. AUC, area under the curve. The figure was redrawn and data were adapted from papers by Chao et al. [78, 79]

These findings reinforce that a high HAS‐BLED score should not be viewed as a reason to withhold or discontinue anticoagulation. Rather, it should serve as a prompt for more intensive review, correction of modifiable bleeding risk factors, and closer follow‐up.

Recommendation Box 2. Recommendations to Assess and Manage Stroke and Bleeding Risk in Patients With Atrial Fibrillation.

Recommendation Class Level
The CHA2DS2‐VASc score is recommended for stroke risk assessment for Asian AF patients [39, 40, 41, 42, 43, 44, 56]. I A
The HAS‐BLED score is recommended for bleeding risk assessment for Asian AF patients [46, 66, 67, 68]. I A
Stroke risk is not static and should be reassessed regularly, with evaluation performed at least once yearly and preferably every 4 months [74, 75, 76]. IIa B
Bleeding risk is not static and should be reassessed regularly [78, 79]. IIa B
The purpose of bleeding risk assessment is to facilitate modification of reversible risk factors and identify patients at high risk of bleeding for closer monitoring and earlier follow‐up, rather than to preclude anticoagulation. IIa C

Abbreviation: AF, atrial fibrillation.

7. Approach to Stroke Prevention in Asian AF Patients

7.1. Three‐Step Approach for Stroke Prevention

Figure 10 shows our recommendations about the prescriptions of OACs for stroke prevention in Asian AF patients, without major changes compared with our prior version of 2021 consensus guidelines [80, 81].

FIGURE 10.

FIGURE 10

Three‐step approach for stroke prevention in Asian AF patients. AF, atrial fibrillation; DOAC, direct oral anticoagulant; OAC, oral anticoagulant; TTR, time in therapeutic range; VKA, vitamin K antagonist. The figure was redrawn and modified from the papers by Chao et al. [80, 81]

In AF patients without significant valvular heart disease (mechanical valves or moderate to severe mitral stenosis; so‐called “non‐valvular AF”), the first step (Step 1) is to identify low‐risk patients (CHA2DS2‐VASc score 0 in males or 1 in females), in whom no antithrombotic therapy (including OACs or antiplatelet agents) is recommended. Antiplatelet therapy with aspirin does not reduce the risk of composite outcomes (cardiovascular death, symptomatic brain infarction, or TIA) compared with placebo, even in low‐risk patients with AF, for example in the randomized trial performed in Japan (Japan Atrial Fibrillation Stroke Trial [JAST]) [82]. In the AVERROES trial, aspirin had a similar risk of major bleeding and intracranial hemorrhage (ICH) compared with apixaban [83]. Therefore, antiplatelet agents should not be regarded as an effective therapy compared with no treatment, nor as a safer alternative to DOACs for stroke prevention in AF.

The next step (Step 2) is to offer stroke prevention (i.e., OACs) to patients with ≥ 1 non‐sex stroke risk factors (i.e., CHA2DS2‐VASc score ≥ 1 in males or ≥ 2 in females). AF patients with a single stroke risk factor beyond sex (i.e., CHA2DS2‐VASc score 1 in males or 2 in females) are a special population that deserves a more nuanced approach to the decision to prescribe DOACs. This population accounted for approximately 7.2% of the AF population in a previous study from Taiwan [84]. In the recent SINGLE‐AF trial, DOACs reduced the composite risk of stroke, systemic embolism, major bleeding, or death from cardiovascular causes at 24 months compared with no anticoagulation [85].

Because the individual CHA2DS2‐VASc risk components contribute unequally to stroke risk, with age being the strongest determinant, decisions regarding OAC should consider both patient age and the specific comorbidities contributing to a CHA2DS2‐VASc score of 1 in men or 2 in women, as summarized in Figure 11 [80, 86, 87, 88]. These recommendations are based on the tipping point of DOACs set at a stroke rate of above 0.9% per year proposed by Eckman et al. [89] Notably, the tipping point could be lowered even further to 0.65%/year, at which DOAC treatment resulted in cumulative quality‐adjusted life‐years equal to those with withholding therapy [90].

FIGURE 11.

FIGURE 11

Recommendations for initiations of OACs in Asian AF patients with a CHA2DS2‐VASc score of 1 (males) or 2 (females). AF, atrial fibrillation; DOAC, direct oral anticoagulant; OAC, oral anticoagulant. The figure was redrawn and modified from the papers by Chao et al. [80, 81]

Step 3 is to make the choice of OACs. We recommend the use of DOACs in preference to warfarin for stroke prevention. In the recent patient‐level meta‐analysis of the COMBINE AF dataset which included 10 202 Asians and 61 471 non‐Asians enrolled in four pivotal randomized trials comparing DOACs and warfarin, Asian patients had a higher risk of stroke/systemic embolic event, ischemic stroke, disabling or fatal stroke, major bleeding, ICH and gastrointestinal (GI) bleeding versus non‐Asians treated with warfarin (Figure 12) [1]. If warfarin is used, a TTR > 70% is recommended for Asian AF patients receiving warfarin, but even among patients with a TTR > 70%, Asian AF patients randomized to warfarin still had a poorer clinical outcome than non‐Asians. Compared with a TTR < 70%, a TTR > 70% was associated with a lower risk of disabling or fatal stroke in non‐Asians (0.63%/year vs. 1.12%/year, p < 0.001), but not in Asians (1.76%/year vs. 1.85%/year, p = 0.792) (Figure 12) [1].

FIGURE 12.

FIGURE 12

Clinical outcomes of Asians versus non‐Asians treated with warfarin. GI, gastrointestinal; ICH, intracranial hemorrhage; SEE, systemic embolic event; TTR, time in therapeutic range. The figure was redrawn and modified from the paper by Chao et al. [1]

Based on the new high‐quality and large sample size data, we recommend DOACs as the preferred choice and vitamin K antagonist (VKA; with TTR ≥ 70%) as a last‐resort option for Asian AF patients. This recommendation is stronger than the prior version. Of note, clinical outcomes with standard‐dose DOACs versus warfarin in AF patients were generally even more favorable in patients of Asian than non‐Asian race (Figure 13) [1]. Figure 14 summarizes the annual risks of clinical events among Asian AF patients treated with standard‐dose DOACs or warfarin in COMBINE AF, which may help inform individualized treatment decisions [1].

FIGURE 13.

FIGURE 13

Clinical outcomes of standard‐dose DOACs versus warfarin in Asian and non‐Asian AF patients. AF, atrial fibrillation; GI, gastrointestinal; ICH, intracranial hemorrhage; NCO, net clinical outcome; Pint, p value for interaction; SD DOAC, standard‐dose direct oral anticoagulant; SEE, systemic embolic event. NCO1—composite of stroke, SEE, major bleeding or all‐cause death; NCO2—composite of stroke, SEE, ICH or all‐cause death. The figure was redrawn and modified from the paper by Chao et al. [1]

FIGURE 14.

FIGURE 14

Annual risks of clinical events of Asian AF patients receiving SD DOACs or warfarin. AF, atrial fibrillation; CRNM, clinically relevant non‐major; CV, cardiovascular; GI, gastrointestinal; ICH, intracranial hemorrhage; MACE, major adverse cardiovascular events; MI, myocardial infarction; NCO, net clinical outcome; SD DOAC, standard‐dose direct oral anticoagulant; SEE, systemic embolic event. NCO1—composite of stroke, SEE, major bleeding, or all‐cause death; NCO2—composite of stroke, SEE, ICH, or all‐cause death. The figure was redrawn and modified from the paper by Chao et al. [1]

7.2. Dosing of DOACs

If DOACs are used, on‐label dose DOACs should remain the default approach, with the best outcomes seen with label‐adherent prescribing [10, 91, 92]. In COMBINE AF, although lower‐dose DOACs reduced the risk of major bleeding by 30% compared with standard‐dose DOACs in Asians, the risk of ischemic stroke was 92% higher [1]. Therefore, lower‐dose DOACs should be reserved for special populations, such as very elderly patients or those with thrombocytopenia, in whom individualized dosing based on shared decision‐making may be warranted. The key principles of DOAC dosing strategy are summarized in Figure 15 [11].

FIGURE 15.

FIGURE 15

Dosing strategy of DOACs for Asian AF patients. AF, atrial fibrillation; DOAC, direct oral anticoagulant. The figure was redrawn and modified from the paper by Chao et al. [11]

7.3. Switching From Warfarin to DOACs

Whether to switch warfarin users to DOACs remains controversial, as studies have yielded conflicting results. The FRAIL‐AF trial demonstrated that routinely switching from VKA treatment to DOACs in frail older patients with AF was associated with more bleeding complications compared with continuing well‐managed VKA treatment, without an associated reduction in thromboembolic complications [93].

However, in COMBINE AF, frail, elderly, VKA‐experienced patients with AF switched to standard‐dose DOAC experienced significant reductions in stroke or systemic embolism, fatal and intracranial bleeding, and death [94]. In a study from Taiwan, even among patients staying well on warfarin (without any event of ischemic stroke or ICH) for a median of 7 years, switching from warfarin to DOACs was associated with a lower subsequent risk of ischemic stroke, major bleeding and the composite endpoint [95]. In a recent study from South Korea, in frail elderly Asian AF patients maintained and stable on warfarin, switching to DOACs was associated with higher risks of adverse clinical events [96].

Given the heterogeneity of these results, the decision to switch to DOACs or continue warfarin in patients with a high TTR (> 70%) who remained stable without ischemic or bleeding events for years should be left to the treating physician, based on shared decision‐making with the patient. Switching to DOACs is recommended for patients treated with warfarin who have a TTR < 70% or experience ischemic or bleeding events. Even in patients with a TTR ≥ 70%, switching to DOACs may still be considered given the difficulty in maintaining a consistently high TTR over the long term and the persistently high risk of disabling or fatal stroke with warfarin in Asians, as clearly demonstrated in COMBINE AF [1].

Recommendation Box 3. Recommendations to Initiate OACs for Stroke Prevention in AF.

Recommendation Class Level
OACs are recommended to prevent thromboembolism for AF patients with a CHA2DS2‐VASc score ≥ 2 (males) or ≥ 3 (females) [1, 97, 98, 99, 100]. I A
OACs should be considered to prevent thromboembolism for AF patients with a CHA2DS2‐VASc score of 1 (males) or 2 (females) [84, 85, 86]. IIa B
In AF patients with a single non‐sex‐related CHA2DS2‐VASc risk factor (score 1 for males and 2 for females), different age thresholds for different comorbidities could help guide the decisions on DOAC initiations (e.g., age 35 years for heart failure, 50 years for hypertension or diabetes mellitus, and 55 years for vascular diseases) [86, 88]. IIa B
Antiplatelet agents are not recommended as an alternative to DOACs for stroke prevention in AF [82, 83]. III A

Abbreviations: AF, atrial fibrillation; DOAC, direct oral anticoagulant; OAC, oral anticoagulant.

Recommendation Box 4. Recommendations of Oral Anticoagulants in Asian AF Patients.

Recommendation Class Level
DOACs are recommended as the preferred choice over warfarin for stroke prevention in Asian AF patients without mechanical valves or moderate to severe mitral stenosis [1, 101]. I A
The use of on‐label DOAC doses, according to pivotal trial criteria or approved labeling, is recommended for stroke prevention in patients with AF [97, 98, 99, 100]. I A
Standard‐dose DOACs are recommended as the default DOAC strategy over lower‐dose DOACs because of their superior efficacy [1]. I A
Off‐label lower‐dose DOACs may be considered in high‐bleeding‐risk patients who were underrepresented or not represented in clinical trials, such as very elderly patients or those with thrombocytopenia, in whom individualized dosing based on shared decision‐making may be warranted. IIb C
Switching to DOACs is recommended for patients on warfarin who have a TTR < 70% or experience ischemic or bleeding events while receiving warfarin. I C
Switching to DOACs may be considered in Asian patients receiving warfarin with a TTR > 70%, where patient factors (e.g., difficulties in attending for warfarin monitoring) and shared decision making are taken into consideration. IIb C

Abbreviations: AF, atrial fibrillation; DOAC, direct oral anticoagulant; TTR, time in therapeutic range.

8. Dosing of DOACs in Asia

DOACs are widely prescribed and generally preferred over VKA for stroke prevention in Asian patients with AF owing to their superior efficacy and safety profiles [80, 81, 97, 98, 99, 100, 102]. However, the optimal dosing of DOACs remains a complex issue in the Asian clinical landscape, as a substantial proportion of Asian patients are very elderly, frail, and of lower body weight than their Western counterparts [97, 98, 99, 100, 102, 103]. Because of concerns about the increased risk of ICH and other major bleeding events, clinicians in Asia frequently prescribe off‐label doses of DOACs, most often inappropriate underdosing [10, 103, 104].

In real‐world studies and nationwide registries across Asia, underdosing has often reached around 30% of all prescriptions [10, 11, 103]. Key factors strongly associated with this underdosing trend include older age, underlying kidney dysfunction, low body weight, and the concomitant use of antiplatelet therapies. Extensive clinical data have demonstrated that underdosing DOACs without adhering to specific dose‐reduction criteria is associated with a significantly higher risk of thromboembolism, without providing a significant reduction in the risk of major bleeding events [10, 11, 103]. Therefore, the APHRS underscores the necessity of adhering to on‐label doses of DOACs, based strictly on established clinical trial criteria, to ensure optimal clinical benefits and prevent thromboembolic or bleeding complications [80, 81].

Of note, two different labeled rivaroxaban dosing regimens exist for stroke prevention in Asian patients with non‐valvular AF, derived from the global ROCKET AF (20 mg daily, or 15 mg daily for those with moderate renal impairment) and the region‐specific J‐ROCKET AF trials (15 mg daily, or 10 mg daily for those with moderate renal impairment) [97, 98]. Furthermore, real‐world comparisons from Asia validating both criteria suggest that the lower J‐ROCKET AF dosage may be as effective and safe as the standard ROCKET AF dosage for stroke prevention [105, 106, 107].

Nevertheless, an important exception exists regarding complex, very elderly “gray area” patients who were often excluded from pivotal randomized controlled trials (RCTs), such as those with extreme frailty, very low body weight, advanced kidney disease, or high bleeding risk. The ELDERCARE‐AF trial has provided evidence supporting the use of a very low dosage of edoxaban 15 mg once daily in patients ineligible for standard DOAC dosing [108]. This very low‐dose regimen of edoxaban demonstrated superiority over placebo in preventing stroke and systemic embolism without causing a significantly increased rate of major bleeding, suggesting a possible alternative for at‐risk Asian populations necessitating tailored anticoagulation management rather than non‐treatment (Table 5).

TABLE 5.

Regional guidelines regarding DOAC dosages for stroke prevention in AF in Asia.

Region/Label Dabigatran Rivaroxaban Apixaban Edoxaban
Non‐Asia
United States

75 mg BID: For patients with a CrCl between 15 and 30 mL/min.

No recommendation: For CrCl < 15 mL/min.

15 mg OD: Indicated if CrCl is < 50 mL/min. 2.5 mg BID: Applies if at least two of the following are met:
  • Age ≥ 80 years

  • WT ≤ 60 kg

  • sCr ≥ 1.5 mg/dL.

30 mg OD: CrCl 15–50 mL/min.
Europe (EMA) 110 mg BID: If at least one condition is present:
  • Age ≥ 80 years

  • Concurrent treatment with verapamil.

15 mg OD: CrCl 15–50 mL/min. Dose reduction criteria are standard globally 30 mg OD: If at least one risk factor applies:
  • CrCl 15–50 mL/min

  • WT ≤ 60 kg

  • Concurrent use of ketoconazole, cyclosporin, dronedarone, or erythromycin.

Asia
China Follows EMA label criteria. 15 mg OD: If at least one condition applies:
  • Age > 75 years or low body weight.

Not approved in China

30 mg OD: Follows EMA label criteria.

15 mg OD: For patients ≥ 80 years with at least one high bleeding risk factor, low WT (≤ 45 kg), CrCl 15–29 mL/min, use of NSAIDs or antiplatelet therapy (ELDERCARE‐AF trial)

Hong Kong Follows EMA label criteria. Follows EMA label criteria. Dose reduction criteria are standard globally

30 mg OD: Follows EMA label criteria.

15 mg OD: Follows the ELDERCARE‐AF trial label criteria.

Japan 110 mg BID: If age ≥ 70 years, CrCl is 30–50 mL/min, history of GI bleeding, or concurrent use of oral P‐glycoprotein inhibitors. 10 mg OD: CrCl 15–50 mL/min. Dose reduction criteria are standard globally

30 mg OD: Applies if CrCl is 15–50 mL/min, weight < 60 kg, or taking P‐glycoprotein inhibitors.

15 mg OD: Follows the ELDERCARE‐AF trial label criteria.

Korea 110 mg BID: If at least one condition applies:
  • CrCl 30–50 mL/min

  • Age ≥ 75 years

  • Elevated bleeding risk (e.g., platelet dysfunction, coagulopathy, recent major biopsy/trauma, infective endocarditis)

  • Concurrent use of NSAIDs, aspirin, clopidogrel, dronedarone, verapamil, or amiodarone.

Reduced dose: Indicated for age ≥ 80 years or a CrCl of 15–50 mL/min. Dose reduction criteria are standard globally

30 mg OD: Follows EMA criteria.

15 mg OD: For patients ≥ 80 years with a high risk of bleeding and CrCl 15–30 mL/min

Taiwan 110 mg BID: For those at risk of bleeding (CrCl 30–50 mL/min, age ≥ 75 years, weight < 50 kg, CHADS2 score > 3, or past gastrointestinal hemorrhage). 10–15 mg OD: CrCl 15–50 mL/min. Dose reduction criteria are standard globally

30 mg OD: Follows EMA criteria.

15 mg OD: For patients > 80 years who meet the risk factor in the ELDERCARE‐AF trial

Thailand 110 mg BID: Age ≥ 80 years. 15 mg OD: CrCl 30–50 mL/min. Dose reduction criteria are standard globally 30 mg OD: Follows EMA criteria.

Abbreviations: AF, atrial fibrillation; BID, twice daily; CHADS2, congestive heart failure, hypertension, age ≥ 75 years, diabetes mellitus, prior stroke/transient ischemic attack; CrCl, creatinine clearance; DOAC, direct oral anticoagulant; EMA, European Medicines Agency; GI, gastrointestinal; NSAID, nonsteroidal anti‐inflammatory drug; OD, once daily; sCr, serum creatinine; WT, body weight.

A critical component of ensuring appropriate, label‐adherent DOAC dosing in Asian patients with AF is accurate assessment of underlying kidney function, as all DOACs necessitate careful dosage adjustments based on varying degrees of renal impairment [81, 102]. All pivotal DOAC trials used the Cockcroft‐Gault (CG) formula to calculate the estimated creatinine clearance (CrCl) for the purpose of defining dose reduction criteria [97, 98, 99, 100].

Despite the well‐established clinical trial methodology, real‐world clinical practice frequently depends on the Modification of Diet in Renal Disease (MDRD) formula or the Chronic Kidney Disease Epidemiology Collaboration (CKD‐EPI) formula, given their automatic reporting by hospital laboratory systems and the absence of a requirement for the patient's body weight input [109, 110, 111]. However, the application of the MDRD or CKD‐EPI formulas overestimates the glomerular filtration rate relative to the CG formula [112, 113]. This overestimation is particularly important in patients older than 75 years and in those with a body weight below 50 kg (58.8% for MDRD and 50.9% for CKD‐EPI), patient groups that are common across Asia. For patients treated with DOACs, approximately 7.6% (MDRD formula) and 6.5% (CKD‐EPI formula) had DOAC doses that were discordant with those derived from the CG formula.

When compared with traditional warfarin therapy, only those Asian patients whose DOAC dosages are genuinely classified as “on‐label” according to the original CG formula derive the statistically significant benefit of a lowered risk of major bleeding complications.

Recommendation Box 5. Recommendations of Dosing of DOACs in Asian AF Patients.

Recommendation Class Level
Creatinine clearance (CrCl), calculated using the Cockcroft‐Gault (CG) formula, is recommended for guiding DOAC dosing. Renal function should be reassessed regularly throughout treatment to ensure appropriate dose adjustment [97, 98, 99, 100, 112, 113]. I A
Routine off‐label underdosing of DOACs is not recommended in Asian patients with AF, as it increases the risk of ischemic stroke compared with on‐label dosing [10, 11, 103]. III B
Very‐low‐dose edoxaban (15 mg once daily) should be considered for elderly patients with AF at high bleeding risk when standard‐dose anticoagulation is considered unsuitable by the treating physician or is declined by the patient, as it provides superior stroke prevention compared with no anticoagulation [108]. IIa B
For elderly patients with AF (≥ 80 years of age) and a CrCl of 15–29 mL/min, the choice between edoxaban 30 mg and 15 mg should be individualized according to the patient's ischemic and bleeding phenotypes and made through shared decision‐making. IIa C
The J‐ROCKET AF rivaroxaban dosing regimen may be considered as an alternative to the ROCKET AF regimen for stroke prevention in Asian patients with AF, particularly in those at high risk of bleeding [98, 105, 106, 107]. IIb B

Abbreviations: AF, atrial fibrillation; CG, Cockcroft‐Gault; CrCl, creatinine clearance; DOAC, direct oral anticoagulant.

9. Plasma Concentrations of Direct Oral Anticoagulants

The expected peak and trough concentrations of individual DOACs are presented in Table 6 [114]. A real‐world study from Asia [115] demonstrated that plasma concentrations of once‐daily factor Xa (FXa) inhibitors (rivaroxaban and edoxaban) varied widely between peak and trough levels, and that trough levels were lower than those of the twice‐daily FXa inhibitor, apixaban, consistent with the findings shown in Table 6. Levels of soluble fibrin monomer complex, a marker of thrombin formation, remained within the normal range, suggesting the effectiveness of once‐daily FXa inhibitors and their comparability to the twice‐daily regimen [115].

TABLE 6.

Peak and trough plasma concentrations of DOACs in patients with atrial fibrillation.

Dabigatran Apixaban Edoxaban Rivaroxaban
Peak 52–383 69–321 101–288 178–343
Trough 28–215 34–230 12–43 12–137

Note: Values are expressed as ng/mL. The data presented in this table were adapted from the paper by Steffel et al. [114]

Abbreviations: AF, atrial fibrillation; DOAC, direct oral anticoagulant.

Drug levels can be reasonably estimated using calibrated diluted thrombin time (dTT) or ecarin chromogenic assay for dabigatran [116, 117], and a chromogenic anti‐FXa assay for FXa inhibitors [117]. Plasma concentrations should be used preferentially over anti‐FXa activity or dTT to assess anticoagulant intensity in patients treated with DOACs, to minimize inter‐ and intra‐laboratory variability [114].

Activated partial thromboplastin time (aPTT), prothrombin time (PT), and thrombin time are widely available and offer rapid turnaround; however, their sensitivity and specificity are limited, and they do not exhibit a reliable dose–response relationship for DOAC activity [118]. These tests should be used as qualitative assays to confirm whether an anticoagulant effect is present, and routine coagulation tests such as PT, aPTT, and activated clotting time cannot reliably assess anticoagulant activity [114, 117]. However, a normal aPTT generally excludes supratherapeutic levels in dabigatran‐treated patients. The effects of apixaban, edoxaban, and rivaroxaban on PT are highly dependent on the reagent used. Therefore, a normal PT does not necessarily exclude therapeutic levels of rivaroxaban, edoxaban, and particularly apixaban [118].

Dosing of each DOAC should be based on the dose adjustment criteria specified for each agent, except for dabigatran, rather than on drug concentrations or laboratory coagulation parameters [114]. Accordingly, routine measurement of DOAC concentrations or assessment of anticoagulation intensity with dTT or anti‐FXa assay is not currently recommended. However, such assessments may be clinically useful in selected patient populations [114], including those undergoing major emergency surgery or invasive procedures to determine the need for a DOAC‐specific antidote; patients with suspected altered pharmacokinetics (e.g., advanced age, marked obesity, low body weight, severe renal impairment, or potential drug–drug interactions); and patients with suspected poor adherence.

9.1. Relationship Between the DOAC Plasma Concentrations and the Probability of Ischemic Stroke and Major Bleeding

In the RE‐LY trial, renal function was the predominant determinant of dabigatran plasma concentrations [119]. Importantly, both efficacy and safety outcomes were closely associated with dabigatran plasma concentrations, with age being the most influential covariate. Even within the therapeutic range, higher dabigatran trough concentrations may provide only a modest increase in efficacy at the cost of a substantially increased risk of major bleeding [119]. Similar findings were obtained from analyses of edoxaban plasma concentrations in the ENGAGE AF‐TIMI 48 trial [120].

A further sub‐analysis of the ENGAGE AF‐TIMI 48 trial by ethnicity, including 2909 Asian patients and 18 195 non‐Asian patients, demonstrated that in Asians, the risk of ischemic stroke exceeded the risk of major bleeding when the edoxaban trough concentration was low (< 15 ng/mL) [121]. As the concentration increased, the risks of major bleeding and ICH increased steeply, whereas the risk of ischemic stroke decreased gradually. In contrast, among non‐Asians, the risk of major bleeding exceeded the risk of ischemic stroke across the entire range of edoxaban concentrations achieved.

In real‐world studies from Asia, when compared with the expected concentration ranges reported in Phase 3 randomized trials, trough DOAC concentrations were lower in 15% of 859 patients studied and higher in 9% [122]. Higher CrCl was associated with low trough concentrations, whereas congestive heart failure was associated with high trough concentrations [122]. Importantly, low trough concentrations were associated with an increased risk of stroke or systemic embolism (hazard ratio [HR] 2.78), whereas high trough concentrations were associated with major bleeding (HR 2.63) [122]. In patients with ischemic stroke occurring during DOAC therapy, low DOAC concentrations at stroke onset were associated with poor functional outcomes, stroke progression, and worse clinical outcomes [123].

9.2. Influencing Factors for DOAC Concentrations (Table 7)

TABLE 7.

Influential factors that may increase DOAC concentration.

  • Higher age

  • Reduced renal function (lower creatinine clearance)

  • Impaired hepatic function

  • Lower body weight

  • Drug–drug interaction

  • Co‐administration of P‐glycoprotein inhibitor

  • Co‐administration of CYP3A4 inhibitor

Abbreviations: CYP3A4, cytochrome P450 3A4; DOAC, direct oral anticoagulant.

Several factors affect DOAC concentrations, and those that increase these concentrations are of particular clinical relevance because of their potential to increase bleeding risk (Table 7). All DOACs are eliminated to some extent via the kidneys (renal clearance: 80% for dabigatran, 35% for rivaroxaban, 27% for apixaban, and 50% for edoxaban); therefore, reduced renal function increases DOAC concentrations [114]. As noted above, renal function is the predominant determinant of dabigatran plasma concentrations [119], and the drug is contraindicated in patients with severe renal impairment, defined as CrCl between 15 and 30 mL/min. Although the RE‐LY trial [124] did not adjust the dose of dabigatran (150 mg twice daily or 110 mg twice daily) according to patient characteristics, the use of 110 mg twice daily in patients with moderate renal impairment (CrCl 30–50 mL/min) may be appropriate [114].

Body weight, one of the dose‐reduction criteria for edoxaban and apixaban, is related to the volume of distribution. Patients weighing ≤ 50 kg have 27% higher mean peak serum concentrations of apixaban than those weighing 65–85 kg [125]. Reduced lean muscle mass in elderly patients with AF is associated with higher trough DOAC levels [126]. Some drugs used to treat AF, such as verapamil, dronedarone, amiodarone, ranolazine, and quinidine, inhibit P‐glycoprotein (P‐gp) and may increase the plasma levels of DOACs [114]. Cytochrome P450 3A4 (CYP3A4)–mediated metabolism contributes to the hepatic clearance of rivaroxaban and apixaban [114]. Hence, concomitant use of DOACs with drugs that strongly inhibit both P‐gp and CYP3A4 is not advisable [114]. A recent meta‐analysis of six studies showed that concomitant therapy with DOACs and diltiazem or verapamil—combined P‐gp and moderate CYP3A4 inhibitors—was significantly associated with increased risks of major and GI bleeding compared with DOAC monotherapy while being associated with a lower risk of stroke or systemic embolism [127].

Aging affects the pharmacokinetics of DOACs through reduced renal and hepatic function, changes in body size and composition, and increased drug–drug interactions and polypharmacy [128], all of which are associated with changes in DOAC concentrations [129, 130, 131, 132]. For example, a pharmacokinetic analysis of the ELDERCARE‐AF trial in very elderly patients with AF demonstrated that trough edoxaban concentrations increased by 65% in patients with severe renal impairment and by 29% in those with low body weight (≤ 45 kg), compared with patients without these conditions [133].

Recommendation Box 6. Recommendations of the Measurements of Plasma Concentration of DOACs.

Recommendation Class Level
Routine measurement of DOAC plasma concentrations and concentration‐guided dose adjustment are not recommended [97, 98, 99, 100]. III A
Measurement of DOAC plasma concentrations may be considered in selected patient populations (e.g., the very elderly, patients with very low body weight, advanced CKD, or advanced liver disease) or in specific clinical situations (e.g., recurrent ischemic stroke or major bleeding despite on‐label DOAC dosing). IIb C

Abbreviations: CKD, chronic kidney disease; DOAC, direct oral anticoagulant.

10. OACs for Device‐Detected AF

The central concept of DDAF is the detection of AF through continuous long‐term monitoring; therefore, even AF with a very low burden can be detected. We categorize DDAF as follows: (1) atrial high‐rate episode (AHRE) recorded by a cardiovascular implantable electronic device; or (2) subclinical AF captured by an insertable cardiac monitor (ICM) or wearable device.

The annual risk of ischemic stroke in DDAF is lower than that in clinically diagnosed AF, being only 1.02% and 1.1% among non‐anticoagulated patients with a mean CHA2DS2‐VASc score of around 4 in the ARTESiA and NOAH‐AFNET6 trials, respectively [134, 135]. This may reflect the lower arrhythmia burden and density in DDAF, both of which are relevant to stroke risk [36]. Therefore, oral anticoagulation (ideally with DOACs) should be prescribed in selected patients with DDAF.

We recommend the adoption of the APHRS 4S‐DDAF approach (Strip documentation and longest AF duration; Symptom; Stroke (ischemic) History; Score) to guide decisions on OAC prescription (Figure 16) [136].

FIGURE 16.

FIGURE 16

The 4S‐DDAF approach to guide DOAC use in DDAF. 4S‐DDAF, Strip, Symptom, Stroke and Score approach to device‐detected AF; AAD, antiarrhythmic drug; AF, atrial fibrillation; AHRE, atrial high‐rate episode; APHRS, Asia Pacific Heart Rhythm Society; DDAF, device‐detected AF; DOAC, direct oral anticoagulant; ECG, electrocardiogram; EGM, electrogram; ICM, insertable cardiac monitor; OAC, oral anticoagulant; TIA, transient ischemic attack. The figure was redrawn and modified from the paper by Chao et al. [136]

10.1. Step 1: Strip Documentation and Longest AF Duration

Physicians must read the electrograms recorded at the atrial lead or the ECG strips obtained by ICM or wearables to confirm the diagnosis. In the ASSERT trial, only patients whose longest durations of AHREs exceeded 24 h demonstrated a statistically significant increase in the risk of ischemic stroke or systemic embolism compared with those without AHREs [137]. Once the diagnosis of DDAF is confirmed with a longest duration exceeding 24 h, initiation of OAC could be considered at the same thresholds suggested for clinical AF.

In the ARTESiA trial, DDAF progression occurred at > 9% per year and was associated with increased all‐cause mortality, especially heart failure‐related and arrhythmic deaths [138]. Aspirin‐treated patients who had DDAF progression had an annual rate of stroke/systemic embolism of 1.42%, which is greater than the threshold currently proposed for OAC prophylaxis [138].

10.2. Step 2: Symptoms at the Time of DDAF

If patients clearly recall symptoms during recorded DDAF, these episodes may be treated as “clinical AF” for the purpose of OAC prescription, since such symptoms might have led to a clinical AF diagnosis if medical attention had been sought.

10.3. Step 3: Stroke (Ischemic) History

We recommend initiation of OACs for secondary stroke prevention in patients with DDAF and a history of stroke or TIA based on the results of a sub‐analysis of the ARTESiA trial [139].

10.4. Step 4: Scoring for Stroke Risk With the CHA2DS2 ‐VASc Score

The intrinsic stroke risk will guide decision‐making. We recommend OAC therapy for patients with DDAF and a CHA2DS2‐VASc score ≥ 4, or in the presence of vascular disease regardless of the score based on the results of ARTESiA and NOAH‐AFNET6 trials [140, 141].

For patients who did not fulfill the criteria to initiate OAC in the 4S‐DDAF approach, close monitoring of clinical AF is important since the annual rate of clinical AF ranges from 6.3% to 8.7% [136]. Furthermore, holistic management of patients with DDAF according to the APHRS‐endorsed ABC pathway is important since this structured approach has consistently been associated with improved clinical outcomes in patients with AF from the Asia‐Pacific region [69, 142, 143, 144, 145].

Recommendation Box 7. Recommendations for Anticoagulation in Patients With DDAF.

Recommendation Class Level
The risk of ischemic stroke is lower in patients with DDAF than in those with clinical AF. Therefore, a different approach to the initiation of OACs is recommended [134, 135]. I A
The 4S‐DDAF approach could be adopted to guide decisions on the initiation of OACs for patients with DDAF. IIa C
Holistic patient care based on the Atrial Fibrillation Better Care (ABC) pathway is recommended for patients with DDAF [69, 142, 143, 144, 145]. I A

Abbreviations: AF, atrial fibrillation; DDAF, device‐detected atrial fibrillation; OAC, oral anticoagulant.

11. Left Atrial Appendage Occlusion/Exclusion in Patients With Atrial Fibrillation

The left atrial appendage (LAA) is uniquely susceptible to thrombus formation in patients with AF, whereby approximately 90% of intra‐atrial thrombi originate within the LAA [146]. Hence, mechanically isolating or surgically removing the LAA may eliminate this primary cardioembolic source. The landmark clinical studies of LAAO for stroke prevention in patients with AF are summarized in Table 8 [147, 148, 149, 150, 151, 152, 153, 154, 155].

TABLE 8.

Review of landmark clinical studies of LAAO.

Clinical trial Design and patient population Key efficacy findings Key safety findings Clinical impact
PROTECT AF and PREVAIL [147, 148, 149] RCTs (n = 707 and n = 407) comparing first‐generation Watchman versus Warfarin. LAAO was non‐inferior to warfarin for the composite of stroke, systemic embolism, and cardiovascular death. Lower rates of hemorrhagic stroke and all‐cause mortality compared to warfarin over 5‐year follow‐up. Provided initial evidence for percutaneous LAAO as an alternative to vitamin K antagonists.
PRAGUE‐17 [150] RCT (n = 402) comparing LAAO (Watchman/Amulet) versus DOACs in patients with high ischemic and bleeding risks. LAAO was non‐inferior to DOACs for the primary composite endpoint of cardioembolic events, bleeding, or death. Non‐procedural clinically relevant bleeding was lower in the LAAO group. Demonstrated non‐inferiority of LAAO to DOACs in patients with high bleeding risk.
CHAMPION‐AF [151] RCT comparing Watchman FLX versus DOACs in OAC‐eligible patients. Met primary non‐inferiority endpoint for the composite of stroke, cardiovascular death, or systemic embolism. Met primary safety endpoint for reduced long‐term major bleeding compared to DOACs. Provides data on LAAO as a potential primary alternative to DOACs in OAC‐eligible patients.
CLOSURE‐AF [152] RCT comparing LAAO versus standard medical therapy in AF patients at high risk of bleeding. Ischemic stroke and systemic embolism rates were comparable to standard medical therapy. Reduced the risk of major bleeding compared to prolonged pharmacotherapy. Supports the use of LAAO as an alternative therapy for patients with a high bleeding hazard.
OPTION [153] RCT (n = 1600) comparing post‐AF ablation LAAO (Watchman FLX) versus continued OAC. LAAO was non‐inferior to OAC for the composite of stroke, systemic embolism, or death at 36 months. Met superiority endpoint for safety, driven by a reduction in long‐term non‐procedural bleeding. Suggests LAAO is a feasible alternative to continued OAC following AF ablation.
COMBINATION [154] RCT evaluating simultaneous catheter ablation and LAAO versus ablation alone Procedural complications and ablation efficacy were similar between the combined and ablation‐alone groups. Early OAC cessation was achieved without an observed increase in periprocedural stroke. Demonstrated the safety and technical feasibility of combined AF ablation and LAAO.
LAAOS III [155] Multi‐center RCT (n = 4770) evaluating surgical LAA exclusion versus no exclusion during cardiac surgery. 33% relative risk reduction in ischemic stroke or systemic embolism (HR = 0.67) over 3.8‐year median follow‐up. No significant increase in perioperative heart failure, major bleeding, or chest re‐exploration. Led to guideline recommendations for concomitant surgical LAA exclusion during open‐heart surgery.

Abbreviations: AF, atrial fibrillation; DOAC, direct oral anticoagulant; HR, hazard ratio; LAA, left atrial appendage; LAAO, left atrial appendage occlusion; OAC, oral anticoagulant; RCT, randomized controlled trial.

11.1. Evidence‐Based Application of Percutaneous LAAO and Surgical Exclusion

The evidence base for LAAO has rapidly expanded from initial non‐inferiority trials to frontline comparisons with contemporary medical therapy. Percutaneous LAAO was non‐inferior to warfarin in PROTECT AF [147] and this was supported by PREVAIL [148] and long‐term pooled analyses [149], with significant reductions in hemorrhagic stroke and non‐procedural bleeding.

Subsequent randomized trials have compared LAAO with DOACs, including PRAGUE‐17 [150], CLOSURE‐AF [152] and CHAMPION‐AF [151]. These trials have been debated with regards to their large non‐inferiority margins, limited statistical power and bleeding advantage that may be overstated [156].

In a meta‐analysis by Chan et al. [157] of four contemporary trials (CHAMPION‐AF, CLOSURE‐AF, OPTION, PRAGUE‐17), no significant differences in all stroke, hemorrhagic stroke, systemic embolism, all‐cause death, or cardiovascular death between LAAO and DOAC were seen. LAAO was even associated with a higher risk of ischemic stroke (relative risk [RR] 1.45; 95% confidence interval [CI] 1.03–2.06; p = 0.03, after exclusion of the OPTION trial). There was a reduced risk of all non‐major and non‐procedure‐related major and non‐major bleeding, but major bleeding and ICH were similar. Similar findings were reported in two other meta‐analyses [158, 159].

The CLOSURE‐AF trial [152] enrolled patients at high stroke and bleeding risk with mean CHA2DS2‐VASc and HAS‐BLED scores of 5.2 and 3.0, respectively; however, LAAO was not non‐inferior to best medical management for the composite endpoint of stroke, systemic embolism, major bleeding, or cardiovascular or unexplained death. LAAO was associated with numerically higher major adverse cardiac and cerebrovascular events, hospitalizations (bleeding or cardiovascular events), cardiovascular or unexplained deaths, and major bleeds.

In the CHAMPION‐AF trial [151], LAAO was non‐inferior to DOAC therapy for the composite outcome (death from cardiovascular causes, stroke/systemic embolism) and was superior to DOAC therapy for non–procedure‐related bleeding. The secondary safety outcome of procedure‐related and non‐procedure‐related major bleeding did not differ significantly. In subgroup analyses, DOACs performed numerically better than LAAO in those with CHA2DS2‐VASc score > 5 (similar to the CLOSURE‐AF population) and those age > 75.

The OPTION [153] and COMBINATION [154] trials support combined or staged LAAO strategies in patients undergoing AF ablation. For surgical patients, LAAOS III [155] established concomitant surgical LAA occlusion as a beneficial standard‐of‐care procedure during cardiac surgery.

11.2. Optimizing Pre‐Procedural Planning, Antithrombotic Therapy, and Surveillance

Procedural success and long‐term safety in LAAO require meticulous pre‐operative preparation, tailored antithrombotic regimens, and structured surveillance to manage device‐related thrombosis (DRT) and peri‐device leak (PDL) [149].

11.2.1. Pre‐Procedural Management

Comprehensive baseline imaging (transesophageal echocardiography [TEE] or cardiac computed tomography [CT]) is mandatory to assess LAA anatomy, optimize device sizing, and unequivocally rule out pre‐existing LAA thrombus—which requires resolution via systemic anticoagulation before intervention can safely proceed.

11.2.2. Tailored Post‐Procedural Therapy

Regimens must balance DRT prevention during device endothelialization against the patient's bleeding risk. Replacing a “one‐size‐fits‐all” approach, brief, tailored courses of DOACs may offer better safety and efficacy than traditional dual antiplatelet therapy [160, 161], followed by a structured step‐down to single antiplatelet therapy (SAPT).

11.2.3. Surveillance

Consensus guidelines mandate routine imaging (TEE or cardiac CT) at 45–90 days post‐implantation to evaluate device integrity, positioning, and healing [160].

11.2.4. Managing Complications (DRT and PDL)

Though rare, DRT significantly increases stroke risk and requires immediate resumption of systemic anticoagulation (typically a DOAC or low‐molecular‐weight heparin) until repeat imaging confirms complete resolution [161]. While micro‐leaks (< 3–5 mm) are generally benign, larger PDLs negate the device's protective effect and necessitate extended antithrombotic therapy or secondary structural interventions (e.g., percutaneous coil/plug placement).

Therefore, clinical pathways must integrate strict pre‐procedural imaging and mandatory 45‐day post‐procedural assessments [161]. These results determine whether a patient can safely transition to indefinite SAPT or requires prolonged therapy due to DRT or significant PDL.

11.3. Specific Patient Populations in Which LAAO May Be Considered as a Primary Alternative

LAAO has evolved from a salvage therapy into a potential primary alternative for the following specific patient cohorts:

11.3.1. Absolute or Relative Contraindications to OAC

Patients with high CHA2DS2‐VASc scores and life‐threatening bleeding (e.g., ICH or severe GI hemorrhage) represent the classic LAAO cohort [162]. Furthermore, the ASAP [163] and EWOLUTION [164] registries confirmed that in OAC‐ineligible patients with prior major bleeding, LAAO use reduced subsequent bleeds and lowered expected ischemic stroke rates by roughly 64%, requiring only brief post‐procedural antiplatelet therapy.

11.3.2. Chronic Kidney Disease (CKD) and End‐Stage Renal Disease (ESRD) on Dialysis

Patients on dialysis have highly elevated risks of both stroke and bleeding, further compounded by uremic platelet dysfunction and systemic anticoagulation. LAAO may be clinically beneficial in patients with ESRD, providing a localized mechanical barrier that bypasses systemic bleeding risks [165, 166, 167, 168].

11.3.3. High Bleeding Risk and Lifestyle or Occupational Factors

Patients with elevated bleeding risks (HAS‐BLED > 3), severe frailty, or high risk for bleeding due to repetitive physical trauma (e.g., recurrent falls) may be potential candidates. However, in the CLOSURE‐AF trial, in which more than 40% of the enrolled patients had a history of major bleeding, LAAO was not shown to be non‐inferior to physician‐directed best medical care with respect to the composite end point of stroke, systemic embolism, major bleeding, or cardiovascular or unexplained death [152].

11.3.4. Failure of Anticoagulation (Breakthrough Stroke)

Managing patients who suffer recurrent cardioembolic strokes despite therapeutic, compliant OAC use is highly challenging. By mechanically isolating the primary cardioembolic source, LAAO may potentially serve as an effective alternative or adjunctive therapy for pharmacological failure.

11.3.5. Concomitant Interventional and Surgical Candidates

LAAO can be combined with AF catheter ablation to facilitate early OAC cessation, a “one‐stop” strategy as suggested by the OPTION [153] and COMBINATION [154] trials. For patients undergoing open‐heart surgery, concomitant surgical LAA exclusion is now established as a standard‐of‐care intervention, driven by the definitive results of the LAAOS III trial [155].

Based on the current evidence comparing LAAO with DOAC therapy, LAAO may reduce non‐procedural bleeding, but this potential benefit may come at the cost of an increased risk of ischemic stroke [157, 158, 159].

Recommendation Box 8. Recommendations for LAAO in Patients With Atrial Fibrillation.

Recommendation Class Level
Percutaneous LAAO reduces the risk of non‐procedural bleeding, but this potential benefit may come at the cost of an increased risk of ischemic stroke. Therefore, the choice between LAAO and DOAC therapy is recommended to be based on shared decision‐making and careful assessment of the individual risk–benefit balance [157, 158, 159]. I A
Percutaneous LAAO may be considered an alternative for stroke prevention in selected patients with AF in whom long‐term oral anticoagulation is not feasible [157, 158, 159]. IIb B
In patients with AF undergoing concomitant cardiac surgery and a CHA2DS2‐VASc score ≥ 2, surgical LAA exclusion or occlusion is recommended as an adjunctive strategy to reduce postoperative thromboembolic events. Long‐term anticoagulation is determined according to the patient's underlying thromboembolic risk [155]. I B

Abbreviations: AF, atrial fibrillation; DOAC, direct oral anticoagulant; LAA, left atrial appendage; LAAO, left atrial appendage occlusion.

12. Anticoagulation in AF Patients With Prior Intracranial Hemorrhage

12.1. Background and Clinical Challenge

Spontaneous ICH occurring in patients with AF represents one of the most challenging clinical dilemmas. These patients carry a dual and paradoxical risk. First, they have a substantial risk of recurrent hemorrhagic stroke from the ICH itself, with reported annual recurrence rates of approximately 2%–4% that vary by hematoma location (higher in lobar ICH than in deep ICH) [169]. Second, they face a high risk of ischemic stroke attributable to AF‐related thromboembolism. Of note, a meaningful proportion of ICH events in patients with AF—particularly in Asian populations—are attributable to hypertensive small vessel disease or cerebral amyloid angiopathy (CAA), each carrying distinct implications for OAC safety [169, 170].

Historically, a prior ICH was regarded as a relative contraindication to OAC. However, given the high ischemic stroke burden in AF patients following ICH, this dogmatic approach has been questioned. Indeed, meta‐analytic evidence shows that adjusted‐dose VKA reduces stroke by approximately 64% and all‐cause mortality by 26% in non‐valvular AF [171]. On the other hand, resumption of OAC risks precipitating recurrent ICH, which carries a case fatality rate of approximately 40% within the first month [172].

These contrasting risks have driven substantial interest in Asia‐Pacific populations, where the proportion of ICH—relative to ischemic stroke—is approximately three‐fold higher in East Asian compared with Western populations (pooled proportion 33% vs. 12% in community‐based studies) [170]. This epidemiological context reinforces the need for Asia‐specific guidance on OAC management after ICH [81, 173].

12.2. Evidence From Randomized Controlled Trials

Until recently, evidence to guide post‐ICH OAC decisions in AF patients was limited. Results of pivotal trials (APACHE‐AF, SoSTART, COCROACH individual patient data meta‐analysis, PRESTIGE‐AF, and ENRICH‐AF) are summarized in Table 9 [174, 175, 176, 177].

TABLE 9.

Randomized evidence on oral anticoagulation in patients with atrial fibrillation and prior intracranial hemorrhage.

Trial (year) Design Population (n) Comparison Key efficacy outcome Key safety outcome
APACHE‐AF (2021) [174] Randomized, open‐label, Phase 2 trial with masked endpoint assessment; 16 hospitals, the Netherlands 101 patients with AF who survived an anticoagulation‐associated intracerebral hemorrhage; CHA2DS2‐VASc ≥ 2 and mRS ≤ 4; randomized 7–90 days (median 46 days) after the hemorrhage Apixaban (5 mg or 2.5 mg twice daily) versus avoid anticoagulation (antiplatelet therapy at the physician's discretion; started in 51%) Primary outcome (non‐fatal stroke or vascular death): 13/50 (26%; 12.6% per year) versus 12/51 (24%; 11.9% per year); adjusted HR 1.05 (95% CI 0.48–2.31); p = 0.90 over a median follow‐up of 1.9 years Non‐outcome serious adverse events 29/50 (58%) versus 29/51 (57%). The trial was designed to estimate event rates to inform a larger trial and was not powered to detect a difference
SoSTART (2021) [175] Randomized, open‐label, assessor‐masked, pilot‐phase, non‐inferiority trial; 67 UK hospitals. Non‐inferiority margin 12% absolute (adjusted HR 3.2) 203 adults with AF who survived ≥ 24 h after a symptomatic spontaneous intracranial hemorrhage (any type, including subdural and subarachnoid) with CHA2DS2‐VASc ≥ 2; randomized a median of 115 days after onset; median follow‐up 1.2 years Start versus avoid long‐term (≥ 1 year) full‐dose oral anticoagulation (DOAC or VKA); the avoid group received standard care (antiplatelet agent or no antithrombotic) Primary outcome (recurrent symptomatic spontaneous intracranial hemorrhage): 8/101 (8%) versus 4/102 (4%); adjusted HR 2.42 (95% CI 0.72–8.09); p = 0.152. Non‐inferiority of starting anticoagulation was not shown and the result was inconclusive Deaths 22 (22%) versus 11 (11%); serious adverse events 17 (17%) versus 15 (15%). Weak signals from three composite secondary outcomes suggested possible benefit of anticoagulation for major vascular events
COCROACH (2023) [176] Prospective individual participant data meta‐analysis of 4 randomized trials: SoSTART, APACHE‐AF, NASPAF‐ICH and the prior‐intracranial‐hemorrhage subgroup of ELDERCARE‐AF (n = 80) 412 participants (310 [75%] aged ≥ 75 years). A DOAC was used in 209 (99%) of the 212 assigned to start anticoagulation; the comparator was antiplatelet monotherapy in 67 (33%) of 200 Start versus avoid oral anticoagulation Any stroke or cardiovascular death 29 (14%) versus 43 (22%); pooled HR 0.68 (95% CI 0.42–1.10). Ischemic MACE 9 (4%) versus 38 (19%); HR 0.27 (95% CI 0.13–0.56) Hemorrhagic MACE 15 (7%) versus 9 (5%); HR 1.80 (95% CI 0.77–4.21). Death from any cause 38 (18%) versus 29 (15%); HR 1.29 (95% CI 0.78–2.11). Neither difference was significant
PRESTIGE‐AF (2025) [177] Multicenter, open‐label, blinded‐endpoint, Phase 3 randomized trial; 75 hospitals in 6 European countries; randomization stratified by intracerebral hemorrhage location and sex. Co‐primary endpoints tested hierarchically: superiority for ischemic stroke and non‐inferiority for recurrent intracerebral hemorrhage (margin HR < 1.735) 319 patients (158 vs. 161) with spontaneous intracerebral hemorrhage, AF, an indication for anticoagulation and mRS ≤ 4; median age 79 years, 35% women; median follow‐up 1.4 years DOAC versus no anticoagulation (1:1) Co‐primary endpoint 1—ischemic stroke: 0.83 versus 8.60 per 100 patient‐years; HR 0.05 (95% CI 0.01–0.36); log‐rank p < 0.0001. All‐cause death 16 (10%) versus 21 (13%) Co‐primary endpoint 2—recurrent intracerebral hemorrhage: 5.00 versus 0.82 per 100 patient‐years; HR 10.89 (90% CI 1.95–60.72); non‐inferiority not met (p = 0.96). Serious adverse events 70 (44%) versus 89 (55%)

ENRICH‐AF (2026)

Presented at ESC Congress 2026 (Hot Line, 29 Aug 2026, Munich); NCT03950076; full publication pending

Investigator‐initiated, open‐label, blinded‐endpoint (PROBE), event‐driven randomized trial. After a Data and Safety Monitoring Board review in 2023, patients with lobar intraparenchymal or convexity subarachnoid hemorrhage were no longer enrolled because of safety concerns 948 survivors of spontaneous or traumatic intracranial hemorrhage with high‐risk AF (CHA2DS2‐VASc ≥ 2); mean age 77 years, 39% women; 13% Asian; mean follow‐up 28 months Edoxaban 60 mg once daily (reduced to 30 mg per label [38%]) versus no anticoagulation (no antithrombotic therapy or single antiplatelet therapy at the clinician's discretion [antiplatelet therapy chosen for control in 52%]) Primary outcome (stroke or systemic embolism): 11.8% versus 12.8%; HR 0.88 (95% CI 0.61–1.26); p = 0.48. Ischemic stroke (HR 0.57; p = 0.02) and myocardial infarction (HR 0.14; p = 0.03) were significantly reduced with edoxaban. ISTH major bleeding 11.6% versus 5.2%; HR 2.23 (95% CI 1.39–3.59); p < 0.001. Intracranial hemorrhage 6.6% versus 2.9%; HR 2.21 (95% CI 1.17–4.15); p = 0.01. The excess of recurrent intracranial hemorrhage was concentrated in patients with lobar or convexity hemorrhage

Note: COCROACH is a pooled analysis of the randomized trials listed and therefore overlaps with SoSTART and APACHE‐AF.

Abbreviations: AF, atrial fibrillation; CI, confidence interval; DOAC, direct oral anticoagulant; HR, hazard ratio; ISTH, International Society on Thrombosis and Haemostasis; MACE, major adverse cardiovascular events; mRS, modified Rankin Scale; PROBE, prospective randomized open blinded endpoint; VKA, vitamin K antagonist.

12.3. Asia‐Pacific Considerations

Patients in the Asia‐Pacific region—particularly those of East Asian ancestry—face a higher baseline risk of ICH compared with their Western counterparts [3, 18], with ICH constituting approximately one‐third of all strokes in Chinese community‐based studies versus roughly one‐eighth in Western community‐based studies [170]. The etiology of ICH in these populations is more frequently hypertensive small vessel disease, while CAA becomes more prominent with advancing age. Registry data from Taiwan using sequential target trial emulation methodology showed that reinitiating DOACs after ICH was associated with lower all‐cause mortality (adjusted HR 0.73; 95% CI 0.61–0.88) without a significant increase in ICH risk (adjusted HR 1.21; 95% CI 0.81–1.80), supporting the generalizability of randomized trial findings to the Asian context [178, 179]. Complementing these data, large nationwide cohort studies from Korea and Taiwan directly compared DOACs with warfarin in AF patients with a prior history of ICH, and both consistently demonstrated that DOACs were associated with significantly lower risks of recurrent ICH, ischemic stroke, and all‐cause mortality, supporting DOACs as the preferred agent class in Asian patients with this profile [180, 181].

LAAO is an emerging alternative for patients who cannot safely receive long‐term OAC. While randomized evidence is limited, observational data support its consideration as part of an individualized strategy in this population [54]. The ongoing A3ICH trial (NCT03243175) randomizes ICH survivors with AF to one of three strategies: apixaban, LAAO, or avoiding anticoagulation.

12.4. Practical Guidance: Optimal Timing and Risk Stratification

Based on available evidence, the decision to initiate or re‐initiate OAC following ICH in an AF patient should be made through a multidisciplinary approach involving neurology, cardiology, and, when applicable, neurosurgery [54]. Key factors to consider include:

  • ICH etiology and location: Non‐lobar (deep) ICH—typically of hypertensive etiology—carries a lower risk of recurrence with OAC than lobar ICH, which is more often associated with CAA. Caution is warranted with OAC in lobar ICH [169].

  • Thromboembolic risk: Patients with CHA2DS2‐VASc ≥ 2 derive the greatest potential net benefit from OAC [171]. The higher the stroke risk, the more compelling the case for OAC initiation.

  • Timing of OAC initiation: There is currently insufficient evidence to make a definitive recommendation on whether and when OAC should be started or restarted after ICH, and we advise an individualized multidisciplinary approach led by an expert neurology team while awaiting the results of ongoing trials [54]. Randomized data support deferring OAC initiation for at least 14 days after the index ICH (consistent with the earliest enrollment window in PRESTIGE‐AF) [177]. In practice, OAC reinitiation is typically deferred 4–8 weeks to allow hematoma resolution and blood pressure optimization. In an Asian sequential target trial emulation study, DOAC reinitiation within 14 days was associated with the greatest benefit in patients with lower ICH severity, whereas reinitiation within 28 days was associated with greater benefit in those with higher ICH severity [178].

  • Choice of anticoagulant: DOACs are preferred over VKA, given their approximately 50% lower risk of ICH compared with warfarin in landmark AF trials, with consistent benefits also demonstrated in Asian nationwide cohorts of AF patients with prior ICH [101, 180, 181].

  • Blood pressure optimization: Strict blood pressure control is a prerequisite for any decision on OAC, as hypertension is the most potent modifiable risk factor for recurrent ICH [54].

LAAO may be considered as an alternative to OAC in carefully selected patients with post‐ICH AF who are deemed at unacceptably high risk of OAC‐related ICH recurrence (e.g., those with lobar ICH and suspected CAA), pending completion of dedicated randomized trials in this population [54].

Recommendation Box 9. Recommendations for Anticoagulation Management in AF Patients With Prior ICH.

Recommendation Class Level
In AF patients with prior ICH, it is recommended that the decision to initiate or re‐initiate OAC must be made through an individualized, multidisciplinary approach (involving cardiology and neurology), carefully balancing the risk of recurrent ICH against the risk of cardioembolic stroke. I C
When OAC is deemed appropriate after ICH in AF patients, DOACs are recommended over VKA given their significantly lower risk of intracranial hemorrhage [1, 180, 181]. I B
OAC reinitiation may be considered after hematoma resolution on neuroimaging, hemodynamic stability, and adequate blood pressure control (target < 130/80 mmHg), typically not earlier than 14 days post‐ICH. Timing should be individualized by ICH severity, with Asian observational data suggesting reinitiation within 14 days for lower severity and within 28 days for higher severity [176, 178]. IIb B
LAAO may be considered as an alternative stroke prevention strategy in selected AF patients with prior ICH who are at prohibitively high risk of OAC‐related hemorrhage and where multidisciplinary evaluation supports this approach, pending results from the ongoing trials (NCT03243175). IIb C
In patients with AF surviving lobar ICH (with cerebral amyloid angiopathy and associated microbleeds), initiation of OAC is not recommended given the elevated risk of recurrent ICH. III C

Abbreviations: AF, atrial fibrillation; DOAC, direct oral anticoagulant; ICH, intracranial hemorrhage; LAAO, left atrial appendage occlusion; OAC, oral anticoagulant; VKA, vitamin K antagonist.

13. Oral Anticoagulation After Acute Ischemic Stroke in AF Patients

13.1. Background and Clinical Rationale

Following an acute AF‐related ischemic stroke, the risk of early recurrent thromboembolic and hemorrhagic events is substantial. In the prospective multicenter RAF cohort study (n = 1029), the 90‐day composite of stroke, TIA, symptomatic systemic embolism, symptomatic cerebral bleeding and major extracranial bleeding occurred in 12.6% of patients, with symptomatic cerebral bleeding alone in 3.6%, underscoring both the early thromboembolic and hemorrhagic risk in this population [182]. In the same cohort, hemorrhagic transformation was observed on follow‐up neuroimaging in 13.0% of patients, and larger ischemic lesion size was an independent predictor of symptomatic cerebral bleeding [182].

The critical question is when DOAC therapy should be initiated or re‐initiated after an acute AF‐related ischemic stroke. Traditional expert consensus, reflected in the “1–3–6–12 day rule”, advocated delaying OAC by 1 day after TIA, 3 days after minor stroke, 6 days after moderate stroke, and 12 days after major stroke [183]. The landmark CATALYST individual patient data meta‐analysis, pooling four randomized trials (TIMING, ELAN, OPTIMAS, START; n = 5441), now provides robust data to substantially revise this approach [184].

13.2. Evidence From Randomized Controlled Trials

Four landmark randomized trials have directly addressed the timing of DOAC initiation after acute ischemic stroke in AF patients: TIMING, ELAN, OPTIMAS, and START (Table 10) [185, 186, 187, 188].

TABLE 10.

Randomized evidence on the timing of DOAC initiation after acute ischemic stroke in patients with atrial fibrillation.

Trial (year) Design Population (n) Comparison Primary outcome Symptomatic intracranial hemorrhage
TIMING (2022) [185] Registry‐based, randomized, open‐label, blinded‐endpoint, non‐inferiority trial at 34 stroke units using the Swedish Stroke Register; pre‐specified non‐inferiority margin 3% 888 patients with acute ischemic stroke and AF randomized within 72 h of stroke onset (early n = 450, delayed n = 438); mean age 78.3 years, 46.2% women Early (≤ 4 days) versus delayed (5–10 days) DOAC initiation; choice of DOAC at the investigator's discretion Recurrent ischemic stroke, symptomatic intracerebral hemorrhage or all‐cause death at 90 days: 6.89% versus 8.68%; absolute risk difference −1.79% (95% CI −5.31% to 1.74%); p for non‐inferiority = 0.004. Ischemic stroke 3.11% versus 4.57%; all‐cause death 4.67% versus 5.71% No symptomatic intracerebral hemorrhage occurred in either group
ELAN (2023) [186] Investigator‐initiated, open‐label randomized trial with masked outcome assessment; 103 sites in 15 countries. Treatment effects were estimated as risk differences with 95% CI, without formal non‐inferiority or superiority hypothesis testing 2013 patients with acute ischemic stroke and AF (1006 early, 1007 later); 37% minor, 40% moderate and 23% major stroke Early (≤ 48 h after a minor or moderate stroke; day 6–7 after a major stroke) versus later (day 3–4 minor; day 6–7 moderate; day 12–14 major) DOAC initiation Recurrent ischemic stroke, systemic embolism, major extracranial bleeding, symptomatic intracranial hemorrhage or vascular death at 30 days: 2.9% versus 4.1%; risk difference −1.18 percentage points (95% CI −2.84 to 0.47). Recurrent ischemic stroke at 30 days 1.4% versus 2.5% (OR 0.57, 95% CI 0.29–1.07) 2 patients (0.2%) in each group by 30 days
OPTIMAS (2024) [187] Multicenter, open‐label, blinded‐endpoint, parallel‐group, Phase 4 randomized controlled trial at 100 UK hospitals; stratified by stroke severity; gatekeeper testing of non‐inferiority (margin 2 percentage points) followed by superiority 3648 patients with acute ischemic stroke and AF were randomized; 3621 were analyzed in the modified intention‐to‐treat population (early 1814, delayed 1807)—the largest individual trial to date Early (≤ 4 days from symptom onset) versus delayed (7–14 days) initiation of any DOAC Recurrent ischemic stroke, symptomatic intracranial hemorrhage, unclassifiable stroke or systemic embolism at 90 days: 59 (3.3%) versus 59 (3.3%); adjusted risk difference 0.000 (95% CI −0.011 to 0.012); p for non‐inferiority = 0.0003. Superiority was not identified (p = 0.96) 11 (0.6%) versus 12 (0.7%); adjusted risk difference 0.001 (95% CI −0.004 to 0.006); p = 0.78
START (2025) [188] Pragmatic, Phase 2, response‐adaptive randomized clinical trial using Bayesian posterior probabilities to adjust allocation; acute care hospitals in Texas, USA (2017–2023) 200 patients with a mild‐to‐moderate AF‐associated ischemic stroke (minimum lesion diameter 1.5 cm) prescribed a DOAC within 2 weeks of onset; median age 75 years, median NIHSS score 6.5 Four DOAC initiation timepoints — day 3–4, day 6, day 10 or day 14 after stroke onset (randomization performed on day 3–4) Composite ischemic (stroke or systemic embolism) or hemorrhagic (symptomatic intracranial hemorrhage or major systemic hemorrhage) event within 30 days: ischemic events 0, 3, 2 and 2 in groups 1–4. The day 3–4 group had the highest posterior probability of being optimal (0.41 vs. 0.26, 0.17 and 0.15). No clearly superior day was identified, but earlier initiation appeared better than later within the first 2 weeks Hemorrhagic events 1, 1, 1 and 0 in the day 3–4, day 6, day 10 and day 14 groups, respectively
CATALYST (2025) [184] Systematic review and prospective individual participant data meta‐analysis of TIMING, ELAN, OPTIMAS and START (one‐stage generalized linear mixed‐effects model); participants overlap with the four trials above 5441 participants (mean age 77.7 years; 2472 [45.4%] women; median NIHSS score 5); primary outcome data available for 5429 Early (≤ 4 days) versus later (≥ 5 days) DOAC initiation Recurrent ischemic stroke, symptomatic intracerebral hemorrhage or unclassified stroke within 30 days of randomization: 57 (2.1%) versus 83 (3.0%); OR 0.70 (95% CI 0.50–0.98); p = 0.039. Recurrent ischemic stroke 45 (1.7%) versus 70 (2.6%); OR 0.66 (95% CI 0.45–0.96); p = 0.029 10 (0.4%) vs. 10 (0.4%); OR 1.02 (95% CI 0.43–2.46); p = 0.96

Note: CATALYST pools individual participant data from TIMING, ELAN, OPTIMAS and START; its participants overlap with those trials and the estimates should not be counted as independent evidence.

Abbreviations: AF, atrial fibrillation; CI, confidence interval; DOAC, direct oral anticoagulant; NIHSS, National Institutes of Health Stroke Scale; OR, odds ratio.

These four trials were prospectively synthesized in the CATALYST individual patient data meta‐analysis, which included 5441 participants [184]. In CATALYST, early DOAC initiation (≤ 4 days) significantly reduced the 30‐day risk of the primary composite outcome of recurrent ischemic stroke, symptomatic ICH, or unclassified stroke compared with later initiation (≥ 5 days), with no evidence of an increased risk of symptomatic ICH [184]. Hence, current trial data support early DOAC initiation in clinical practice, with the caveat that patients with very severe strokes and those with extensive space‐occupying hemorrhagic transformation were underrepresented [184].

13.3. Asia‐Pacific Perspectives

Patients in the Asia‐Pacific region with AF‐related acute ischemic stroke may differ from Western cohorts in stroke subtype distribution, including a higher proportion of ICH and possibly a higher proportion of lacunar ischemic stroke, although methodological heterogeneity precludes definitive comparison [170].

No Asia‐Pacific–specific randomized trial data on the timing of DOAC initiation after acute ischemic stroke in AF are currently available. The CATALYST individual patient data meta‐analysis enrolled participants predominantly from European and North American sites (UK, Sweden, other European countries, and the USA), and ethnicity data were available for only one of the four constituent trials, limiting direct generalizability to Asian populations [184].

In the broader setting of AF patients with a history of stroke, large Asian real‐world data consistently support DOAC over warfarin as the first‐choice anticoagulant. For example, a Korean nationwide cohort of 61 568 OAC‐naïve AF patients with prior stroke showed that DOACs were associated with lower risks of recurrent stroke (HR 0.67, 95% CI 0.62–0.72), major bleeding (HR 0.73, 95% CI 0.66–0.80), and mortality compared with warfarin, with consistent benefits across subgroups including severe, disabling, and recent stroke [189].

In Asian patients, the early period after reperfusion therapy (intravenous thrombolysis or mechanical thrombectomy) is associated with substantial hemorrhagic transformation risk, with large ischemic lesion size as a key predictor [182]. Anticoagulation is not recommended within 48 h of acute ischemic stroke onset; during this interval, low‐dose aspirin should be administered in the absence of contraindications [54]. After confirmed hemostasis and assessment of hemorrhagic transformation on follow‐up imaging, early DOAC initiation (≤ 4 days from stroke onset, per CATALYST) is reasonable for minor‐to‐moderate strokes, with continued individualized decision‐making in patients with severe stroke or extensive hemorrhagic transformation [184].

Recommendation Box 10. Recommendations for Timing of OAC Initiation After Acute Ischemic Stroke in AF Patients.

Recommendation Class Level
In AF patients with minor to moderate acute ischemic stroke (NIHSS ≤ 15) without significant hemorrhagic transformation, early initiation of DOAC within 4 days of stroke onset is recommended to reduce recurrent ischemic stroke without increasing the risk of symptomatic intracranial hemorrhage [184]. I A
DOACs are recommended over VKA for stroke prevention in AF patients after acute ischemic stroke [101, 190]. I A
In AF patients with severe acute ischemic stroke or large territorial infarction at high risk of hemorrhagic transformation, later DOAC initiation should be considered after multidisciplinary stroke team evaluation and repeat neuroimaging. IIa C
In patients with AF who have received intravenous thrombolysis or mechanical thrombectomy for acute ischemic stroke, DOAC initiation within 24 h of reperfusion therapy is not recommended; timing of subsequent initiation should be individualized based on post‐reperfusion neuroimaging and clinical status. III C

Abbreviations: AF, atrial fibrillation; DOAC, direct oral anticoagulant; NIHSS, National Institutes of Health Stroke Scale; OAC, oral anticoagulant; VKA, vitamin K antagonist.

14. Stroke Prevention in AF Patients With End‐Stage Renal Disease

AF is highly prevalent in patients with ESRD on renal replacement therapy, that is, maintenance peritoneal dialysis (PD) or hemodialysis. Such patients carry a dual burden of elevated thromboembolic and hemorrhagic risk [191, 192].

There may be some risk differences between PD and hemodialysis. In an observational cohort from Hong Kong of AF patients with CKD on PD, who had a similar ischemic stroke risk to their non‐CKD counterparts, warfarin therapy was associated with a lower risk of ischemic stroke compared with aspirin [HR 0.16, 95% CI 0.04–0.66, p = 0.01] and no therapy (HR 0.19, 95% CI 0.06–0.65, p = 0.01), without a higher risk of ICH [193].

Whether AF is a causal driver of cardioembolic stroke in this population, or a marker of underlying cardiovascular disease, remains uncertain, and the attributable stroke risk of AF may be lower than in the general population. The CHA2DS2‐VASc score has had limited validation in the dialysis population and, on external validation, has shown only modest‐to‐poor discrimination (c‐statistics approximately 0.5–0.7) and poor calibration; it also does not account for the high competing risk of death, and no dialysis‐specific stroke prediction model has yet been prospectively validated [194, 195]. Decisions to anticoagulate should instead be individualized within a shared decision‐making framework.

Anticoagulation decisions should be viewed along the continuum of declining kidney function rather than as a single choice made at dialysis initiation. In advanced non‐dialysis CKD (Stage 4, CrCl 15–30 mL/min), the evidence base is stronger than in dialysis: subgroup analyses of the pivotal AF trials and a recent systematic review and meta‐analysis support a reduced‐dose DOAC (e.g., apixaban 2.5 mg twice daily or rivaroxaban 15 mg once daily or edoxaban 30 mg once daily) in preference to a VKA, with a favorable bleeding and mortality profile [196, 197, 198, 199]. As patients progress from CKD Stage 4 to Stage 5 and onto maintenance dialysis, however, the pharmacokinetic predictability of DOACs diminishes, competing risks of bleeding and death rise, and the quality of supporting evidence falls. The indication for anticoagulation, the choice of agent, and the dose should therefore be actively reassessed at each transition.

Randomized evidence dedicated to ESRD on hemodialysis is limited and largely underpowered. The VALKYRIE trial demonstrated a superior net clinical benefit for a reduced dose of rivaroxaban over VKAs, driven by fewer cardiovascular events and less major bleeding, without a difference in stroke [200, 201]. RENAL‐AF and AXADIA‐AFNET 8 compared apixaban with a VKA; both were curtailed by slow recruitment and established neither non‐inferiority nor superiority, though each consistently showed that ischemic events were far less frequent than major bleeding events [202, 203]. An observational analysis found that apixaban did not reduce stroke versus no anticoagulation but significantly increased fatal or intracranial bleeding, an effect driven by the standard 5 mg twice‐daily dose [204].

A recent systematic review and meta‐analysis of 23 studies enrolling more than 465 000 patients across the spectrum of CKD reported that DOACs were associated with significantly less major bleeding (RR 0.63, 95% CI 0.50–0.79) and lower all‐cause mortality (RR 0.63, 95% CI 0.44–0.92) than VKAs, with a non‐significant trend toward fewer thromboembolic events (RR 0.69, 95% CI 0.43–1.11); however, patients with advanced CKD and those on dialysis were underrepresented, so these findings should be extrapolated to ESRD with caution [199].

In a further systematic review and meta‐analysis confined to DOACs, the oral FXa inhibitors were associated with a reduced risk of major bleeding compared with VKAs (RR 0.64, 95% CI 0.42–0.99; p = 0.04), but no significant difference in systemic embolism (RR 0.46, 95% CI 0.20–1.02; p = 0.06) [205]. The FXa inhibitors were associated with lower risk of intracranial bleeding (RR 0.40, 95% CI 0.17–0.96; p = 0.04), but no differences in other outcomes, including mortality. These findings were similar to those of another meta‐analysis [206].

When anticoagulation is chosen, a reduced‐dose DOAC (apixaban 2.5 mg twice daily or rivaroxaban 10 mg once daily) is therefore preferred over a VKA, which is further undermined by low TTR and associations with hemorrhagic stroke and calciphylaxis [207, 208]. The more fundamental question of whether anticoagulation confers any net benefit over no treatment in dialysis remains unresolved and is being addressed by two ongoing randomized trials: DANWARD (NCT03862859), which compares warfarin (target international normalized ratio [INR] 2.0–3.0) with no oral anticoagulation, and SACK (NCT05679024), which compares reduced‐dose apixaban (2.5 mg twice daily) with no oral anticoagulation [209].

Much of the observational evidence derives from large Asian national registries. In a Taiwanese National Health Insurance cohort with an accompanying meta‐analysis, DOACs and warfarin had comparable rates of ischemic stroke/systemic embolism and major bleeding, and, notably, OAC was not associated with a lower risk of stroke/systemic embolism than no anticoagulation [210]. Korean National Health Insurance analyses have been more favorable to DOACs: in OAC‐naïve dialysis patients, DOACs were associated with a markedly lower ischemic stroke risk than warfarin, with comparable bleeding [211]. In patients with CKD including ESRD, DOACs were associated with lower all‐cause mortality and less intracranial and GI bleeding [212]. These Asian data are consistent with the wider literature in favoring DOACs over warfarin on safety while leaving the benefit of anticoagulation itself unproven.

Because the benefit of anticoagulation in ESRD is inconsistent and anticoagulation is often contraindicated, LAAO is a strategy to reduce cardioembolic risk without imposing a chronic bleeding burden. In the multicenter OCEAN‐LAAC registry, device‐implantation success in hemodialysis patients (97.1%) was comparable to that in non‐hemodialysis patients (97.3%), with no in‐hospital deaths and comparable periprocedural complication rates [166]. Importantly, the post‐LAAO ischemic stroke rate in hemodialysis patients was 1.1 per 100 patient‐years, comparable to the 2.6 per 100 patient‐years in non‐hemodialysis patients and markedly lower than historical stroke rates in dialysis AF cohorts not receiving effective therapy [166]. A large US Renal Data System analysis similarly found LAAO associated with lower recurrent bleeding and death than OACs in dialysis patients with AF [213]. Collectively, the effectiveness signal for stroke prevention with LAAO in ESRD is at least comparable to that observed in patients with preserved renal function.

A key uncertainty is the optimal antithrombotic regimen after device implantation in ESRD. Conventional post‐LAAO protocols, which require short‐term OAC followed by dual and then single antiplatelet therapy, were derived from trials that excluded advanced kidney disease, and there is at present no definitive evidence favoring continued antiplatelet therapy over long‐term anticoagulation (warfarin or a DOAC) in this setting [166, 213]. Registry experience suggests that most hemodialysis patients can successfully discontinue anticoagulation, with only approximately 5% remaining on an OAC at 1 year and no apparent excess of bleeding or embolic events, supporting an abbreviated, individualized regimen that favors the least intense effective therapy given the high bleeding risk of this population [166].

Recommendation Box 11. Recommendations for Anticoagulation and LAAO in ESRD.

Recommendation Class Level
Vitamin K antagonists are not recommended in ESRD, given low TTR and increased hemorrhagic and vascular risk without a demonstrated stroke‐prevention benefit [214, 215, 216]. III B
When oral anticoagulation is pursued, a reduced‐dose DOAC (apixaban 2.5 mg twice daily or rivaroxaban 10 mg once daily) should be considered over a vitamin K antagonist in ESRD patients on hemodialysis [200, 202, 203, 205, 206]. IIa B
LAAO may be considered in AF patients with ESRD on dialysis, particularly when anticoagulation is contraindicated or poorly tolerated [166, 213]. IIb B
There is no definitive evidence to recommend a specific antithrombotic regimen after LAAO in ESRD; the choice among short‐term antiplatelet therapy, dual antiplatelet therapy, or continued anticoagulation should be individualized. IIa C

Abbreviations: AF, atrial fibrillation; DOAC, direct oral anticoagulant; ESRD, end‐stage renal disease; LAAO, left atrial appendage occlusion; TTR, time in therapeutic range.

15. Elderly

Elderly patients with AF are at high risk of both thromboembolism and bleeding, not only in the absence of OAC therapy [217, 218, 219] but also during OAC treatment [220]. Both risks increase further with advancing age [217, 218, 219, 220]. In aging societies, the prevalence of AF will continue to increase, particularly in elderly and very elderly populations [221, 222], indicating an increase in the number of high‐risk patients with AF.

15.1. Influence of Age on the Effectiveness of OACs

Phase 3 randomized DOAC studies demonstrated that in elderly patients aged ≥ 75 years, the efficacy of DOACs in stroke prevention is comparable to that of warfarin (for rivaroxaban and edoxaban) or superior to warfarin (for dabigatran 150 mg twice daily and apixaban) [129, 130, 131, 198]. For the efficacy of individual DOACs versus warfarin across different age strata (< 75, 75–79, 80–84, and ≥ 85 years), a post hoc analysis demonstrated no significant treatment‐by‐age interaction [219]. Similarly, among Asian patients with AF in the COMBINE AF study, the efficacy, safety, and net clinical benefit of DOACs compared with warfarin were consistent across patients aged < 75 and ≥ 75 years [1]. In a nationwide real‐world study from Taiwan, the superior safety profile of DOACs compared with warfarin was consistently observed across all age groups and was most pronounced among the very elderly (≥ 90 years) [220].

15.2. Influence of Age on the Safety of OACs

As outlined above, aging affects the pharmacokinetics of DOACs [128] and is associated with increased DOAC concentrations, particularly in very elderly patients. Aging also affects pharmacodynamics, which may enhance the effect of DOACs [223, 224]. Along with age‐related physiological changes such as renal impairment, low body weight, frailty, and cognitive impairment as well as comorbidities and polypharmacy, the risk of major bleeding increases with age [129, 130, 131, 198]. Elderly patients commonly represent the “clinical complexity phenotype,” which requires a multidimensional holistic or integrated care management approach [225]. The latter has been shown in the subgroup analyses of elderly subjects from two prospective cluster RCTs from Asia (mAFA, MIRACLE‐AF) to be associated with improved clinical outcomes compared with usual care [226, 227].

Furthermore, elderly patients often have a history of bleeding, which is associated with an increased risk of bleeding during OAC therapy. In the ARISTOTLE trial, patients with AF and a history of bleeding had a higher risk of major bleeding than those without a bleeding history (adjusted HR 1.35) [228]. The Japanese J‐ELD AF Registry showed that a history of bleeding was an independent predictor of bleeding requiring hospitalization (HR 3.81) in elderly patients treated with on‐label doses of apixaban [229]. A sub‐analysis of the Japanese ANAFIE Registry of patients with AF aged ≥ 80 years reported that major bleeding was more frequent in patients with a history of major bleeding than in those without such a history (HR 1.62) [230].

15.3. DOAC Versus Warfarin in Elderly Patients

Landmark DOAC trials demonstrated that in patients aged ≥ 75 years, dabigatran 150 mg twice daily showed a trend toward a higher risk of major bleeding compared with warfarin, whereas dabigatran 110 mg twice daily showed a similar bleeding risk [129]. Rivaroxaban, compared with warfarin, showed a numerically higher risk of major bleeding in patients aged ≥ 75 years [130]. In contrast, apixaban [131] and standard‐dose edoxaban (60 mg and 30 mg for patients with dose reduction criteria) [132, 198] were associated with significantly lower risks of major bleeding than warfarin in this age group. A post hoc analysis of these four phase 3 randomized trials demonstrated a significant interaction with age for the safety of dabigatran and rivaroxaban, whereas no significant interaction with age was observed for apixaban and edoxaban compared with warfarin [219].

In very elderly patients, edoxaban and apixaban are better tolerated and associated with improved outcomes compared with warfarin [231]. However, even with DOAC use, the risk of bleeding increases with age, particularly in very elderly patients.

15.4. DOAC Therapy in Very Elderly, High‐Bleeding‐Risk Patients

Four DOAC trials included only a small proportion of patients aged ≥ 85 years (4% in RE‐LY [232], ARISTOTLE, and ENGAGE AF‐TIMI 48 [132], and 5% in ROCKET AF [130]). Furthermore, patients with severe renal impairment (CrCl < 30 mL/min in RE‐LY [124], ROCKET AF [197], and ENGAGE AF‐TIMI 48 [198], and < 25 mL/min in ARISTOTLE [196]), as well as those with a previous history of major bleeding or GI bleeding, were excluded from these trials.

Thus, evidence regarding the efficacy and safety of DOACs in very elderly patients with AF at high risk of bleeding remains limited. In an analysis from the Taiwan registries, DOACs (whether reduced or full dose) were associated with a lower risk of ischemic stroke, mortality, and the composite endpoint, when compared with no anticoagulation in high‐risk elderly AF patients at increased bleeding risk [233]. Furthermore, in the “very elderly” patients (aged ≥ 90 years) who were perceived to be at high risk of bleeding, for example, those with a history of ICH, GI bleeding, or CKD, the use of warfarin was associated with a similar or even higher risk of composite clinical outcomes compared with no anticoagulation [234]. In contrast, DOACs were associated with a lower risk of the composite endpoint.

The ELDERCARE‐AF trial evaluated the efficacy and safety of very‐low‐dose edoxaban (15 mg once daily) in very elderly Japanese patients (aged ≥ 80 years) with AF and high bleeding risk who were considered unsuitable for standard‐dose OAC therapy and had at least one bleeding risk factor, including CrCl 15–30 mL/min, body weight ≤ 45 kg, a history of bleeding from critical organs, or concomitant use of nonsteroidal anti‐inflammatory drugs (NSAIDs) or antiplatelet therapy [108]. Very‐low‐dose edoxaban reduced the risk of stroke/systemic embolism compared with placebo (HR 0.34), with a non‐significant increase in major bleeding (HR 1.87, p = 0.09). There were no cases of fatal bleeding and no increase in ICH with edoxaban; however, GI bleeding was substantially increased (HR 2.85). Thus, very‐low‐dose edoxaban may be an option for the treatment of very elderly patients at high risk of bleeding. The beneficial effect was consistent across subgroups stratified by age [235], frailty status [236], body weight [237], and renal function [238]. However, the risk of major bleeding was notably increased in patients aged ≥ 90 years and in those with CrCl of 15–29 mL/min, suggesting that caution is warranted in these populations [235, 238].

Recommendation Box 12. Recommendations for Oral Anticoagulants in Elderly Patients With AF.

Recommendation Class Level
Apixaban and edoxaban may be preferable for stroke prevention in patients with AF aged ≥ 75 years [129, 130, 131, 132, 231]. IIb B
Edoxaban 15 mg once daily should be considered as an anticoagulant option for very elderly patients (aged ≥ 80 years) who are considered unsuitable for standard‐dose anticoagulant therapy because of low creatinine clearance (15–30 mL/min), low body weight (≤ 45 kg), or a history of bleeding in a critical area or organ [108]. IIa B

Abbreviation: AF, atrial fibrillation.

16. Trigger‐Related Atrial Fibrillation

16.1. Definition of Trigger‐Related AF

Trigger‐related AF refers to AF occurring in close temporal association with an acute, potentially reversible condition such as critical illness (including sepsis), surgery, or endocrine disorders (notably hyperthyroidism) [239]. This entity has also been termed “secondary AF” or “acute AF,” but such episodes may represent the first manifestation of an underlying AF substrate rather than a purely transient phenomenon [239].

Depending on the “trigger,” it may reflect the individual's predisposition to AF; alternatively, the patient may have had asymptomatic episodes before the trigger that were documented only when the “triggered” episode presented. Evidence suggests that recurrence rates are substantial, and long‐term thromboembolic risk may persist beyond resolution of the trigger [240, 241].

16.2. Thromboembolic Risk of Trigger‐Related AF

Observational studies show that AF during infection or sepsis is associated with increased stroke risk both during hospitalization and after discharge [242, 243, 244]. Similarly, postoperative AF (POAF)—particularly after non‐cardiac surgery—is associated with a long‐term thromboembolic risk comparable to non‐triggered AF [245, 246]. However, this is not homogeneous, and there may be differences in AF burden after cardiac surgery that affect thromboembolic risk.

Importantly, registry data indicate that thromboembolic risk in secondary AF may approach that of primary AF when adjusted for CHA2DS2‐VASc risk factors [247]. Therefore, stroke risk assessment should not assume a benign course simply because the precipitating factor is reversible. In Asia‐Pacific populations, hyperthyroidism‐related AF has been associated with increased ischemic stroke risk, reinforcing the need for careful risk stratification [248].

16.3. Thromboembolic Risk of Acute Cardioversion

Acute cardioversion in triggered AF carries a risk of thromboembolism similar to that in other AF settings. Data from cardioversion cohorts demonstrate that thromboembolic events can occur even in AF of short duration (< 48 h), particularly in patients with risk factors [249]. Mechanistically, atrial stunning following cardioversion contributes to thrombus formation [250]. Accordingly, anticoagulation strategies around cardioversion should follow standard principles irrespective of the trigger, with periprocedural anticoagulation or TEE‐guided approaches when appropriate [54, 251].

16.4. Anticoagulation During the Acute Event

Management of anticoagulation in triggered AF requires balancing thromboembolic and bleeding risks, which may be dynamic in acute illness. In critically ill or septic patients, bleeding risk is often elevated due to coagulopathy, invasive procedures, or organ dysfunction [252]. Routine anticoagulation during sepsis‐associated AF does not consistently reduce stroke but increases bleeding risk [253].

In the perioperative setting, anticoagulation decisions should consider surgical bleeding risk and timing of hemostasis. Short‐term anticoagulation may be deferred in high bleeding risk situations, with reassessment once hemostasis is secured [54, 251].

In hyperthyroidism‐related AF, a prothrombotic state may exist acutely due to alterations in coagulation and fibrinolysis [254], supporting consideration of anticoagulation when stroke risk factors are present.

16.5. Consideration for Long‐Term Anticoagulation

Long‐term anticoagulation decisions should be guided primarily by stroke risk assessment (e.g., CHA2DS2‐VASc score), rather than the transient nature of the trigger alone [54, 251]. Patients with triggered AF frequently experience recurrence and remain at elevated thromboembolic risk [240, 255].

Guidelines recommend that if AF persists or recurs, or if stroke risk is elevated, long‐term OAC should be considered similarly to non‐triggered AF [54]. Even in patients with apparent resolution, follow‐up and rhythm monitoring are important to detect recurrence before discontinuing anticoagulation [256].

16.6. Issues Specific to Critical Care and Sepsis

AF in sepsis is common and associated with increased mortality and stroke risk [257, 258]. However, anticoagulation during the acute septic phase remains controversial due to high bleeding risk and lack of randomized evidence [259]. Current data support a cautious, individualized approach, with deferral of anticoagulation in unstable patients and reassessment after clinical stabilization [239]. Post‐discharge evaluation is essential, as long‐term stroke risk remains elevated [243].

16.7. Issues Specific to Surgery

POAF is frequent after both cardiac and non‐cardiac surgery. While often transient, POAF is associated with increased long‐term stroke risk [246]. Short‐term anticoagulation may be considered after surgery once bleeding risk is acceptable, particularly in patients with elevated CHA2DS2‐VASc scores [54].

Duration of anticoagulation remains uncertain; however, many experts support at least 4 weeks of anticoagulation for POAF episodes lasting > 24–48 h, with reassessment for long‐term therapy based on recurrence and stroke risk [54, 260].

16.8. Issues Specific to Hyperthyroidism

Hyperthyroidism is a well‐recognized reversible trigger of AF; however, AF may persist even after restoration of euthyroidism, and recurrence is common [261]. Importantly, hyperthyroidism‐related AF is associated with increased thromboembolic risk in the acute setting, particularly in older patients or those with comorbidities [248, 262].

After achieving euthyroid status, anticoagulation decisions should follow standard stroke risk stratification rather than thyroid status alone. Temporary anticoagulation during the thyrotoxic phase is often appropriate in high‐risk patients, with reassessment after achieving euthyroidism.

16.9. Issues Specific to the Asia‐Pacific Region

In the Asia‐Pacific region, several factors influence management of triggered AF. First, higher rates of ICH in Asian populations necessitate careful balancing of bleeding and thromboembolic risks when initiating OAC [54]. Second, conditions such as untreated hyperthyroidism and infection‐related AF may be more prevalent in certain regions, increasing the burden of triggered AF [248].

Access to DOACs, variability in healthcare systems, and differences in perioperative practices also influence treatment decisions. Regional data support the use of DOACs for stroke prevention in eligible patients, given their favorable safety profile compared with warfarin, particularly in Asian populations [1].

Overall, trigger‐related AF should not be considered benign. Stroke prevention strategies should be individualized, incorporating dynamic risk assessment, careful timing of anticoagulation, and region‐specific considerations (Figure 17).

FIGURE 17.

FIGURE 17

Integrated algorithm for stroke prevention in trigger‐related AF. AF, atrial fibrillation; APHRS, Asia Pacific Heart Rhythm Society; DOAC, direct oral anticoagulant; OAC, oral anticoagulant; TEE, transesophageal echocardiography.

Recommendation Box 13. Recommendations for Stroke Prevention and Anticoagulation in Trigger‐Related AF.

Recommendation Class Level
In patients with trigger‐related AF, stroke risk assessment using CHA2DS2‐VASc score is recommended, irrespective of the transient or reversible nature of the trigger. I C
Long‐term OAC should be considered in patients with trigger‐related AF and elevated CHA2DS2‐VASc score, similar to non‐triggered AF. IIa C
Reassessment for initiation or continuation of OAC after resolution of the acute trigger is recommended before hospital discharge or early follow‐up. I C
Peri‐cardioversion anticoagulation (or TEE‐guided strategy) is recommended in trigger‐related AF according to standard AF protocols, regardless of AF trigger. I C
Short‐term anticoagulation (≥ 4 weeks) should be considered in postoperative AF lasting > 24–48 h, once bleeding risk is acceptable. Long‐term anticoagulation decisions should be based on the CHA2DS2‐VASc score [246, 260]. IIa B
In hyperthyroidism‐related AF, anticoagulation should be considered in the acute setting; however, long‐term anticoagulation is based on CHA2DS2‐VASc score and not deferred solely due to reversible thyroid status [248, 262]. IIa B
In sepsis or critical illness with AF, initiation of anticoagulation should be individualized based on dynamic thromboembolic and bleeding risks. IIa C
Long‐term rhythm monitoring may be considered after triggered AF to detect recurrence, assess arrhythmia burden, and guide anticoagulation decisions [253, 256]. IIb B
In patients with high bleeding risk during acute illness (e.g., sepsis, early postoperative phase), temporary deferral of oral anticoagulation may be considered. IIb C
Discontinuation of anticoagulation solely based on apparent resolution of the trigger without reassessment of stroke risk and AF recurrence is not recommended [240, 241]. III B

Abbreviations: AF, atrial fibrillation; OAC, oral anticoagulant; TEE, transesophageal echocardiography.

17. AF Patients With Anemia

AF patients with concomitant anemia represent a substantial subgroup, in whom the balance between stroke prevention and bleeding risk is particularly delicate, as anemia affects approximately 13%–34% of individuals with non‐valvular AF, with a higher prevalence among elderly patients [263, 264]. The presence of anemia is an indicator of “high risk,” being an independent predictor of major bleeding, heart failure, and all‐cause mortality; however, it is not associated with an increased risk of ischemic stroke or systemic embolism [263, 265, 266, 267].

Anemia (or predisposition to anemia) is incorporated into several bleeding risk stratification scores and is recognized as a modifiable risk factor that requires active management across the disease continuum [251]. Clinicians are encouraged to treat the anemia itself rather than simply withhold anticoagulant therapy [251]. This necessitates a systematic evaluation of the underlying etiology, as addressing and correcting reversible causes prior to or concurrently with OAC initiation is crucial, as unexplained or progressive anemia may reveal an occult bleeding source that could be aggravated by anticoagulation [251, 263].

Observational studies and pooled data showed the superiority of DOACs over VKAs owing to their more favorable bleeding profile, with emerging comparative evidence suggesting that certain DOACs, such as apixaban, are often preferred when bleeding concern predominates [265, 268]. Continuous monitoring is essential, including periodic reassessment of hemoglobin, renal function, and concurrent medications, especially antiplatelet agents and NSAIDs. In cases of severe anemia that is rapidly worsening or accompanied by overt hemorrhage, a multidisciplinary assessment, transfusion support, and temporary interruption of anticoagulation followed by timely reinitiation may be required [251].

18. AF Patients With Thrombocytopenia

AF patients with concurrent thrombocytopenia present a clinical challenge requiring a delicate balance between thromboembolism prevention and the reduction of severe bleeding risks, especially in frail or elderly populations [114, 269, 270, 271]. Some of the major trials excluded patients with platelet counts < 100 × 103/μL, although clinicians still initiate DOACs in those whose platelet counts are 50–100 × 103/μL (e.g., idiopathic thrombocytopenia) with careful follow‐up and monitoring. The administration of OAC in patients with platelet counts < 100 × 103/μL requires an individualized, multidisciplinary team approach with collaborative decision‐making and continuous reassessment [114, 270].

Although thrombocytopenia is a recognized bleeding risk factor, conditions such as immune thrombocytopenia or active malignancy may paradoxically increase thrombotic risk due to hyperactive platelets and procoagulant microparticles, indicating that a low platelet count does not inherently protect against stroke or systemic embolism [272, 273]. Because patients with platelet counts < 100 × 103/μL were largely excluded from pivotal DOAC trials, therapeutic strategies currently rely heavily on expert consensus and observational data [267, 274]. As a general consideration, regular DOAC dosage according to the dose‐reduction criteria for each agent is recommended for patients with platelet counts > 50 × 103/μL, provided other modifiable bleeding risk factors are optimized [114]. For patients with moderate thrombocytopenia (20–50 × 103/μL), a dose‐reduced DOAC regimen may be considered cautiously, particularly in those with an exceptionally high thrombotic risk, though rigorous clinical monitoring is mandatory [114]. Conversely, severe thrombocytopenia (platelet count < 20 × 103/μL) is generally regarded as an absolute contraindication to OAC therapy, except in cases of life‐threatening thrombosis, which may necessitate non‐pharmacological alternatives such as mechanical LAAO [114].

Beyond static thresholds, clinicians must continually evaluate platelet kinetics; a rapidly falling platelet count or signs of consumptive coagulopathy requires urgent therapy reassessment [275]. In select high‐risk scenarios with profound thrombocytopenia, temporary bridging strategies utilizing platelet transfusions, intravenous immunoglobulins, or thrombopoietin‐receptor agonists might be necessary to establish safe therapeutic windows for anticoagulation management [275].

19. Oral Anticoagulant Use for Intracardiac Thrombus

In patients with AF, a left atrial (LA) or LAA thrombus identifies a subgroup at high risk of ischemic stroke and systemic embolism, and its detection contraindicates cardioversion and catheter ablation until it resolves. Where there is associated heart failure or left ventricular (LV) dysfunction, LV thrombus may also be present, and the investigation and management of such patients has been reviewed [276, 277].

Thrombus is common in the absence of anticoagulation and, although markedly reduced by guideline‐directed OAC, it is not abolished. In a systematic review and meta‐analysis of 35 studies enrolling 14 653 anticoagulated patients, the mean‐weighted LA thrombus prevalence after at least 3 weeks of continuous therapeutic anticoagulation was approximately 2.7%, similar for VKAs and DOACs (2.8% vs. 3.1%) [278]. A pooled analysis of 56 660 patients undergoing TEE reported a residual thrombus prevalence, among adequately anticoagulated patients, of approximately 1.3%–1.8% before catheter ablation and 4.9%–5.5% before cardioversion, with lower rates on DOACs than VKAs (1.3% vs. 2.0% before ablation; 3.5% vs. 7.6% before cardioversion) [279].

Both analyses converge on the same higher‐risk phenotype: non‐paroxysmal AF, cardioversion rather than ablation, prior stroke, hypertension, heart failure, and an elevated thromboembolic risk score (CHADS2 ≥ 2 or CHA2DS2‐VASc ≥ 3), in whom prevalence rose several‐fold (e.g., 6.3% for CHA2DS2‐VASc ≥ 3 vs. 1.1% for ≤ 2) [278, 279]. These data support selective pre‐procedural imaging in higher‐risk patients rather than reflexive imaging in all.

Thrombus that persists despite apparently adequate anticoagulation should first prompt a systematic search for a remediable cause. In a multicenter study of 414 patients receiving DOACs, LAA thrombus was detected in 3.6% despite at least 3 weeks of guideline‐dose DOAC use, with no difference between agents; a CHA2DS2‐VASc score > 3 predicted thrombus, and every affected patient cleared the thrombus after being switched to warfarin (target INR 2.5–3.5) for 4–8 weeks [280].

In a single‐center cohort of 352 DOAC‐treated patients, LA/LAA thrombus was found in 7.7%, with a CHA2DS2‐VASc score > 3 (odds ratio [OR] 4.54) and obesity (OR 6.01) as independent predictors, alongside heart failure, diabetes, and prior stroke/TIA on univariable analysis, and again every thrombus resolved after 1 month of a VKA titrated to an INR of 2–3 [281]. Hence, much “resistant” thrombus reflects subtherapeutic exposure rather than true treatment failure: for example, fixed‐dose DOAC may be inadequate in selected patients (e.g., obesity, extremes of body weight, or renal dysfunction), while inappropriately reduced dosing, poor adherence, and clinically relevant drug–drug interactions all attenuate anticoagulant efficacy. Confirming true drug exposure and correcting underdosing or non‐adherence, rather than assuming failure, is therefore the essential first step [280, 281].

When anticoagulation has been verified as adequate and thrombus persists, a European Heart Rhythm Association (EHRA) survey found that most centers would switch a VKA‐treated patient to a DOAC, intensify the VKA to a higher target INR of 2.5–3.5, or switch a DOAC‐treated patient to a VKA or to an alternative DOAC, with repeat imaging generally arranged within 3–6 weeks [282]. A minority of centers would instead transition selected patients to low‐molecular‐weight heparin, and the timing of repeat imaging after any change remains heterogeneous, with most re‐imaging at 3–6 weeks and a small proportion deferring beyond 2 months [282].

Hence, management be individualized, that adherence be reassessed, and that a switch to an anticoagulant with a different mechanism be considered [114]. Adding an antiplatelet agent to anticoagulation has not been shown to improve thrombus resolution and is not supported outside a separate antiplatelet indication such as coronary artery disease [283].

Observational data suggest that DOACs are at least as effective as VKAs for thrombus resolution and may act more rapidly [284]. In a single‐center registry, thrombus resolution occurred in roughly half of patients over one year with no significant difference in efficacy between DOACs and VKAs, but a significantly shorter mean time to resolution with DOACs [285].

Prospective data for a DOAC are provided by the X‐TRA study and its companion CLOT‐AF registry. In X‐TRA, a prospective, single‐arm, open‐label, multicenter study, 6 weeks of rivaroxaban in patients with non‐valvular AF or atrial flutter and a TEE‐confirmed LA/LAA thrombus, most of whom were anticoagulant‐naïve or had received suboptimal VKA therapy, achieved complete thrombus resolution, centrally adjudicated by blinded expert review of TEE or cardiovascular magnetic resonance imaging, in 41.5% and resolved or reduced thrombus in 60.4%, with no stroke, systemic embolism, or major bleeding during treatment or the 30‐day follow‐up. In the companion retrospective CLOT‐AF registry, in which standard‐of‐care anticoagulation was predominantly a VKA, the reported thrombus resolution rate over 3–12 weeks was 62.5% [286].

These findings extend to East Asian populations. A Chinese systematic review and meta‐analysis of 982 patients found a higher thrombus resolution rate with DOACs than VKAs (78.0% vs. 63.5%; OR 2.32), most marked for rivaroxaban and without excess embolism or bleeding [287]. Also, a Japanese multicenter study of 260 patients with confirmed LA thrombus reported higher resolution with DOACs than warfarin (74% vs. 54%), highest with standard‐dose DOACs and lowest when the warfarin TTR was under 60% (49%), with DOAC use independently associated with both greater resolution (OR 2.91) and fewer bleeding events (OR 0.26) [288]. Case series and small prospective studies indicate that dabigatran, the only DOAC that is a direct thrombin inhibitor, can dissolve thrombus resistant to FXa inhibitors, and that twice‐daily rivaroxaban (15 mg) may resolve thrombus when standard once‐daily therapy fails [289, 290, 291]. In a multicenter prospective study conducted in South Korea, 36 patients with AF and LAA thrombus received 6 weeks of edoxaban therapy. Complete thrombus resolution was achieved in 66.7% of patients, while thrombus size was reduced in an additional 16.7% [292].

For thrombus that persists despite an adequate and appropriately switched anticoagulant regimen, or where anticoagulation is contraindicated or poorly tolerated, percutaneous LAAO may be considered. The feasibility of LAAO in patients with LAA thrombus, including distally situated thrombus, although device selection and technique must account for the risk of thrombus dislodgement during implantation [293].

Overall, the choice of agent, dose, and duration of anticoagulation for LA/LAA thrombus remains supported mainly by observational data and expert consensus; management should be individualized on the basis of each patient's thrombotic and bleeding risk, and adequately powered randomized trials are needed to define the optimal agent, dose, and duration [114, 284].

Recommendation Box 14. Recommendations for Left Atrial/Left Atrial Appendage Thrombus in AF.

Recommendation Class Level
Selective pre‐procedural TEE to exclude LA/LAA thrombus should be considered in anticoagulated AF patients with higher thromboembolic risk (non‐paroxysmal AF, high CHA2DS2‐VASc score) before cardioversion or catheter ablation [278, 279]. IIa B
When LA/LAA thrombus is detected despite oral anticoagulation, it is recommended that adherence, dosing, and drug–drug interactions should be reassessed and any subtherapeutic or underdosed regimen corrected before declaring treatment failure. I C
In patients with persistent LA/LAA thrombus despite verified adequate anticoagulation, switching to an anticoagulant with a different mechanism of action (e.g., DOAC to VKA, VKA to DOAC, or between DOAC classes) with repeat imaging in 3–6 weeks may be considered. IIb C
A DOAC should be considered as a reasonable alternative to a vitamin K antagonist for LA/LAA thrombus resolution, as observational data showed at least comparable efficacy and a shorter time to resolution without excess bleeding [285, 286, 287, 288, 292]. IIa B
Adding an antiplatelet agent to anticoagulation solely to promote thrombus resolution is not recommended in the absence of a separate antiplatelet indication. III C
Percutaneous LAAO may be considered for thrombus that persists despite adequate, appropriately switched anticoagulation, or when anticoagulation is contraindicated or poorly tolerated; both deferred closure after intensified antithrombotic therapy and direct closure are feasible, with individualized selection by bleeding and thrombotic risk, attention to thrombus location and device technique, and post‐procedural surveillance for device‐related thrombosis. IIb C

Abbreviations: AF, atrial fibrillation; DOAC, direct oral anticoagulant; LA, left atrial; LAA, left atrial appendage; LAAO, left atrial appendage occlusion; TEE, transesophageal echocardiography; VKA, vitamin K antagonist.

20. Long‐Term OAC After AF Ablation

Following catheter ablation for AF, continuous OAC for 2–3 months is standard of care to mitigate periprocedural thromboembolic risk, regardless of the patient's baseline risk profile [294]. Beyond this initial blanking period, the decision to maintain long‐term OAC should be guided strictly by the patient's intrinsic thromboembolic risk (e.g., CHA2DS2‐VASc score), rather than the perceived rhythm success of the ablation procedure [54, 251, 294]. This conservative recommendation stems from a lack of definitive randomized trial data proving that successful ablation entirely abolishes the risk of stroke.

While the reduction of AF burden is generally associated with a lower stroke risk, observational data regarding OAC discontinuation remain mixed [295, 296, 297, 298, 299]; notably, large‐scale real‐world registries have demonstrated that withdrawing OAC therapy in high‐risk individuals (CHA2DS2‐VASc ≥ 2) after 3 months significantly increases the risk of stroke compared with continuous therapy [300].

Despite these recommendations, the paradigm of mandatory lifetime anticoagulation is increasingly being challenged by recent trials evaluating the safety of OAC discontinuation in patients demonstrating durable sinus rhythm post‐ablation. The OCEAN trial (Optimal Anticoagulation for Enhanced Risk Patients Post‐Catheter Ablation for Atrial Fibrillation) randomized patients who were free from AF for at least 1 year after ablation and had risk factors for stroke (mean CHA2DS2‐VASc score of 2.2) to receive rivaroxaban (at a dose of 15 mg) or aspirin [301]. The thromboembolic event rate was numerically lower with rivaroxaban than with aspirin (0.31%/year vs. 0.66%/year), although major bleeding was more frequent with rivaroxaban.

Similarly, findings from the ALONE‐AF trial (Anticoagulation 1 year after Ablation of Atrial Fibrillation in Patients with Atrial Fibrillation) provided further evidence regarding OAC cessation [302]. In this trial, which also included patients with at least 1 non–sex‐related stroke risk factor (mean CHA2DS2‐VASc score of 2.1) and no documented recurrence of atrial arrhythmia for at least 1 year after catheter ablation for AF, discontinuation of OAC (with 91.4% receiving no antithrombotic therapy) was associated with a lower risk of the composite outcome of stroke, systemic embolism, and major bleeding compared with continued therapy. This benefit was primarily driven by a reduction in major bleeding, while the incidence of stroke remained reassuringly low after OAC discontinuation (0.3% at 2 years).

In a systematic review including 32 studies comprising 271 808 patients, discontinuation of OACs after AF ablation did not significantly affect the overall incidence of thromboembolism but was associated with a significant reduction in major bleeding events. However, among patients with a CHA2DS2‐VASc score > 2, OAC discontinuation was associated with a significantly increased risk of thromboembolism [303].

Hence, withholding OAC may be a reasonable, highly individualized strategy (especially in those at low stroke risk, e.g., CHA2DS2‐VASc score 0–2) rather than an absolute contraindication, particularly for patients who experience bleeding complications or strongly prefer to stop anticoagulation. However, the safety of such an approach hinges entirely on the absence of subclinical or asymptomatic AF, and catheter ablation has been shown to increase the likelihood of asymptomatic paroxysmal AF in patients who were previously symptomatic [304]. Therefore, discontinuing long‐term OAC in at‐risk patients should only be considered if comprehensive and continuous rhythm surveillance is established. Under a shared decision‐making framework, if rigorous rhythm monitoring confirms a sustained absence of AF, clinicians and patients may cautiously consider OAC discontinuation, but anticoagulation must be rapidly reinitiated upon the detection of any AF recurrence.

Recommendation Box 15. Recommendations for Long‐Term Anticoagulation After AF Ablation.

Recommendation Class Level
Long‐term oral anticoagulation following AF ablation should be determined by the patient's stroke risk profile (CHA2DS2‐VASc score). I C
Discontinuation of long‐term oral anticoagulation after AF ablation may be considered in selected patients when the estimated stroke risk is low (e.g., CHA2DS2‐VASc 0–2), provided that comprehensive rhythm surveillance is ensured and decisions are made through shared decision‐making to reduce bleeding risk [301, 302, 303, 305]. IIb A

Abbreviation: AF, atrial fibrillation.

21. Acute Coronary Syndrome (ACS) and Coronary Artery Disease (CAD)

AF complicates between 2% and 23% of ACS presentations [306]. The interplay between CAD and AF is mutually amplifying. An ACS event increases the likelihood of incident AF by approximately 60%–77%, an effect largely mediated by acute ischemic injury, atrial wall stress, and sympathetic overdrive [307]. Conversely, established AF acts as a frequent trigger for both ST‐segment elevation myocardial infarction (STEMI) and non‐ST‐segment elevation myocardial infarction (NSTEMI) [308]. In the broader AF population, roughly 10%–15% of patients will require percutaneous coronary intervention (PCI) to manage comorbid CAD [309].

Clinically, there is a need to balance stroke prevention (requiring OAC), prevention of stent thrombosis (needing antiplatelets), recurrent cardiac ischemia in an ACS setting (again, needing antiplatelets), and the risk of bleeding with the combination of OAC and antiplatelets.

Observational data reveal a concerning trend: owing to a fear of hemorrhagic complications, clinicians often under‐prescribe optimal antithrombotic regimens in AF patients presenting with ACS [310]. This deviation from evidence‐based care directly translates to an inferior prognosis, characterized by a heightened incidence of stroke, recurrent infarction, heart failure hospitalizations, and overall mortality compared with their non‐AF counterparts [311].

Managing AF in patients undergoing PCI for ACS or chronic CAD requires carefully weighing the risk of stent thrombosis against clinically significant bleeding (Figure 18). Multiple RCTs (PIONEER AF‐PCI, RE‐DUAL PCI, AUGUSTUS, ENTRUST‐AF PCI) have consistently shown that DOACs combined with antiplatelet therapy reduce major bleeding by approximately 42% compared with VKA‐based regimens, without increasing ischemic events [312, 313, 314, 315, 316]. Furthermore, dual antithrombotic therapy (DAT: OAC plus a single P2Y12 inhibitor) significantly lowers major bleeding risk by approximately 40% compared with triple antithrombotic therapy (TAT: OAC plus aspirin and a P2Y12 inhibitor) without a substantial increase in ischemic events [312, 313, 314, 316, 317]. When selecting an antiplatelet agent, clopidogrel is the preferred P2Y12 inhibitor, as ticagrelor and prasugrel are associated with higher bleeding risks [312, 313, 314, 315, 317, 318].

FIGURE 18.

FIGURE 18

Antithrombotic therapy in patients with AF and acute coronary syndrome or stable coronary artery disease. ACS, acute coronary syndrome; AF, atrial fibrillation; CAD, coronary artery disease; OAC, oral anticoagulant; P2Y12i, P2Y12‐receptor inhibitor antiplatelet agent (clopidogrel, prasugrel, ticagrelor); PCI, percutaneous coronary intervention. aIn patients with diabetes mellitus undergoing coronary stent implantation, prolonging triple antithrombotic therapy for up to 3 months may be of value if thrombotic risk outweighs the bleeding risk.

In the majority of cases following an ACS or PCI, a brief course of TAT (up to 7 days) preceding DAT—comprising a DOAC and a single P2Y12 inhibitor, preferably clopidogrel—serves as the standard of care. Meta‐analyses demonstrate that while DAT carries a modestly elevated risk of stent thrombosis relative to TAT, this is offset by a marked decline in clinically relevant and major bleeding events [316, 318, 319, 320, 321]. Specifically, the number needed to treat to avert one major bleeding episode is only 42, whereas the number needed to harm for stent thrombosis is considerably higher at 223 [316]. Consequently, extending TAT for up to 30 days is justifiable only in individuals carrying a heightened perceived risk of stent thrombosis (e.g., those presenting with STEMI, multi‐vessel interventions, complex coronary anatomy, or a documented history of stent thrombosis). For patients with diabetes receiving stents, a prolonged TAT phase of up to 1–3 months might be warranted, provided the ischemic threat clearly exceeds hemorrhagic concerns. In the context of medically managed ACS without revascularization, a DAT regimen for 6 to 12 months is generally adequate [322].

For patients who reach the chronic stable phase of CAD (typically ≥ 12 months after revascularization, or stable CAD not requiring intervention), discontinuing antiplatelet agents and maintaining DOAC monotherapy is recommended.

This monotherapy approach is bolstered by robust evidence from meta‐analyses of six clinical trials [323, 324] that included three contemporary Asia‐Pacific landmark trials—namely AFIRE, EPIC‐CAD, and ADAPT AF‐DES [325, 326, 327]. These studies indicate that DOAC monotherapy offers superior safety (a marked reduction in major bleeding) and non‐inferior efficacy regarding composite ischemic endpoints (including stroke, systemic embolism, myocardial infarction, and all‐cause mortality) when matched against combination therapy (DOAC plus predominantly low‐dose aspirin in the AFIRE and EPIC‐CAD trials, and DOAC plus clopidogrel in the ADAPT AF‐DES trial). Although the trials reached a common conclusion, their enrollment criteria varied slightly: the AFIRE trial included patients ≥ 1 year post‐intervention (PCI or coronary artery bypass grafting) or with stable CAD managed medically; the EPIC‐CAD trial targeted a higher‐risk population by initiating monotherapy earlier (≥ 6 months post‐revascularization for stable CAD or ≥ 12 months for ACS); and the ADAPT AF‐DES trial specifically enrolled patients ≥ 12 months after receiving drug‐eluting stents (Table 11) [325, 326, 327].

TABLE 11.

Detailed comparison of landmark trials on DOAC monotherapy in Asian patients with AF and stable CAD.

AFIRE (2019) [325] EPIC‐CAD (2024) [326] ADAPT AF‐DES (2026) [327]
Number of patients 2236 1040 960
Type of patients ≥ 12 months post‐PCI or CABG; or medically managed angiographically confirmed CAD without intervention ≥ 6 months post‐revascularization for stable CAD; or ≥ 12 months post‐ACS ≥ 12 months after receiving PCI with drug‐eluting stents
Intervention therapy DOAC monotherapy (Rivaroxaban) DOAC monotherapy (Edoxaban) DOAC monotherapy (Apixaban 61%, Rivaroxaban 34%, and Edoxaban 4%)
Comparator therapy DOAC (Rivaroxaban) + Antiplatelet agent (Aspirin 70%, Clopidogrel 25%) DOAC (Edoxaban) + Antiplatelet agent (Aspirin 62%, Clopidogrel 38%) DOAC (Apixaban 63%, Rivaroxaban 33%, Edoxaban 5%) + Antiplatelet agent (Clopidogrel)
Primary endpoint
  • Efficacy endpoint (stroke, systemic embolism, MI, unstable angina, or death)

  • Safety end point: major bleeding.

  • Composite of death from any cause, MI, stroke, systemic embolism, unplanned urgent revascularization, and major or CRNMB at 12 months

  • Net adverse clinical events: composite of death, MI, stent thrombosis, stroke, systemic embolism, major bleeding, or CRNMB at 12 months

Results
  • Efficacy endpoint: DOAC monotherapy was noninferior to combination therapy (HR 0.72; 95% CI, 0.55–0.95)

  • Safety endpoint: the incidence of major bleeding was lower in the DOAC monotherapy group (HR 0.59; 95% CI, 0.39–0.89).

  • Primary endpoint: DOAC monotherapy is superior to combination therapy (HR 0.44; 95% CI, 0.30–0.65).

  • Major ischemic events: similar between groups (HR 1.23, 95% CI, 0.48–3.10).

  • Major bleeding or CRNMB: lower in the DOAC monotherapy group (HR 0.34; 95% CI, 0.22–0.53).

  • Primary endpoint: DOAC monotherapy is superior to combination therapy (HR 0.54; 95% CI, 0.37–0.77)

  • Composite of cardiovascular death, MI, stent thrombosis, stroke, or systemic embolism: similar between groups (HR 0.84, 95% CI, 0.43–1.63).

  • Major bleeding or CRNMB: lower in the DOAC monotherapy group (HR 0.38; 95% CI, 0.24–0.60).

Abbreviations: ACS, acute coronary syndrome; AF, atrial fibrillation; CABG, coronary artery bypass grafting; CAD, coronary artery disease; CRNMB, clinically relevant non‐major bleeding; DOAC, direct oral anticoagulant; HR, hazard ratio; MI, myocardial infarction; PCI, percutaneous coronary intervention.

Recommendation Box 16. Recommendations for Anticoagulation in Patients With Acute Coronary Syndrome or Coronary Artery Disease.

Recommendation Class Level
After uncomplicated PCI in patients with AF, early aspirin discontinuation (within 1 week) with continuation of dual therapy (DOAC plus a P2Y12 inhibitor) for up to 6 months (chronic CAD) or 12 months (ACS) is recommended to minimize major bleeding risk, especially when thrombotic risk is low or bleeding risk is high [312, 313, 314, 315, 316, 328, 329]. I A
Extension of triple therapy with aspirin, clopidogrel, and oral anticoagulation beyond 1 week (up to 1 month) should be considered when ischemic risk exceeds bleeding risk, with the overall duration determined by individualized risk assessment and clearly specified in the discharge treatment plan [328]. IIa B
In patients with AF and CAD more than 1 year after revascularization—or with CAD not requiring revascularization—and no prior history of stent thrombosis, oral anticoagulation alone is recommended over combined therapy with an antiplatelet agent to minimize the risk of major bleeding [325, 326, 327]. I A

Abbreviations: ACS, acute coronary syndrome; AF, atrial fibrillation; CAD, coronary artery disease; DOAC, direct oral anticoagulant; PCI, percutaneous coronary intervention.

22. Perioperative and Periprocedural Anticoagulation Management

22.1. General Principles and Risk Stratification

The primary objective during periprocedural management is to carefully navigate the competing risks of thromboembolism and surgical hemorrhage. This requires minimizing the duration of anticoagulant cessation while ensuring adequate restoration of hemostasis at the time of the intervention. Interventions are generally stratified into varying levels of hemorrhagic risk: low‐risk procedures include dental extractions, diagnostic endoscopies, minor ophthalmologic surgeries, and percutaneous vascular access; high‐risk surgeries encompass major orthopedic, intra‐abdominal, cardiac, and transvenous lead extraction procedures; and very high‐risk interventions involve neuraxial anesthesia or spinal/neurological surgeries. Furthermore, clinicians must evaluate individual patient factors that predispose to bleeding, such as hepatic or renal impairment, concomitant use of antiplatelet agents or NSAIDs, and a recent history of major bleeding. Reassuringly, the absolute risk of thromboembolism during brief periods of anticoagulation interruption remains very low, generally occurring in less than 1% of patients.

22.2. Management of Vitamin K Antagonists and the Role of Bridging

Historically, bridging therapy with low‐molecular‐weight heparin or unfractionated heparin was frequently employed during the temporary interruption of VKAs. However, contemporary evidence strongly discourages this practice for the vast majority of patients with AF.

The BRIDGE (Bridging Anticoagulation in Patients who Require Temporary Interruption of Warfarin Therapy for an Elective Invasive Procedure or Surgery) trial demonstrated that foregoing bridging therapy significantly reduced the incidence of major bleeding without compromising efficacy or increasing the risk of thromboembolic events [330]. Findings from the PERIOP‐2 trial were more neutral. In this randomized controlled study of patients with AF or mechanical heart valves undergoing temporary warfarin interruption, postoperative bridging with dalteparin did not significantly reduce major thromboembolism compared with placebo (1.0% vs. 1.2%) and was not associated with a significant difference in major bleeding (1.3% vs. 2.0%) [331]. Hence, routine postoperative bridging does not confer clear benefit in either ischemic or bleeding outcomes.

Consequently, bridging therapy should be strictly reserved for highly selected populations with an exceptionally high baseline thrombotic risk, such as those with a very recent thromboembolic event or those possessing specific mechanical heart valves, where individualized management is paramount. Because VKAs require several days to re‐establish a therapeutic effect, they can typically be safely restarted on the evening of the procedure.

22.3. Interruption and Resumption of DOACs

The management of DOACs in the perioperative setting is simplified by their predictable pharmacokinetics, rapid onset, and short half‐lives, which eliminates the need for bridging therapy. The precise timing for holding a DOAC should be tailored to the specific agent, the patient's CrCl, and the procedural bleeding risk (Table 12 and Figure 19) [332, 333]. A meta‐analysis of periprocedural outcomes from the pivotal trials of the four currently available DOACs demonstrated comparable efficacy between DOACs and warfarin, with a lower incidence of major bleeding observed with uninterrupted DOAC therapy [334]. Clinical protocols, such as the PAUSE strategy, have shown that withholding DOACs for one to two full days prior to the procedure successfully achieves minimal residual anticoagulant levels in the vast majority of patients, resulting in notably low rates of both major bleeding and thromboembolic complications [332].

TABLE 12.

Categorization of planned surgical procedures by bleeding risk.

Category Specific procedures and interventions
Minor Risk (Rare bleeding events with low clinical consequences)
  • Minor Dental Procedures: Extraction of 1–3 teeth, periodontal surgery, implant positioning, subgingival scaling/cleaning

  • Ophthalmic Procedures: Glaucoma and cataract surgeries

  • Diagnostic Endoscopy: Endoscopy without tissue biopsy or lesion removal

  • Superficial Surgery: Minor dermatological excisions, skin biopsies, and abscess drainage

  • Pacemaker or ICD implantation (except complex procedures)

  • Cardiac Electrophysiology: Electrophysiological study or catheter ablation (except complex procedures)

  • Vascular Interventions: Standard scheduled percutaneous coronary or peripheral interventions (excluding complex cases)

  • Intramuscular Injections: Including routine vaccinations

Low Risk (Infrequent bleeding, or bleeding with non‐severe clinical outcomes)
  • Advanced Dental Surgery: Complex or extensive dental procedures

  • Endoscopy with Biopsy: Endoscopic exams involving minor tissue sampling

  • Minor Orthopedic Operations: Arthroscopy, as well as surgeries involving the hands or feet

High Risk (Frequent bleeding events and/or significant clinical consequences)
  • Cardiac Surgery: Open‐heart and major cardiac operations

  • Vascular Reconstruction: Peripheral arterial bypass grafting and aortic aneurysm repair

  • Advanced Cardiovascular Interventions: Complex procedures such as epicardial VT ablation, lead extraction, and chronic total occlusion PCI

  • Neurosurgery: Brain and spinal cord operations

  • Regional Anesthesia & Punctures: Spinal/epidural anesthesia and diagnostic lumbar punctures

  • Advanced Therapeutic Endoscopy: ERCP with sphincterotomy, and removal of large or multiple polyps

  • Intra‐abdominal Surgery: Major abdominal operations, including hepatic biopsies

  • Thoracic Surgery: Chest and lung operations

  • Major Urological Surgery: Extensive urologic procedures and biopsies (including renal surgeries)

  • Lithotripsy: Extracorporeal shockwave lithotripsy

  • Major Orthopedic Surgery: Extensive bone and joint operations (e.g., joint replacements)

Abbreviations: ERCP, endoscopic retrograde cholangiopancreatography; ICD, implantable cardioverter‐defibrillator; PCI, percutaneous coronary intervention; VT, ventricular tachycardia.

FIGURE 19.

FIGURE 19

Timing of stopping and re‐initiation of DOAC in elective procedures. DOAC, direct oral anticoagulant.

Recent data from the PERIXa protocol confirmed that for patients undergoing procedures with minimal to low bleeding risk, giving the last dose of an FXa inhibitor just 24 h prior was associated with very low rates of major bleeding and thromboembolic events [335]. Since DOACs exert an immediate anticoagulant effect upon ingestion, the timing of post‐procedural resumption is a critical decision that must integrate surgical input. For low‐risk procedures, DOACs can generally be reinitiated on the first postoperative day. In contrast, for high‐risk surgical interventions, it is advisable to delay resumption until the evening of the second or third postoperative day to ensure that robust hemostasis is fully secured [332].

Recommendation Box 17. Recommendations for Periprocedural Anticoagulation in Patients With AF.

Recommendation Class Level
For patients with AF—excluding those with a recent stroke or TIA or with mechanical heart valves—who are receiving oral anticoagulation (VKA or DOAC) and are planned for an invasive procedure or surgery, it is recommended to withhold anticoagulation temporarily without the use of bridging therapy [330, 331, 332, 336]. I B
For patients with AF receiving a DOAC who require an invasive procedure or surgery that cannot be safely performed under continued anticoagulation, the timing of DOAC interruption should be individualized based on the specific agent used, renal function, and the procedural bleeding risk [332, 333]. IIa B
In patients with AF receiving VKA who require temporary interruption for surgery or an invasive procedure, bridging with low‐molecular‐weight heparin is not recommended, except in those with a mechanical heart valve or a recent stroke or TIA [330, 331, 336, 337]. III B

Abbreviations: AF, atrial fibrillation; DOAC, direct oral anticoagulant; TIA, transient ischemic attack; VKA, vitamin K antagonist.

23. Management of Bleeding in Patients With Atrial Fibrillation Receiving OACs

23.1. General Considerations

Bleeding is a major complication of OAC therapy in patients with AF, and its clinical impact ranges from minor nuisance bleeding to life‐threatening events such as ICH and major GI bleeding [54, 81, 173, 338, 339]. The risk of bleeding is influenced by patient‐specific factors (e.g., age, renal function, prior bleeding), concomitant medications, and the type of anticoagulant used.

Bleeding is generally classified into major bleeding, clinically relevant non‐major bleeding (CRNMB), and minor bleeding according to standardized definitions [101, 340, 341]. Major bleeding includes fatal bleeding, bleeding in critical organs, or bleeding associated with significant hemoglobin drop or transfusion requirement. Standardized definitions of major bleeding and CRNMB used in AF and anticoagulation trials are well recognized [101, 340, 341].

Management principles include prompt assessment of bleeding severity, temporary interruption of anticoagulation when appropriate, rapid stabilization, targeted use of reversal agents in severe cases, and timely resumption of anticoagulation to prevent thromboembolic complications.

23.2. Steps of Management of Bleeding in Patients With AF Who Are on OAC

Management should follow a structured and systematic approach, integrating clinical assessment, supportive care, and targeted therapy (Figure 20) [54, 81, 251, 339]. OACs should not be regarded as causing bleeding but rather as unmasking a predisposition to bleeding.

FIGURE 20.

FIGURE 20

Integrated algorithm for management of bleeding in atrial fibrillation patients who are on oral anticoagulants. AF, atrial fibrillation; APHRS, Asia Pacific Heart Rhythm Society; CRNM, clinically relevant non‐major; GI, gastrointestinal; Hb, hemoglobin; ICH, intracranial hemorrhage; INR, international normalized ratio; OAC, oral anticoagulant; PCC, prothrombin complex concentrate.

Initial assessment should focus on determining hemodynamic stability and identifying the bleeding source. Patients presenting with hypotension, tachycardia, or signs of shock require urgent resuscitation. Laboratory investigations, including hemoglobin, platelet count, renal function, and coagulation parameters, should be obtained to guide management [342, 343].

Immediate measures include temporary discontinuation of OAC therapy and implementation of local hemostatic interventions where feasible, such as mechanical compression, endoscopic therapy, or surgical control of bleeding. Fluid resuscitation and blood transfusion should be initiated as needed to stabilize the patient [344].

Subsequently, bleeding severity should be stratified. Minor bleeding may be managed conservatively without reversal of anticoagulation, whereas moderate‐to‐severe bleeding often requires hospitalization and more aggressive intervention. Life‐threatening bleeding, including bleeding in critical organs, mandates urgent reversal of anticoagulation.

Supportive care is essential and includes transfusion of packed red blood cells for significant anemia, platelet transfusion in thrombocytopenic patients, and correction of coagulopathy. Contributing factors such as drug interactions (e.g., NSAIDs, selective serotonin reuptake inhibitors), renal impairment, and concomitant antiplatelet therapy should be identified and corrected where possible [345, 346].

The decision to administer reversal agents depends on the type of anticoagulant, severity of bleeding, and clinical context. Once bleeding is controlled, careful reassessment is required to determine the optimal timing for restarting anticoagulation.

Resumption of anticoagulation is a critical step, as interruption increases the risk of stroke and systemic embolism. For GI bleeding, anticoagulation is often resumed within 3–7 days if clinically stable, whereas after ICH, the timing is individualized and may be delayed for several weeks depending on risk assessment [347, 348, 349, 350, 351]. Evidence suggests that resuming anticoagulation reduces thromboembolic events and mortality despite a modest increase in recurrent bleeding risk [352].

23.3. Use of Reversal Agents

Reversal of anticoagulation is indicated in patients with life‐threatening bleeding or bleeding in critical sites. The choice of reversal strategy depends on the type of anticoagulant.

For patients receiving VKAs such as warfarin, reversal is achieved with intravenous vitamin K combined with 4‐factor prothrombin complex concentrate (PCC), which provides rapid correction of coagulopathy and is preferred over fresh frozen plasma due to faster onset and lower volume load [353, 354, 355].

In patients treated with dabigatran, idarucizumab is a specific reversal agent that provides rapid and complete neutralization of anticoagulant activity. It is indicated in life‐threatening bleeding or when urgent procedures are required [356, 357].

For FXa inhibitors (e.g., apixaban, rivaroxaban, edoxaban), andexanet alfa is a specific reversal agent that effectively reverses anticoagulant effects. However, its availability and cost may limit use in many settings. In such cases, 4‐factor PCC can be considered as an alternative, although evidence is less robust [358, 359, 360, 361, 362, 363].

Reversal agents should not be used routinely in minor bleeding but should be reserved for severe cases due to cost, limited availability, and potential thrombotic risks. In ICH, immediate reversal is mandatory, along with strict blood pressure control and multidisciplinary management. In GI bleeding, endoscopic intervention remains the cornerstone of treatment, with reversal considered in severe or ongoing bleeding.

23.4. Issues Specific to the Asia‐Pacific Region

The Asia‐Pacific region presents unique challenges in the management of bleeding in AF patients receiving OACs. Epidemiological data indicate a substantially higher risk of ICH among Asian patients compared with non‐Asian populations, which strongly influences anticoagulation strategies [102, 364].

Differences in body size, genetic factors, and pharmacokinetics may affect drug exposure and bleeding risk, necessitating careful dose adjustment, particularly for DOACs. In addition, comorbid conditions such as hypertension, prior stroke, and CKD are more prevalent and contribute to both bleeding and thrombotic risks. Observational data from Asian populations suggest that resumption of anticoagulation especially after ICH may reduce the risk of ischemic stroke and mortality, but decisions must be individualized based on patient risk profiles [365].

Hospitalization and management of major bleeding events, especially GI bleeding, are associated with substantial healthcare costs. Preventive strategies, such as the use of proton pump inhibitors in high‐risk patients, may reduce the incidence of upper GI bleeding and overall healthcare burden [366].

Although DOACs may have higher upfront costs compared with VKAs, they are associated with lower rates of ICH and may be cost‐effective in the long term by reducing complications and hospitalizations. As more DOACs become generic, the associated costs have fallen in recent years.

Recommendation Box 18. Recommendations for Management of Bleeding in AF Patients Receiving OAC.

Recommendation Class Level
DOACs are recommended in preference to VKAs for most patients with AF to reduce intracranial hemorrhage risk, particularly in Asian populations [1]. I A
Structured bleeding risk assessment and correction of modifiable risk factors are recommended, with periodic reassessment during follow‐up [78, 79]. I B
Temporary discontinuation of OAC and initiation of supportive measures (e.g., resuscitation, transfusion, local hemostasis) are recommended while the bleeding source is identified and treated. I C
Correction of reversible causes of bleeding is recommended, including drug interactions and renal dysfunction [345, 346]. I B
A thorough evaluation for occult malignancy should be performed in patients experiencing OAC‐related bleeding [367, 368, 369, 370]. IIa B
Use of specific reversal agents is recommended in patients with life‐threatening bleeding or bleeding in a critical organ [353, 354, 357, 362]. I B
Administration of idarucizumab for dabigatran‐related major bleeding and andexanet alfa for FXa inhibitor–related life‐threatening bleeding should be considered; use 4‐factor PCC if specific agents are unavailable [353, 356, 357, 358, 360, 361, 362, 363]. IIa A
Routine use of reversal agents in minor bleeding is not recommended. III C
Resumption of anticoagulation after bleeding control is recommended in most patients to reduce thromboembolic risk [347, 349, 350, 352]. I B
Restarting OAC within 3–7 days after gastrointestinal bleeding should be considered if the patient is clinically stable; after intracranial hemorrhage, delayed and individualized resumption should be considered [347, 348, 349, 350, 365]. IIa B

Abbreviations: AF, atrial fibrillation; DOAC, direct oral anticoagulant; FXa, factor Xa; OAC, oral anticoagulant; PCC, prothrombin complex concentrate; VKA, vitamin K antagonist.

24. Residual Risk of Stroke Despite OAC: the 4C‐AF Approach

Although OAC reduces the risks of stroke, mortality, and other cardiovascular events in AF, it does not abolish them completely. In patients with AF who present with stroke (or other MACE) despite taking OAC, medication non‐compliance or dosing errors and suboptimally managed comorbidities should be considered [371]; these factors can be summarized as the 4C‐AF approach (Figure 21) [372].

FIGURE 21.

FIGURE 21

The 4C‐AF framework for residual stroke risk despite OAC. AF, atrial fibrillation; DOAC, direct oral anticoagulant; HFrEF, heart failure with reduced ejection fraction; LV, left ventricular; OAC, oral anticoagulant; TTR, time in therapeutic range; VKA, vitamin K antagonist.

DOACs are relatively short‐acting drugs, and compliance with the prescribed regimen is essential, as missing even one or two doses may leave the patient unprotected. In addition, off‐label underdosing of DOACs has been associated with stroke and other MACE.

Concomitant carotid disease and other comorbidities should also be investigated. Carotid disease is present in approximately 25% of patients with AF. Heart failure is associated with an increased risk of stroke, and some of these patients have (often silent) paroxysmal AF. Severe heart failure with reduced ejection fraction or LV aneurysm is associated with LV thrombus, which may cause stroke if it remains undiagnosed. Suboptimally managed comorbidities, such as uncontrolled hypertension, may also lead to stroke and MACE in patients with AF [372].

Once the 4C‐AF framework has been fully considered and optimized, a change from VKA to DOAC is recommended for stroke prevention if TTR has been suboptimal; however, a change from DOAC to VKA is not recommended, nor is the use of a DOAC dose outside the approved label [373, 374, 375]. In the study by Hsieh et al., among patients who had a stroke while on a DOAC, switching from a DOAC to a VKA was associated with a higher risk of recurrent cerebrovascular and cardiovascular events [373]. This observation was also reported by Liao et al. [375] There is little evidence to support the routine addition of antiplatelet therapy to OAC, which has not been associated with a lower risk of ischemic stroke [374, 375], even in patients with extracranial artery stenosis [376]. Whether to change from one DOAC to another is a further issue for which strong evidence is lacking. Retrospective studies have shown inconsistent results. Ip et al. and Liao et al. found an increased risk of ischemic stroke associated with a DOAC‐to‐DOAC switch [374, 375], while Hsieh et al. reported a lower risk of MACE associated with switching [373]. LAAO has been proposed for patients with breakthrough stroke despite DOAC therapy, but trial evidence is limited.

Recommendation Box 19. Recommendations for Residual Risk of Stroke Despite OAC.

Recommendation Class Level
In patients with AF who sustain a stroke despite being on OAC, assessment according to the 4C‐AF framework (see Figure 21) is recommended. I C
If the 4C‐AF framework is fully considered and optimized, then with regard to anticoagulation for stroke prevention, a change from VKA to DOAC is recommended if TTR has been suboptimal. I C
A change from one DOAC to another is not well supported by the available evidence and may only be considered after shared decision‐making with patients [374, 375]. IIb B
Routine addition of antiplatelet therapy to OAC, or a change from a DOAC to a VKA, is not recommended [373, 374, 375, 376]. III B

Abbreviations: AF, atrial fibrillation; DOAC, direct oral anticoagulant; OAC, oral anticoagulant; TTR, time in therapeutic range; VKA, vitamin K antagonist.

25. Factor XI/XIa Inhibitors

Factor XI amplifies thrombin generation but plays a comparatively minor role in normal hemostasis, a trade‐off of particular relevance in Asia, where the risk of ICH is higher than in non‐Asians [18]. In the Phase 2 PACIFIC‐AF trial, asundexian caused less bleeding than apixaban [377]. In AZALEA‐TIMI 71, abelacimab 90 mg and 150 mg monthly reduced major bleeding or CRNMB to 2.64 and 3.22 events per 100 person‐years, respectively, compared with 8.38 events with rivaroxaban, leading to early termination for benefit [378]. However, the phase 3 OCEANIC‐AF trial was stopped prematurely because asundexian 50 mg daily was inferior to apixaban for stroke or systemic embolic events (HR 3.79), despite a 68% reduction in major bleeding [379]. A meta‐analysis of these three trials, including 16 852 patients, captured this dissociation, with a lower risk of major bleeding (risk ratio 0.30) but a higher risk of ischemic stroke (risk ratio 3.53) with factor XI/XIa inhibitors [380, 381].

This anticoagulant class therefore remains investigational [382]. Whether adequate protection against ischemic events can be achieved with a different agent, dose, or patient population is being tested in other AF trials such as LIBREXIA‐AF (milvexian versus apixaban) and LILAC‐TIMI 76 (abelacimab versus placebo in patients considered unsuitable for anticoagulation), the latter targeting patients in whom an anticoagulant with a lower bleeding risk would matter most. Dedicated Asian data, including subgroup analyses of the ongoing phase 3 trials, will be needed before factor XI/XIa inhibitors can be recommended for stroke prevention in Asian AF patients.

Conflicts of Interest

Tze‐Fan Chao reports speaking fees from Abbott, Boehringer Ingelheim, Bayer, Pfizer, Daiichi‐Sankyo, Biotronik and Medtronic. Gregory Y.H. Lip reports institutional consultancy, advisory and/or speaker roles for BMS/Pfizer, Boehringer Ingelheim, Anthos, Boston Scientific, Huawei (No fees are received personally). Ken Okumura received remuneration from Daiichi Sankyo, Bristol‐Myers Squibb, Medtronic, Japan Lifeline and Johnson & Johnson. Hung‐Fat Tse has received research grant or remuneration from Abbott, Amgen, Boehringer Ingelheim, Boston Scientific, Bayer, Bristol‐Myers Squibb, Daiichi Sankyo, GSK, Johnson & Johnson, Medtronic, MSD, Novartis, Pfizer, and Sanofi. Eue‐Keun Choi reports research grants or speaking fees from Abbott, Bayer, BMS/Pfizer, Biosense Webster, Chong Kun Dang, Daewoong Pharmaceutical Co., Daiichi‐Sankyo, DeepQure, Jeil Pharmaceutical Co. Ltd., Medtronic, Samjinpharm, Samsung Electronics Co. Ltd., Seers Technology, Skylabs, and Yuhan Corporation. Minglong Chen reports speaking fees from Abbott, Johnson and Johnson, Boston Scientific and Medtronic. Boyoung Joung has served as speaker for Bayer, BMS/Pfizer, Medtronic, and Daiichi‐Sankyo and received research funds from Samjin, Yuhan, Medtronic, Boston Scientifics and Abbott Korea. Rungroj Krittayaphong reports speaking fees from Boehringer Ingelheim, Bayer, Pfizer, Daiichi‐Sankyo. Hui‐Nam Pak reports honoraria from Abbott, Medtronic, and Boston Scientific Inc., and research grants from Medtronic and Abbott Inc. Yi‐Hsin Chan, So‐Ryoung Lee, Mingfang Li, Daehoon Kim, Ling Kuo, Melissa E. Middeldorp, Kyoko Soejima: The authors declare no conflicts of interest.

Contributor Information

Tze‐Fan Chao, Email: eyckeyck@gmail.com.

Gregory Y. H. Lip, Email: gregory.lip@liverpool.ac.uk.

Data Availability Statement

The data that support the findings of this study are available on request from the corresponding author. The data are not publicly available due to privacy or ethical restrictions.

References

  • 1. Chao T. F., Braunwald E., Palazzolo M. G., et al., “Direct Oral Anticoagulants vs Warfarin in Asian vs Non‐Asian Patients With Atrial Fibrillation: A Patient‐Level Meta‐Analysis From COMBINE AF,” European Heart Journal 47, no. 36 (2026): 5172–5185. [DOI] [PubMed] [Google Scholar]
  • 2. Kang D. S., Yang P. S., Kim D., et al., “Racial Differences in Ischemic and Hemorrhagic Stroke: An Ecological Epidemiological Study,” Thrombosis and Haemostasis 124 (2024): 883–892. [DOI] [PubMed] [Google Scholar]
  • 3. Kang D. S., Yang P. S., Kim D., et al., “Racial Differences in Bleeding Risk: An Ecological Epidemiological Study Comparing Korea and United Kingdom Subjects,” Thrombosis and Haemostasis 124 (2024): 842–851. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 4. Chao T. F., Choi E. K., Guo Y., Shimizu W., Tse H. F., and Lip G. Y. H., “Strategies for the Prevention of Ischemic Stroke in Atrial Fibrillation in East Asia: Clinical Features, Changes and Challenges,” Lancet Regional Health – Western Pacific 56 (2025): 101495. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 5. Liao J. N., Chan Y. H., Kuo L., et al., “Temporal Trends of Prescription Rates, Oral Anticoagulants Dose, Clinical Outcomes, and Factors Associated With Non‐Anticoagulation in Patients With Incident Atrial Fibrillation,” European Heart Journal – Quality of Care and Clinical Outcomes 11 (2025): 300–311. [DOI] [PubMed] [Google Scholar]
  • 6. Krittayaphong R., Pumprueg S., Kaewkumdee P., Yindeengam A., and Lip G. Y., “Three‐Year Outcomes of Patients With Non‐Valvular Atrial Fibrillation: the COOL‐AF Registry,” Journal of Geriatric Cardiology 20 (2023): 163–173. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 7. Krittayaphong R., Winijkul A., Rungpradubvong V., et al., “The COOL‐AF Phase 2 Registry: COhort of Antithrombotic Use and Clinical Outcomes in Atrial Fibrillation Patients,” JACC Asia 5 (2025): 191–202. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 8. Chao T. F., Chiang C. E., Lin Y. J., et al., “Evolving Changes of the Use of Oral Anticoagulants and Outcomes in Patients With Newly Diagnosed Atrial Fibrillation in Taiwan,” Circulation 138 (2018): 1485–1487. [DOI] [PubMed] [Google Scholar]
  • 9. Akao M., Ogawa H., Masunaga N., et al., “10‐Year Trends of Antithrombotic Therapy Status and Outcomes in Japanese Atrial Fibrillation Patients—The Fushimi AF Registry,” Circulation Journal 86 (2022): 726–736. [DOI] [PubMed] [Google Scholar]
  • 10. Chan Y. H., Chao T. F., Chen S. W., et al., “Off‐Label Dosing of Non‐Vitamin K Antagonist Oral Anticoagulants and Clinical Outcomes in Asian Patients With Atrial Fibrillation,” Heart Rhythm 17 (2020): 2102–2110. [DOI] [PubMed] [Google Scholar]
  • 11. Chao T. F., Chan N. Y., Chan Y. H., et al., “Direct Oral Anticoagulant Dosing in Patients With Atrial Fibrillation: An Asian Perspective,” JACC Asia 3 (2023): 707–723. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 12. Lee S.‐R., Kim D., Lee S. H., et al., “Atrial Fibrillation Fact Sheet in Korea 2024 (Part 1): Epidemiology of Atrial Fibrillation in Korea,” International Journal of Arrhythmia 20 (2024): 25. [Google Scholar]
  • 13. Zhao M., Bucci T., Lam S. H. M., et al., “Ethnic Differences in Clinical Outcomes Following Major Bleeding in Atrial Fibrillation Patients: A Report From Two Prospective Regional Registries in Europe and Asia,” European Journal of Preventive Cardiology (2025): zwaf489, 10.1093/eurjpc/zwaf489. [DOI] [PubMed] [Google Scholar]
  • 14. Rigutini A. G., Bucci T., Rossi M., et al., “Clinical Complexity in Patients With Atrial Fibrillation: Exploring Differential Risk Profiles From European and Asian Cohorts,” Europace 27, no. 12 (2025): euaf229, 10.1093/europace/euaf229. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 15. Mei D. A., Proietti M., Romiti G. F., et al., “Multimorbidity, Frailty and Polypharmacy in European and Asian Patients With Atrial Fibrillation: A Comparison of Two Regional Prospective Observational Registries,” Geroscience 48, no. 5 (2025): 6871–6885. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 16. Chan Y. H., Kao Y. W., Chen S. W., and Chao T. F., “Performance of DOAC and HAS‐BLED Scores in Predicting Major Bleeding in Asian Patients With Non‐Valvular Atrial Fibrillation Receiving Direct Oral Anticoagulants,” Europace 27, no. 11 (2025): euaf251, 10.1093/europace/euaf251. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 17. Kim M. H., Yang P. S., Kim D., et al., “Racial Differences and Similarities in Atrial Fibrillation Epidemiology and Risk Factors in UK Biobank and Korean NHIS‐HEALS Cohort Studies,” Heart Rhythm: The Official Journal of the Heart Rhythm Society 22 (2025): e277–e284. [DOI] [PubMed] [Google Scholar]
  • 18. Kang D. S., Yang P. S., Kim D., et al., “Racial Differences in Bleeding Risks Among Patients With Atrial Fibrillation: An Ecological Epidemiological Study Comparing Korea and UK Population,” Thrombosis and Haemostasis 126 (2026): 754–764. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 19. Chao T. F., Braunwald E., Palazzolo M. G., et al., “Regional Differences in Clinical Outcomes in Patients of Asian Race With Atrial Fibrillation Randomized to Direct Oral Anticoagulants vs Warfarin: A Patient‐Level Meta‐Analyses From COMBINE AF,” European Heart Journal 46, no. Supplement_1 (2025): ehaf784.528, 10.1093/eurheartj/ehaf784.528. [DOI] [Google Scholar]
  • 20. Lip G. Y. H., “The ABC Pathway: An Integrated Approach to Improve AF Management,” Nature Reviews Cardiology 14 (2017): 627–628. [DOI] [PubMed] [Google Scholar]
  • 21. Romiti G. F., Corica B., Bucci T., et al., “The ‘Atrial Fibrillation Better Care’ (ABC) Pathway for Integrated Care of Atrial Fibrillation: A Systematic Review and Meta‐Analysis,” Thrombosis and Haemostasis (2026), 10.1055/a-2787-0186. [DOI] [PubMed] [Google Scholar]
  • 22. Bai Y., Wang Y. L., Shantsila A., and Lip G. Y. H., “The Global Burden of Atrial Fibrillation and Stroke: A Systematic Review of the Clinical Epidemiology of Atrial Fibrillation in Asia,” Chest 152 (2017): 810–820. [DOI] [PubMed] [Google Scholar]
  • 23. Pisters R., Lane D. A., Marin F., Camm A. J., and Lip G. Y., “Stroke and Thromboembolism in Atrial Fibrillation,” Circulation Journal 76 (2012): 2289–2304. [DOI] [PubMed] [Google Scholar]
  • 24. Noubiap J. J., Feteh V. F., Middeldorp M. E., et al., “A Meta‐Analysis of Clinical Risk Factors for Stroke in Anticoagulant‐Naive Patients With Atrial Fibrillation,” Europace 23 (2021): 1528–1538. [DOI] [PubMed] [Google Scholar]
  • 25. Szymanski F. M., Lip G. Y., Filipiak K. J., Platek A. E., Hrynkiewicz‐Szymanska A., and Opolski G., “Stroke Risk Factors Beyond the CHA(2)DS(2)‐VASc Score: Can we Improve Our Identification of “High Stroke Risk” Patients With Atrial Fibrillation?,” American Journal of Cardiology 116 (2015): 1781–1788. [DOI] [PubMed] [Google Scholar]
  • 26. Decker J. J., Norby F. L., Rooney M. R., et al., “Metabolic Syndrome and Risk of Ischemic Stroke in Atrial Fibrillation: ARIC Study,” Stroke 50 (2019): 3045–3050. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 27. Vinereanu D., Lopes R. D., Mulder H., et al., “Echocardiographic Risk Factors for Stroke and Outcomes in Patients With Atrial Fibrillation Anticoagulated With Apixaban or Warfarin,” Stroke 48 (2017): 3266–3273. [DOI] [PubMed] [Google Scholar]
  • 28.“Echocardiographic Predictors of Stroke in Patients With Atrial Fibrillation: A Prospective Study of 1066 Patients From 3 Clinical Trials,” Archives of Internal Medicine 158 (1998): 1316–1320. [DOI] [PubMed] [Google Scholar]
  • 29. Ntaios G., Lip G. Y., Lambrou D., et al., “Leukoaraiosis and Stroke Recurrence Risk in Patients With and Without Atrial Fibrillation,” Neurology 84 (2015): 1213–1219. [DOI] [PubMed] [Google Scholar]
  • 30. Wang Y., Li H., Pan Y., et al., “Cerebral Small Vessel Disease Was Associated With the Prognosis in Ischemic Stroke With Atrial Fibrillation,” CNS Neuroscience & Therapeutics 30 (2024): e70052. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 31. Ioannou A., Papageorgiou N., Falconer D., et al., “Biomarkers Associated With Stroke Risk in Atrial Fibrillation,” Current Medicinal Chemistry 26 (2019): 803–823. [DOI] [PubMed] [Google Scholar]
  • 32. Sepehri Shamloo A., Bollmann A., Dagres N., Hindricks G., and Arya A., “Natriuretic Peptides: Biomarkers for Atrial Fibrillation Management,” Clinical Research in Cardiology: Official Journal of the German Cardiac Society 109 (2020): 957–966. [DOI] [PubMed] [Google Scholar]
  • 33. Ganesan A. N., Chew D. P., Hartshorne T., et al., “The Impact of Atrial Fibrillation Type on the Risk of Thromboembolism, Mortality, and Bleeding: A Systematic Review and Meta‐Analysis,” European Heart Journal 37 (2016): 1591–1602. [DOI] [PubMed] [Google Scholar]
  • 34. Becher N., Metzner A., Toennis T., Kirchhof P., and Schnabel R. B., “Atrial Fibrillation Burden: A New Outcome Predictor and Therapeutic Target,” European Heart Journal 45 (2024): 2824–2838. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 35. Go A. S., Reynolds K., Yang J., et al., “Association of Burden of Atrial Fibrillation With Risk of Ischemic Stroke in Adults With Paroxysmal Atrial Fibrillation: The KP‐RHYTHM Study,” JAMA Cardiology 3 (2018): 601–608. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 36. Rosman L., Wang K., Sarkar S., Ziegler P. D., and Passman R. S., “Atrial Fibrillation Density as a Biomarker for Ischaemic Stroke Risk Prediction,” European Heart Journal 47, no. 36 (2026): 5112–5124. [DOI] [PubMed] [Google Scholar]
  • 37.“Independent Predictors of Stroke in Patients With Atrial Fibrillation: A Systematic Review,” Neurology 69 (2007): 546–554. [DOI] [PubMed] [Google Scholar]
  • 38. Lip G. Y., Nieuwlaat R., Pisters R., Lane D. A., and Crijns H. J., “Refining Clinical Risk Stratification for Predicting Stroke and Thromboembolism in Atrial Fibrillation Using a Novel Risk Factor‐Based Approach: the Euro Heart Survey on Atrial Fibrillation,” Chest 137 (2010): 263–272. [DOI] [PubMed] [Google Scholar]
  • 39. Chao T. F., Liu C. J., Wang K. L., et al., “Using the CHA2DS2‐VASc Score for Refining Stroke Risk Stratification in ‘low‐Risk’ Asian Patients With Atrial Fibrillation,” Journal of the American College of Cardiology 64 (2014): 1658–1665. [DOI] [PubMed] [Google Scholar]
  • 40. Xiong Q., Chen S., Senoo K., Proietti M., Hong K., and Lip G. Y., “The CHADS2 and CHA2DS2‐VASc Scores for Predicting Ischemic Stroke Among East Asian Patients With Atrial Fibrillation: A Systemic Review and Meta‐Analysis,” International Journal of Cardiology 195 (2015): 237–242. [DOI] [PubMed] [Google Scholar]
  • 41. Chao T. F., Liu C. J., Tuan T. C., et al., “Comparisons of CHADS2 and CHA2DS2‐VASc Scores for Stroke Risk Stratification in Atrial Fibrillation: Which Scoring System Should Be Used for Asians?,” Heart Rhythm 13 (2016): 46–53. [DOI] [PubMed] [Google Scholar]
  • 42. Kang S. H., Choi E. K., Han K. D., et al., “Risk of Ischemic Stroke in Patients With Non‐Valvular Atrial Fibrillation Not Receiving Oral Anticoagulants—Korean Nationwide Population‐Based Study,” Circulation Journal 81 (2017): 1158–1164. [DOI] [PubMed] [Google Scholar]
  • 43. Kim T. H., Yang P. S., Uhm J. S., et al., “CHA(2)DS(2)‐VASc Score (Congestive Heart Failure, Hypertension, Age >/=75 [Doubled], Diabetes Mellitus, Prior Stroke or Transient Ischemic Attack [Doubled], Vascular Disease, Age 65‐74, Female) for Stroke in Asian Patients With Atrial Fibrillation: A Korean Nationwide Sample Cohort Study,” Stroke 48 (2017): 1524–1530. [DOI] [PubMed] [Google Scholar]
  • 44. Kim T. H., Yang P. S., Kim D., et al., “CHA(2)DS(2)‐VASc Score for Identifying Truly Low‐Risk Atrial Fibrillation for Stroke: A Korean Nationwide Cohort Study,” Stroke 48 (2017): 2984–2990. [DOI] [PubMed] [Google Scholar]
  • 45. Chao T. F., Potpara T. S., and Lip G. Y. H., “Atrial Fibrillation: Stroke Prevention,” Lancet Regional Health Europe 37 (2024): 100797. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 46. Chao T. F., Lip G. Y. H., Lin Y. J., et al., “Major Bleeding and Intracranial Hemorrhage Risk Prediction in Patients With Atrial Fibrillation: Attention to Modifiable Bleeding Risk Factors or Use of a Bleeding Risk Stratification Score? A Nationwide Cohort Study,” International Journal of Cardiology 254 (2018): 157–161. [DOI] [PubMed] [Google Scholar]
  • 47. Fox K. A. A., Lucas J. E., Pieper K. S., et al., “Improved Risk Stratification of Patients With Atrial Fibrillation: An Integrated GARFIELD‐AF Tool for the Prediction of Mortality, Stroke and Bleed in Patients With and Without Anticoagulation,” BMJ Open 7 (2017): e017157. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 48. Zhu W., Fu L., Ding Y., et al., “Meta‐Analysis of ATRIA Versus CHA(2)DS(2)‐VASc for Predicting Stroke and Thromboembolism in Patients With Atrial Fibrillation,” International Journal of Cardiology 227 (2017): 436–442. [DOI] [PubMed] [Google Scholar]
  • 49. Singer D. E., Chang Y., Borowsky L. H., et al., “A New Risk Scheme to Predict Ischemic Stroke and Other Thromboembolism in Atrial Fibrillation: the ATRIA Study Stroke Risk Score,” Journal of the American Heart Association 2 (2013): e000250. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 50. Hijazi Z., Lindback J., Alexander J. H., et al., “The ABC (Age, Biomarkers, Clinical History) Stroke Risk Score: A Biomarker‐Based Risk Score for Predicting Stroke in Atrial Fibrillation,” European Heart Journal 37 (2016): 1582–1590. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 51. Oldgren J., Hijazi Z., Lindback J., et al., “Performance and Validation of a Novel Biomarker‐Based Stroke Risk Score for Atrial Fibrillation,” Circulation 134 (2016): 1697–1707. [DOI] [PubMed] [Google Scholar]
  • 52. Berg D. D., Ruff C. T., Jarolim P., et al., “Performance of the ABC Scores for Assessing the Risk of Stroke or Systemic Embolism and Bleeding in Patients With Atrial Fibrillation in ENGAGE AF‐TIMI 48,” Circulation 139 (2019): 760–771. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 53. Xie Y., Li W., Meng Y., et al., “Development and Validation of the GLORIA‐AF Stroke Weighted Risk Score for Patients With Atrial Fibrillation,” Europace 28, no. 10 (2026): euag236, 10.1093/europace/euag236. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 54. Van Gelder IC , Rienstra M., Bunting K. V., et al., “ESC Guidelines for the Management of Atrial Fibrillation Developed in Collaboration With the European Association for Cardio‐Thoracic Surgery (EACTS),” European Heart Journal 2024, no. 45 (2024): 3314–3414. [DOI] [PubMed] [Google Scholar]
  • 55. Krittayaphong R., Apiyasawat S., Methavigul K., Komoltri C., and Lip G. Y. H., “Prediction of Ischemic Stroke by the CHA(2)DS(2)‐VA Score in an Asian Population: A Report From the Prospective Nationwide COOL‐AF Registry,” Heart Rhythm 22 (2025): e658–e667. [DOI] [PubMed] [Google Scholar]
  • 56. Cheng W. H., Chan Y. H., Kuo L., et al., “Stroke Risks in Women vs Men in Asian Patients With Atrial Fibrillation: A Temporal Trend Analysis and a Comparison of the CHA(2)DS(2)‐VASc and CHA(2)DS(2)‐VA Stroke Risk Stratification Scores,” Heart Rhythm 22 (2025): 2515–2523. [DOI] [PubMed] [Google Scholar]
  • 57. Nielsen P. B., Larsen T. B., Skjoth F., Overvad T. F., and Lip G. Y., “Stroke and Thromboembolic Event Rates in Atrial Fibrillation According to Different Guideline Treatment Thresholds: A Nationwide Cohort Study,” Scientific Reports 6 (2016): 27410. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 58. Maura C., Blotiere P. O., Wastersson J. W., Johnell K., Lip G. Y. H., and Veltrano D. L., “Sex Differences in Stroke Risk and Predictive Value of CHA2DS2‐VASc vs. CHA2DS2‐VA in Older Patients With Newly Diagnosed Atrial Fibrillation. A Nationwide Cohort Study Based on Swedish Registry Data (2009–2019),” Presentation at EuGMS Congress (2025). [Google Scholar]
  • 59. Pilcher S. M., Alamneh E. A., Chalmers L., and Bereznicki L. R., “The Tasmanian Atrial Fibrillation Study (TAFS): Differences in Stroke Prevention According to Sex,” Annals of Pharmacotherapy 54 (2020): 837–845. [DOI] [PubMed] [Google Scholar]
  • 60. Boettger P., Sedighi J., Piayda K., et al., “Clinical Implications of the Recalibrated CHA2DS2‐VA Score for Women After Ischemic Stroke: A Prospective Cohort Study,” Acta Neurologica Belgica 125 (2025): 1653–1662. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 61. Lip G. Y. H., Banerjee A., Boriani G., et al., “Antithrombotic Therapy for Atrial Fibrillation: CHEST Guideline and Expert Panel Report,” Chest 154 (2018): 1121–1201. [DOI] [PubMed] [Google Scholar]
  • 62. Gorog D. A., Gue Y. X., Chao T. F., et al., “Assessment and Mitigation of Bleeding Risk in Atrial Fibrillation and Venous Thromboembolism: Executive Summary of a European and Asia‐Pacific Expert Consensus Paper,” Thrombosis and Haemostasis 122 (2022): 1625–1652. [DOI] [PubMed] [Google Scholar]
  • 63. Lip G. Y. and Lane D. A., “Bleeding Risk Assessment in Atrial Fibrillation: Observations on the Use and Misuse of Bleeding Risk Scores,” Journal of Thrombosis and Haemostasis 14 (2016): 1711–1714. [DOI] [PubMed] [Google Scholar]
  • 64. Serna M. J., Rivera‐Caravaca J. M., López‐Gálvez R., et al., “Dynamic Assessment of CHA(2)DS(2)‐VASc and HAS‐BLED Scores for Predicting Ischemic Stroke and Major Bleeding in Atrial Fibrillation Patients,” Revista Espanola de Cardiologia (English Ed) 77 (2024): 835–842. [DOI] [PubMed] [Google Scholar]
  • 65. Pisters R., Lane D. A., Nieuwlaat R., de Vos C. B., Crijns H. J., and Lip G. Y., “A Novel User‐Friendly Score (HAS‐BLED) to Assess 1‐Year Risk of Major Bleeding in Patients With Atrial Fibrillation: the Euro Heart Survey,” Chest 138 (2010): 1093–1100. [DOI] [PubMed] [Google Scholar]
  • 66. Chichareon P., Winijkul A., Lip G. Y. H., and Krittayaphong R., “Comparative Validation of HAS‐BLED, GARFIELD‐AF and ORBIT Bleeding Risk Scores in Asian People With Atrial Fibrillation Treated With Oral Anticoagulant: A Report From the COOL‐AF Registry,” British Journal of Clinical Pharmacology 89 (2023): 2472–2482. [DOI] [PubMed] [Google Scholar]
  • 67. Guo Y., Zhu H., Chen Y., and Lip G. Y. H., “Comparing Bleeding Risk Assessment Focused on Modifiable Risk Factors Only Versus Validated Bleeding Risk Scores in Atrial Fibrillation,” American Journal of Medicine 131 (2018): 185–192. [DOI] [PubMed] [Google Scholar]
  • 68. Wattanaruengchai P., Nathisuwan S., Karaketklang K., Wongcharoen W., Phrommintikul A., and Lip G. Y. H., “Comparison of the HAS‐BLED Versus ORBIT Scores in Predicting Major Bleeding Among Asians Receiving Direct‐Acting Oral Anticoagulants,” British Journal of Clinical Pharmacology 88 (2022): 2203–2212. [DOI] [PubMed] [Google Scholar]
  • 69. Guo Y., Lane D. A., Wang L., et al., “Mobile Health Technology to Improve Care for Patients With Atrial Fibrillation,” Journal of the American College of Cardiology 75 (2020): 1523–1534. [DOI] [PubMed] [Google Scholar]
  • 70. Guo Y., Lane D. A., Chen Y., Lip G. Y. H., and m AFAIITi , “Regular Bleeding Risk Assessment Associated With Reduction in Bleeding Outcomes: The mAFA‐II Randomized Trial,” American Journal of Medicine 133, no. 1195–1202 (2020): e1192. [DOI] [PubMed] [Google Scholar]
  • 71. Oldgren J., Hijazi Z., Arheden H., et al., “Biomarker‐Based ABC‐AF Risk Scores for Personalized Treatment to Reduce Stroke or Death in Atrial Fibrillation: A Registry‐Based, Multicenter, Randomized, Controlled Study,” Circulation 152 (2025): 1457–1469. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 72. Xie Y., Li W., Meng Y., et al., “Development and External Validation of the GLORIA‐AF Bleeding Weighted Risk Score for Patients With Atrial Fibrillation,” European Journal of Preventive Cardiology (2026): zwag447, 10.1093/eurjpc/zwag447. [DOI] [PubMed] [Google Scholar]
  • 73. Domek M., Gumprecht J., Mazurek M., Chao T. F., and Lip G. Y. H., “Should we Judge Stroke Risk by Static or Dynamic Risk Scores? A Focus on the Dynamic Nature of Stroke and Bleeding Risks in Patients With Atrial Fibrillation,” Journal of Cardiovascular Pharmacology 74 (2019): 491–498. [DOI] [PubMed] [Google Scholar]
  • 74. Chao T. F., Lip G. Y. H., Liu C. J., et al., “Relationship of Aging and Incident Comorbidities to Stroke Risk in Patients With Atrial Fibrillation,” Journal of the American College of Cardiology 71 (2018): 122–132. [DOI] [PubMed] [Google Scholar]
  • 75. Yoon M., Yang P. S., Jang E., et al., “Dynamic Changes of CHA2DS2‐VASc Score and the Risk of Ischaemic Stroke in Asian Patients With Atrial Fibrillation: A Nationwide Cohort Study,” Thrombosis and Haemostasis 118 (2018): 1296–1304. [DOI] [PubMed] [Google Scholar]
  • 76. Chao T. F., Liao J. N., Tuan T. C., et al., “Incident co‐Morbidities in Patients With Atrial Fibrillation Initially With a CHA2DS2‐VASc Score of 0 (Males) or 1 (Females): Implications for Reassessment of Stroke Risk in Initially ‘Low‐Risk’ Patients,” Thrombosis and Haemostasis 119 (2019): 1162–1170. [DOI] [PubMed] [Google Scholar]
  • 77. Fauchier L., Bodin A., Bisson A., et al., “Incident Comorbidities, Aging and the Risk of Stroke in 608,108 Patients With Atrial Fibrillation: A Nationwide Analysis,” Journal of Clinical Medicine 9, no. 4 (2020): 1234, 10.3390/jcm9041234. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 78. Chao T. F., Chan Y. H., Chiang C. E., et al., “Continuation or Discontinuation of Oral Anticoagulants After HAS‐BLED Scores Increase in Patients With Atrial Fibrillation,” Clinical Research in Cardiology 111 (2022): 23–33. [DOI] [PubMed] [Google Scholar]
  • 79. Chao T. F., Lip G. Y. H., Lin Y. J., et al., “Incident Risk Factors and Major Bleeding in Patients With Atrial Fibrillation Treated With Oral Anticoagulants: A Comparison of Baseline, Follow‐Up and Delta HAS‐BLED Scores With an Approach Focused on Modifiable Bleeding Risk Factors,” Thrombosis and Haemostasis 118 (2018): 768–777. [DOI] [PubMed] [Google Scholar]
  • 80. Chao T. F., Joung B., Takahashi Y., et al., “2021 Focused Update of the 2017 Consensus Guidelines of the Asia Pacific Heart Rhythm Society (APHRS) on Stroke Prevention in Atrial Fibrillation,” Journal of Arrhythmia 37 (2021): 1389–1426. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 81. Chao T. F., Joung B., Takahashi Y., et al., “2021 Focused Update Consensus Guidelines of the Asia Pacific Heart Rhythm Society on Stroke Prevention in Atrial Fibrillation: Executive Summary,” Thrombosis and Haemostasis 122 (2022): 20–47. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 82. Sato H., Ishikawa K., Kitabatake A., et al., “Low‐Dose Aspirin for Prevention of Stroke in Low‐Risk Patients With Atrial Fibrillation: Japan Atrial Fibrillation Stroke Trial,” Stroke 37 (2006): 447–451. [DOI] [PubMed] [Google Scholar]
  • 83. Connolly S. J., Eikelboom J., Joyner C., et al., “Investigators. Apixaban in Patients With Atrial Fibrillation,” New England Journal of Medicine 364 (2011): 806–817. [DOI] [PubMed] [Google Scholar]
  • 84. Hung Y., Chao T. F., Liu C. J., et al., “Is an Oral Anticoagulant Necessary for Young Atrial Fibrillation Patients With a CHA2DS2‐VASc Score of 1 (Men) or 2 (Women)?,” Journal of the American Heart Association 5, no. 10 (2016): e003839, 10.1161/JAHA.116.003839. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 85. Kim D., Lee Y. S., Shim J., et al., “Anticoagulation for Atrial Fibrillation With Intermediate Stroke Risk,” New England Journal of Medicine 395, no. 12 (2026): 1155–1165. [DOI] [PubMed] [Google Scholar]
  • 86. Chao T. F., Liu C. J., Wang K. L., et al., “Should Atrial Fibrillation Patients With 1 Additional Risk Factor of the CHA2DS2‐VASc Score (Beyond Sex) Receive Oral Anticoagulation?,” Journal of the American College of Cardiology 65 (2015): 635–642. [DOI] [PubMed] [Google Scholar]
  • 87. Chao T. F., Wang K. L., Liu C. J., et al., “Age Threshold for Increased Stroke Risk Among Patients With Atrial Fibrillation: A Nationwide Cohort Study From Taiwan,” Journal of the American College of Cardiology 66 (2015): 1339–1347. [DOI] [PubMed] [Google Scholar]
  • 88. Chao T. F., Lip G. Y. H., Lin Y. J., et al., “Age Threshold for the Use of Non‐Vitamin K Antagonist Oral Anticoagulants for Stroke Prevention in Patients With Atrial Fibrillation: Insights Into the Optimal Assessment of Age and Incident Comorbidities,” European Heart Journal 40 (2019): 1504–1514. [DOI] [PubMed] [Google Scholar]
  • 89. Eckman M. H., Singer D. E., Rosand J., and Greenberg S. M., “Moving the Tipping Point: the Decision to Anticoagulate Patients With Atrial Fibrillation,” Circulation. Cardiovascular Quality and Outcomes 4 (2011): 14–21. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 90. Winsten A. K., Langen V., Airaksinen K. E. J., and Teppo K., “Estimating the Stroke Risk Threshold for Initiating Non‐Vitamin K Antagonist Oral Anticoagulation in Atrial Fibrillation: Markov Decision Model Analysis,” Circulation. Cardiovascular Quality and Outcomes 18 (2025): e012090. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 91. Yu H. T., Yang P. S., Jang E., et al., “Label Adherence of Direct Oral Anticoagulants Dosing and Clinical Outcomes in Patients With Atrial Fibrillation,” Journal of the American Heart Association 9 (2020): e014177. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 92. Lee S. R., Choi E. K., Park S. H., et al., “Off‐Label Underdosed Apixaban Use in Asian Patients With Non‐Valvular Atrial Fibrillation,” European Heart Journal—Cardiovascular Pharmacotherapy 7 (2021): 415–423. [DOI] [PubMed] [Google Scholar]
  • 93. Joosten L. P. T., van Doorn S., van de Ven P. M., et al., “Safety of Switching From a Vitamin K Antagonist to a Non‐Vitamin K Antagonist Oral Anticoagulant in Frail Older Patients With Atrial Fibrillation: Results of the FRAIL‐AF Randomized Controlled Trial,” Circulation 149 (2024): 279–289. [DOI] [PubMed] [Google Scholar]
  • 94. Nicolau A. M., Giugliano R. P., Zimerman A., et al., “Outcomes in Older Patients After Switching to a Newer Anticoagulant or Remaining on Warfarin: The COMBINE‐AF Substudy,” Journal of the American College of Cardiology 86 (2025): 426–439. [DOI] [PubMed] [Google Scholar]
  • 95. Liu S. H., Chao T. F., Chan Y. H., et al., “Non‐Vitamin K Antagonist Oral Anticoagulants in Atrial Fibrillation Patients Without Previous Oral Anticoagulants or Stable Under Warfarin: A Nationwide Cohort Study,” Europace 25, no. 5 (2023): euad120, 10.1093/europace/euad120. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 96. Lee S. R., Go Y. H., Choi E. K., et al., “Switching From Warfarin to Direct Oral Anticoagulants in Frail Elderly Asian Patients With Atrial Fibrillation: A Korean Nationwide Study,” European Heart Journal 47 (2026): 2937–2947. [DOI] [PubMed] [Google Scholar]
  • 97. Wong K. S., Hu D. Y., Oomman A., et al., “Rivaroxaban for Stroke Prevention in East Asian Patients From the ROCKET AF Trial,” Stroke 45 (2014): 1739–1747. [DOI] [PubMed] [Google Scholar]
  • 98. Hori M., Matsumoto M., Tanahashi N., et al., “Rivaroxaban vs. Warfarin in Japanese Patients With Atrial Fibrillation—the J‐ROCKET AF Study,” Circulation Journal 76 (2012): 2104–2111. [DOI] [PubMed] [Google Scholar]
  • 99. Goto S., Zhu J., Liu L., et al., “Efficacy and Safety of Apixaban Compared With Warfarin for Stroke Prevention in Patients With Atrial Fibrillation From East Asia: A Subanalysis of the Apixaban for Reduction in Stroke and Other Thromboembolic Events in Atrial Fibrillation (ARISTOTLE) Trial,” American Heart Journal 168 (2014): 303–309. [DOI] [PubMed] [Google Scholar]
  • 100. Yamashita T., Koretsune Y., Yang Y., et al., “Edoxaban vs. Warfarin in East Asian Patients With Atrial Fibrillation—An ENGAGE AF‐TIMI 48 Subanalysis,” Circulation Journal 80 (2016): 860–869. [DOI] [PubMed] [Google Scholar]
  • 101. Ruff C. T., Giugliano R. P., Braunwald E., et al., “Comparison of the Efficacy and Safety of New Oral Anticoagulants With Warfarin in Patients With Atrial Fibrillation: A Meta‐Analysis of Randomised Trials,” Lancet 383 (2014): 955–962. [DOI] [PubMed] [Google Scholar]
  • 102. Hori M., Connolly S. J., Zhu J., et al., “Dabigatran Versus Warfarin: Effects on Ischemic and Hemorrhagic Strokes and Bleeding in Asians and Non‐Asians With Atrial Fibrillation,” Stroke: A Journal of Cerebral Circulation 44 (2013): 1891–1896. [DOI] [PubMed] [Google Scholar]
  • 103. Cheng W. H., Chan Y. H., Liao J. N., Kuo L., Chen S. A., and Chao T. F., “Optimal Management of Anticoagulation Therapy in Asian Patients With Atrial Fibrillation,” Circulation Journal 85 (2021): 1245–1253. [DOI] [PubMed] [Google Scholar]
  • 104. Romiti G. F., Corica B., Proietti M., et al., “Patterns of Oral Anticoagulant Use and Outcomes in Asian Patients With Atrial Fibrillation: A Post‐Hoc Analysis From the GLORIA‐AF Registry,” EClinicalMedicine 63 (2023): 102039. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 105. Chan Y. H., Chan C. Y., Chen S. W., Chao T. F., and Lip G. Y. H., “Comparisons of Effectiveness and Safety Between On‐Label Dosing, Off‐Label Underdosing, and Off‐Label Overdosing in Asian and Non‐Asian Atrial Fibrillation Patients Treated With Rivaroxaban: A Systematic Review and Meta‐Analysis of Observational Studies,” Europace 25, no. 10 (2023): euad288, 10.1093/europace/euad288. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 106. Kim J. Y., Kim J., Park S. J., et al., “Comparison of High‐ and Low‐Dose Rivaroxaban Regimens in Elderly East Asian Patients With Atrial Fibrillation,” Journal of Korean Medical Science 39 (2024): e72. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 107. Chan Y. H., Lee H. F., Wang C. L., et al., “Comparisons of Rivaroxaban Following Different Dosage Criteria (ROCKET AF or J‐ROCKET AF Trials) in Asian Patients With Atrial Fibrillation,” Journal of the American Heart Association 8 (2019): e013053. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 108. Okumura K., Akao M., Yoshida T., et al., “Investigators. Low‐Dose Edoxaban in Very Elderly Patients With Atrial Fibrillation,” New England Journal of Medicine 383 (2020): 1735–1745. [DOI] [PubMed] [Google Scholar]
  • 109. Stevens L. A., Coresh J., Feldman H. I., et al., “Evaluation of the Modification of Diet in Renal Disease Study Equation in a Large Diverse Population,” Journal of the American Society of Nephrology 18 (2007): 2749–2757. [DOI] [PubMed] [Google Scholar]
  • 110. Kidney Disease: Improving Global Outcomes CKDWG and KDIGO , “Clinical Practice Guideline for the Evaluation and Management of Chronic Kidney Disease,” Kidney International 2024, no. 105 (2024): S117–S314. [DOI] [PubMed] [Google Scholar]
  • 111. Miller W. G., “Reporting Estimated GFR: A Laboratory Perspective,” American Journal of Kidney Diseases 52 (2008): 645–648. [DOI] [PubMed] [Google Scholar]
  • 112. Chan Y. H., Chao T. F., Lee H. F., et al., “Different Renal Function Equations and Dosing of Direct Oral Anticoagulants in Atrial Fibrillation,” JACC Asia 2 (2022): 46–58. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 113. Chan Y. H., Chao T. F., Lee H. F., et al., “Impacts of Different Renal Function Estimation Formulas on Dosing of DOACs and Clinical Outcomes,” Journal of the American College of Cardiology 76 (2020): 1808–1810. [DOI] [PubMed] [Google Scholar]
  • 114. Steffel J., Collins R., Antz M., et al., “European Heart Rhythm Association Practical Guide on the Use of Non‐Vitamin K Antagonist Oral Anticoagulants in Patients With Atrial Fibrillation,” Europace 2021, no. 23 (2021): 1612–1676. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 115. Suwa M., Morii I., Kino M., et al., “Efficacy and Safety of Rivaroxaban, Apixaban, and Edoxaban for Nonvalvular Atrial Fibrillation Based on Blood Coagulation Activity and Drug Plasma Concentration: SETtsu and North Osaka Multicenter Direct Oral AntiCoagulant (SET DOAC) Registry,” Pharmaceuticals (Basel) 17, no. 11 (2024): 1431, 10.3390/ph17111431. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 116. Jaffer I. H., Chan N., Roberts R., Fredenburgh J. C., Eikelboom J. W., and Weitz J. I., “Comparison of the Ecarin Chromogenic Assay and Diluted Thrombin Time for Quantification of Dabigatran Concentrations,” Journal of Thrombosis and Haemostasis 15 (2017): 2377–2387. [DOI] [PubMed] [Google Scholar]
  • 117. Dale B. J., Chan N. C., and Eikelboom J. W., “Laboratory Measurement of the Direct Oral Anticoagulants,” British Journal of Haematology 172 (2016): 315–336. [DOI] [PubMed] [Google Scholar]
  • 118. Conway S. E., Hwang A. Y., Ponte C. D., and Gums J. G., “Laboratory and Clinical Monitoring of Direct Acting Oral Anticoagulants: What Clinicians Need to Know,” Pharmacotherapy 37 (2017): 236–248. [DOI] [PubMed] [Google Scholar]
  • 119. Reilly P. A., Lehr T., Haertter S., et al., “The Effect of Dabigatran Plasma Concentrations and Patient Characteristics on the Frequency of Ischemic Stroke and Major Bleeding in Atrial Fibrillation Patients: the RE‐LY Trial (Randomized Evaluation of Long‐Term Anticoagulation Therapy),” Journal of the American College of Cardiology 63 (2014): 321–328. [DOI] [PubMed] [Google Scholar]
  • 120. Ruff C. T., Giugliano R. P., Braunwald E., et al., “Association Between Edoxaban Dose, Concentration, Anti‐Factor Xa Activity, and Outcomes: An Analysis of Data From the Randomised, Double‐Blind ENGAGE AF‐TIMI 48 Trial,” Lancet 385 (2015): 2288–2295. [DOI] [PubMed] [Google Scholar]
  • 121. Chao T. F., Chen S. A., Ruff C. T., et al., “Clinical Outcomes, Edoxaban Concentration, and Anti‐Factor Xa Activity of Asian Patients With Atrial Fibrillation Compared With Non‐Asians in the ENGAGE AF‐TIMI 48 Trial,” European Heart Journal 40 (2019): 1518–1527. [DOI] [PubMed] [Google Scholar]
  • 122. Lin S. Y., Tang S. C., Kuo C. H., et al., “Impact of Direct Oral Anticoagulant Concentration on Clinical Outcomes in Asian Patients With Atrial Fibrillation,” Clinical Pharmacology and Therapeutics 114 (2023): 230–238. [DOI] [PubMed] [Google Scholar]
  • 123. Lin S. Y., Kuo C. H., Ho L. T., et al., “Association Between Apixaban Concentration and Clinical Outcomes in Asians With Atrial Fibrillation,” Circulation. Arrhythmia and Electrophysiology 15 (2022): e010693. [DOI] [PubMed] [Google Scholar]
  • 124. Connolly S. J., Ezekowitz M. D., Yusuf S., et al., “Investigators. Dabigatran Versus Warfarin in Patients With Atrial Fibrillation,” New England Journal of Medicine 361 (2009): 1139–1151. [DOI] [PubMed] [Google Scholar]
  • 125. Upreti V. V., Wang J., Barrett Y. C., et al., “Effect of Extremes of Body Weight on the Pharmacokinetics, Pharmacodynamics, Safety and Tolerability of Apixaban in Healthy Subjects,” British Journal of Clinical Pharmacology 76 (2013): 908–916. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 126. Bendayan M., Mardigyan V., Williamson D., et al., “Muscle Mass and Direct Oral Anticoagulant Activity in Older Adults With Atrial Fibrillation,” Journal of the American Geriatrics Society 69 (2021): 1012–1018. [DOI] [PubMed] [Google Scholar]
  • 127. Kido K., Shimizu M., Shiga T., and Hashiguchi M., “Evaluating the Concomitant Use of Diltiazem or Verapamil With Direct Oral Anticoagulants: A Meta‐Analysis,” Annals of Pharmacotherapy 60 (2026): 36–41. [DOI] [PubMed] [Google Scholar]
  • 128. Okumura K., Akao M., Suzuki S., and Yamashita T., “Stroke Prevention With Oral Anticoagulants in High‐Risk Atrial Fibrillation in an Aging Population,” JACC Advances 4 (2025): 101757. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 129. Eikelboom J. W., Wallentin L., Connolly S. J., et al., “Risk of Bleeding With 2 Doses of Dabigatran Compared With Warfarin in Older and Younger Patients With Atrial Fibrillation: An Analysis of the Randomized Evaluation of Long‐Term Anticoagulant Therapy (RE‐LY) Trial,” Circulation 123 (2011): 2363–2372. [DOI] [PubMed] [Google Scholar]
  • 130. Halperin J. L., Hankey G. J., Wojdyla D. M., et al., “Efficacy and Safety of Rivaroxaban Compared With Warfarin Among Elderly Patients With Nonvalvular Atrial Fibrillation in the Rivaroxaban Once Daily, Oral, Direct Factor Xa Inhibition Compared With Vitamin K Antagonism for Prevention of Stroke and Embolism Trial in Atrial Fibrillation (ROCKET AF),” Circulation 130 (2014): 138–146. [DOI] [PubMed] [Google Scholar]
  • 131. Halvorsen S., Atar D., Yang H., et al., “Efficacy and Safety of Apixaban Compared With Warfarin According to Age for Stroke Prevention in Atrial Fibrillation: Observations From the ARISTOTLE Trial,” European Heart Journal 35 (2014): 1864–1872. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 132. Kato E. T., Giugliano R. P., Ruff C. T., et al., “Efficacy and Safety of Edoxaban in Elderly Patients With Atrial Fibrillation in the ENGAGE AF‐TIMI 48 Trial,” Journal of the American Heart Association 5, no. 5 (2016): e003432. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 133. Yamashita T., Igawa Y., Fukuzawa M., Hayashi T., Hennig S., and Okumura K., “Pharmacokinetics of Edoxaban 15 mg in Very Elderly Patients With Nonvalvular Atrial Fibrillation: A Subanalysis of the ELDERCARE‐AF Study,” Thrombosis and Haemostasis 124 (2024): 874–882. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 134. Healey J. S., Lopes R. D., Granger C. B., et al., “Apixaban for Stroke Prevention in Subclinical Atrial Fibrillation,” New England Journal of Medicine 390 (2024): 107–117. [DOI] [PubMed] [Google Scholar]
  • 135. Kirchhof P., Toennis T., Goette A., et al., “Investigators N‐A, Sites N‐A, investigators. Anticoagulation With Edoxaban in Patients With Atrial High‐Rate Episodes,” New England Journal of Medicine 389 (2023): 1167–1179. [DOI] [PubMed] [Google Scholar]
  • 136. Chao T. F., Lau C. P., Choi E. K., et al., “Asia Pacific Heart Rhythm Society (APHRS) Scientific Statement on Stroke Prevention Strategies in Patients With Device‐Detected Atrial Fibrillation: the 4S‐DDAF Approach,” Lancet Regional Health – Western Pacific 65 (2025): 101770. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 137. Van Gelder I. C., Healey J. S., Crijns H., et al., “Duration of Device‐Detected Subclinical Atrial Fibrillation and Occurrence of Stroke in ASSERT,” European Heart Journal 38 (2017): 1339–1344. [DOI] [PubMed] [Google Scholar]
  • 138. Boriani G., McIntyre W. F., Ramasundarahettige C., et al., “Atrial Fibrillation Progression in Patients With Device‐Detected Subclinical Atrial Fibrillation: Insights From the ARTESiA Trial,” Heart Rhythm 22 (2025): e1260–e1268. [DOI] [PubMed] [Google Scholar]
  • 139. Shoamanesh A., Field T. S., Coutts S. B., et al., “Apixaban Versus Aspirin for Stroke Prevention in People With Subclinical Atrial Fibrillation and a History of Stroke or Transient Ischaemic Attack: Subgroup Analysis of the ARTESiA Randomised Controlled Trial,” Lancet Neurology 24 (2025): 140–151. [DOI] [PubMed] [Google Scholar]
  • 140. Lopes R. D., Granger C. B., Wojdyla D. M., et al., “Apixaban vs Aspirin According to CHA(2)DS(2)‐VASc Score in Subclinical Atrial Fibrillation: Insights From ARTESiA,” Journal of the American College of Cardiology 84 (2024): 354–364. [DOI] [PubMed] [Google Scholar]
  • 141. Schnabel R. B., Benezet‐Mazuecos J., Becher N., et al., “Anticoagulation in Device‐Detected Atrial Fibrillation With or Without Vascular Disease: A Combined Analysis of the NOAH‐AFNET 6 and ARTESiA Trials,” European Heart Journal 45 (2024): 4902–4916. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 142. Bucci T., Proietti M., Shantsila A., et al., “Integrated Care for Atrial Fibrillation Using the ABC Pathway in the Prospective APHRS‐AF Registry,” JACC Asia 3 (2023): 580–591. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 143. Bucci T., Nabradalik K., Irlik K., et al., “Adherence to the ABC (Atrial Fibrillation Better Care) Pathway and Risk of Adverse Outcomes in Patients With Chronic Kidney Disease: A Report From the Prospective APHRS‐AF Registry,” Lancet Regional Health – Western Pacific 58 (2025): 101570. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 144. Chu M., Zhang S., Gong J., et al., “Telemedicine‐Based Integrated Management of Atrial Fibrillation in Village Clinics: A Cluster Randomized Trial,” Nature Medicine 31 (2025): 1276–1285. [DOI] [PubMed] [Google Scholar]
  • 145. Bucci T., Romiti G. F., Mantovani M., et al., “Adverse Events and ABC Pathway Adherence Across AF Clinical Phenotypes: APHRS‐AF Registry Cluster Analysis Study,” JACC Asia (2026): S2772‐3747(26)00553‐3, 10.1016/j.jacasi.2026.06.038. [DOI] [PubMed] [Google Scholar]
  • 146. Al‐Saady N. M., Obel O. A., and Camm A. J., “Left Atrial Appendage: Structure, Function, and Role in Thromboembolism,” Heart (British Cardiac Society) 82 (1999): 547–554. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 147. Holmes D. R., Reddy V. Y., Turi Z. G., et al., “Percutaneous Closure of the Left Atrial Appendage Versus Warfarin Therapy for Prevention of Stroke in Patients With Atrial Fibrillation: A Randomised Non‐Inferiority Trial,” Lancet 374 (2009): 534–542. [DOI] [PubMed] [Google Scholar]
  • 148. D. R. Holmes, Jr. , Kar S., Price M. J., et al., “Prospective Randomized Evaluation of the Watchman Left Atrial Appendage Closure Device in Patients With Atrial Fibrillation Versus Long‐Term Warfarin Therapy: the PREVAIL Trial,” Journal of the American College of Cardiology 64 (2014): 1–12. [DOI] [PubMed] [Google Scholar]
  • 149. Reddy V. Y., Doshi S. K., Kar S., et al., “5‐Year Outcomes After Left Atrial Appendage Closure: From the PREVAIL and PROTECT AF Trials,” Journal of the American College of Cardiology 70 (2017): 2964–2975. [DOI] [PubMed] [Google Scholar]
  • 150. Osmancik P., Herman D., Neuzil P., et al., “Left Atrial Appendage Closure Versus Direct Oral Anticoagulants in High‐Risk Patients With Atrial Fibrillation,” Journal of the American College of Cardiology 75 (2020): 3122–3135. [DOI] [PubMed] [Google Scholar]
  • 151. Doshi S. K., Kar S., Nair D. G., et al., “Left Atrial Appendage Closure or Anticoagulation for Atrial Fibrillation,” New England Journal of Medicine 394 (2026): 2083–2094. [DOI] [PubMed] [Google Scholar]
  • 152. Landmesser U., Skurk C., Kirchhof P., et al., “Investigators C‐AT. Left Atrial Appendage Closure or Medical Therapy in Atrial Fibrillation,” New England Journal of Medicine 394 (2026): 1270–1280. [DOI] [PubMed] [Google Scholar]
  • 153. Wazni O. M., Saliba W. I., Nair D. G., et al., “Left Atrial Appendage Closure After Ablation for Atrial Fibrillation,” New England Journal of Medicine 392 (2025): 1277–1287. [DOI] [PubMed] [Google Scholar]
  • 154. Du X., Chu H., Yang B., et al., “Strategy Optimization for a Combined Procedure in Patients With Atrial Fibrillation: The COMBINATION Randomized Clinical Trial,” JAMA Network Open 7 (2024): e2445084. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 155. Whitlock R. P., Belley‐Cote E. P., Paparella D., et al., “Left Atrial Appendage Occlusion During Cardiac Surgery to Prevent Stroke,” New England Journal of Medicine 384 (2021): 2081–2091. [DOI] [PubMed] [Google Scholar]
  • 156. Ruzieh M., Foy A. J., and Mandrola J., “Left Atrial Appendage Closure Lacks Sufficient Evidence for Routine Use,” Thrombosis and Haemostasis (2026), 10.1055/a-2862-6722. [DOI] [PubMed] [Google Scholar]
  • 157. Chan Y. H., Cheng W. H., Yeh Y. H., et al., “Left Atrial Appendage Closure vs Direct Oral Anticoagulants in Atrial Fibrillation: Meta‐Analysis of Randomized Trials,” JACC Advances 5 (2026): 102933. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 158. Laudani C., Bujak K., Giacoppo D., et al., “Catheter‐Based Left Atrial Appendage Closure vs Oral Anticoagulation in Patients With Atrial Fibrillation: A Systematic Review and Meta‐Analysis,” JAMA Cardiology (2026), 10.1001/jamacardio.2026.2640. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 159. Karakasis P., Tzeis S., Samaras A., et al., “Long‐Term Efficacy and Safety of Left Atrial Appendage Closure vs. Oral Anticoagulation in Atrial Fibrillation: A Meta‐Analysis of Randomized Controlled Trials,” Europace 28, no. 7 (2026): euag159, 10.1093/europace/euag159. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 160. Potpara T., Grygier M., Haeusler K. G., et al., “An International Consensus Practical Guide on Left Atrial Appendage Closure for the Non‐Implanting Physician: Executive Summary,” Thrombosis and Haemostasis 125 (2025): 825–846. [DOI] [PubMed] [Google Scholar]
  • 161. Kaisaier W., Xu Z., Ye M., et al., “Direct Oral Anticoagulants vs Dual Antiplatelet Therapy Following Left Atrial Appendage Closure in Atrial Fibrillation,” Heart Rhythm 23, no. 9 (2026): e1947–e1957. [DOI] [PubMed] [Google Scholar]
  • 162. Nielsen‐Kudsk J. E., Johnsen S. P., Wester P., et al., “Left Atrial Appendage Occlusion Versus Standard Medical Care in Patients With Atrial Fibrillation and Intracerebral Haemorrhage: A Propensity Score‐Matched Follow‐Up Study,” EuroIntervention: Journal of EuroPCR in Collaboration With the Working Group on Interventional Cardiology of the European Society of Cardiology 13 (2017): 371–378. [DOI] [PubMed] [Google Scholar]
  • 163. Reddy V. Y., Mobius‐Winkler S., Miller M. A., et al., “Left Atrial Appendage Closure With the Watchman Device in Patients With a Contraindication for Oral Anticoagulation: the ASAP Study (ASA Plavix Feasibility Study With Watchman Left Atrial Appendage Closure Technology),” Journal of the American College of Cardiology 61 (2013): 2551–2556. [DOI] [PubMed] [Google Scholar]
  • 164. Boersma L. V., Ince H., Kische S., et al., “Efficacy and Safety of Left Atrial Appendage Closure With WATCHMAN in Patients With or Without Contraindication to Oral Anticoagulation: 1‐Year Follow‐Up Outcome Data of the EWOLUTION Trial,” Heart Rhythm: The Official Journal of the Heart Rhythm Society 14 (2017): 1302–1308. [DOI] [PubMed] [Google Scholar]
  • 165. Urbanek L., Heine G. H., Reddavid C., et al., “Left Atrial Appendage Occlusion in Patients With Atrial Fibrillation and Hemodialysis: An International,” Multicentric Registry. JACC Clinical Electrophysiology 11 (2025): 71–82. [DOI] [PubMed] [Google Scholar]
  • 166. Tanaka S., Imamura T., Fukuda N., et al., “Outcomes of Left Atrial Appendage Closure in Hemodialysis Patients With Atrial Fibrillation: The OCEAN‐LAAC Registry,” JACC Asia 5 (2025): 174–186. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 167. Munir M. B., Tan Z., Pun P. H., et al., “Association of Chronic Kidney Disease and Kidney Failure With Replacement Therapy With Procedural and Long‐Term Outcomes After First‐Generation Watchman Device: Insights From the NCDR LAAO Registry,” Heart Rhythm 22 (2025): 1443–1451. [DOI] [PubMed] [Google Scholar]
  • 168. Rodriguez‐Riascos J. F., Vemulapalli H. S., Akin I., et al., “Left Atrial Appendage Occlusion in Patients With End‐Stage Renal Disease: An Individual Patient‐Level Meta‐Analysis,” Europace 27, no. 10 (2025): euaf198, 10.1093/europace/euaf198. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 169. Poon M. T., Fonville A. F., and Al‐Shahi S. R., “Long‐Term Prognosis After Intracerebral Haemorrhage: Systematic Review and Meta‐Analysis,” Journal of Neurology, Neurosurgery, and Psychiatry 85 (2014): 660–667. [DOI] [PubMed] [Google Scholar]
  • 170. Tsai C. F., Thomas B., and Sudlow C. L., “Epidemiology of Stroke and Its Subtypes in Chinese vs White Populations: A Systematic Review,” Neurology 81 (2013): 264–272. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 171. Hart R. G., Pearce L. A., and Aguilar M. I., “Meta‐Analysis: Antithrombotic Therapy to Prevent Stroke in Patients Who Have Nonvalvular Atrial Fibrillation,” Annals of Internal Medicine 146 (2007): 857–867. [DOI] [PubMed] [Google Scholar]
  • 172. van Asch C. J., Luitse M. J., Rinkel G. J., van der Tweel I., Algra A., and Klijn C. J., “Incidence, Case Fatality, and Functional Outcome of Intracerebral Haemorrhage Over Time, According to Age, Sex, and Ethnic Origin: A Systematic Review and Meta‐Analysis,” Lancet Neurology 9 (2010): 167–176. [DOI] [PubMed] [Google Scholar]
  • 173. Chiang C. E., Chao T. F., Choi E. K., et al., “Stroke Prevention in Atrial Fibrillation: A Scientific Statement of JACC: Asia (Part 1),” JACC Asia 2 (2022): 395–411. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 174. Schreuder F., van Nieuwenhuizen K. M., Hofmeijer J., et al., “Apixaban Versus no Anticoagulation After Anticoagulation‐Associated Intracerebral Haemorrhage in Patients With Atrial Fibrillation in The Netherlands (APACHE‐AF): A Randomised, Open‐Label, Phase 2 Trial,” Lancet Neurology 20 (2021): 907–916. [DOI] [PubMed] [Google Scholar]
  • 175. So S. C., “Effects of Oral Anticoagulation for Atrial Fibrillation After Spontaneous Intracranial Haemorrhage in the UK: A Randomised, Open‐Label, Assessor‐Masked, Pilot‐Phase, Non‐Inferiority Trial,” Lancet Neurology 20 (2021): 842–853. [DOI] [PubMed] [Google Scholar]
  • 176. Al‐Shahi Salman R., Stephen J., Tierney J. F., et al., “Collaboration of Controlled Randomised Trials of Long‐Term Oral Antithrombotic Agents After Spontaneous Intracranial H. Effects of Oral Anticoagulation in People With Atrial Fibrillation After Spontaneous Intracranial Haemorrhage (COCROACH): Prospective, Individual Participant Data Meta‐Analysis of Randomised Trials,” Lancet Neurology 22 (2023): 1140–1149. [DOI] [PubMed] [Google Scholar]
  • 177. Veltkamp R., Korompoki E., Harvey K. H., et al., “Direct Oral Anticoagulants Versus no Anticoagulation for the Prevention of Stroke in Survivors of Intracerebral Haemorrhage With Atrial Fibrillation (PRESTIGE‐AF): A Multicentre, Open‐Label, Randomised, Phase 3 Trial,” Lancet 405 (2025): 927–936. [DOI] [PubMed] [Google Scholar]
  • 178. Wu Y. H., Lin S. Y., Lin F. J., Tang S. C., and Wang C. C., “Outcomes of Reinitiating Direct Oral Anticoagulants After Intracranial Hemorrhage: A Sequential Target Trial Emulation Study,” JACC Asia 5 (2025): 361–370. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 179. Lee S. R., “Balancing Risks and Timing: Reinitiating DOACs After Intracranial Hemorrhage in Atrial Fibrillation Patients,” JACC Asia 5 (2025): 371–373. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 180. Lee S. R., Choi E. K., Kwon S., et al., “Oral Anticoagulation in Asian Patients With Atrial Fibrillation and a History of Intracranial Hemorrhage,” Stroke 51 (2020): 416–423. [DOI] [PubMed] [Google Scholar]
  • 181. Tsai C. T., Liao J. N., Chiang C. E., et al., “Association of Ischemic Stroke, Major Bleeding, and Other Adverse Events With Warfarin Use vs Non‐Vitamin K Antagonist Oral Anticoagulant Use in Patients With Atrial Fibrillation With a History of Intracranial Hemorrhage,” JAMA Network Open 3 (2020): e206424. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 182. Paciaroni M., Agnelli G., Falocci N., et al., “Early Recurrence and Cerebral Bleeding in Patients With Acute Ischemic Stroke and Atrial Fibrillation: Effect of Anticoagulation and Its Timing: The RAF Study,” Stroke:A Journal of Cerebral Circulation 46 (2015): 2175–2182. [DOI] [PubMed] [Google Scholar]
  • 183. Seiffge D. J., Werring D. J., Paciaroni M., et al., “Timing of Anticoagulation After Recent Ischaemic Stroke in Patients With Atrial Fibrillation,” Lancet Neurology 18 (2019): 117–126. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 184. Dehbi H. M., Fischer U., Asberg S., et al., “Collaboration on the Optimal Timing of Anticoagulation After Ischaemic Stroke and Atrial Fibrillation: A Systematic Review and Prospective Individual Participant Data Meta‐Analysis of Randomised Controlled Trials (CATALYST),” Lancet 406 (2025): 43–51. [DOI] [PubMed] [Google Scholar]
  • 185. Oldgren J., Asberg S., Hijazi Z., et al., “Early Versus Delayed Non‐Vitamin K Antagonist Oral Anticoagulant Therapy After Acute Ischemic Stroke in Atrial Fibrillation (TIMING): A Registry‐Based Randomized Controlled Noninferiority Study,” Circulation 146 (2022): 1056–1066. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 186. Fischer U., Koga M., Strbian D., et al., “Early Versus Later Anticoagulation for Stroke With Atrial Fibrillation,” New England Journal of Medicine 388 (2023): 2411–2421. [DOI] [PubMed] [Google Scholar]
  • 187. Werring D. J., Dehbi H. M., Ahmed N., et al., “Optimal Timing of Anticoagulation After Acute Ischaemic Stroke With Atrial Fibrillation (OPTIMAS): A Multicentre, Blinded‐Endpoint, Phase 4, Randomised Controlled Trial,” Lancet (2024): S0140‐6736(24)02197‐4, 10.1016/s0140-6736(24)02197-4. [DOI] [PubMed] [Google Scholar]
  • 188. Warach S. J., Davis L. A., Lawrence P., et al., “Optimal Delay Time to Initiate Anticoagulation After Ischemic Stroke in Atrial Fibrillation: A Pragmatic, Response‐Adaptive Randomized Clinical Trial,” JAMA Neurology 82 (2025): 470–476. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 189. Park J., Lee S. R., Choi E. K., et al., “Effectiveness and Safety of Direct Oral Anticoagulant for Secondary Prevention in Asians With Atrial Fibrillation,” Journal of Clinical Medicine 8, no. 12 (2019): 2228, 10.3390/jcm8122228. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 190. Zhao J., Chen C., Lu L., Wang L., and Chen F., “NOACs Effects in the Secondary Prevention of Atrial Fibrillation‐Related Ischemic Stroke/TIA: A Systematic Review and Meta‐Analysis,” Journal of Neurology 273 (2026): 113. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 191. Olesen J. B., Lip G. Y., Kamper A. L., et al., “Stroke and Bleeding in Atrial Fibrillation With Chronic Kidney Disease,” New England Journal of Medicine 367 (2012): 625–635. [DOI] [PubMed] [Google Scholar]
  • 192. Parker K., Power A., Buka R., et al., “Anticoagulation for Atrial Fibrillation in Adults With Advanced Kidney Disease: UK Kidney Association Clinical Practice Guideline,” BMC Nephrology (2026), 10.1186/s12882-026-05270-9. [DOI] [Google Scholar]
  • 193. Chan P. H., Huang D., Yip P. S., et al., “Ischaemic Stroke in Patients With Atrial Fibrillation With Chronic Kidney Disease Undergoing Peritoneal Dialysis,” Europace 18 (2016): 665–671. [DOI] [PubMed] [Google Scholar]
  • 194. De Vriese A. S. and Heine G., “Anticoagulation Management in Haemodialysis Patients With Atrial Fibrillation: Evidence and Opinion,” Nephrology, Dialysis, Transplantation 37 (2022): 2072–2079. [DOI] [PubMed] [Google Scholar]
  • 195. Travlos C. K., Chirgwin‐Dasgupta A., Trinh E., Sniderman A. D., Alam A., and Mavrakanas T. A., “Prediction Models for Ischemic Stroke and Bleeding in Dialysis Patients: A Systematic Review and Meta‐Analysis,” Clinical Kidney Journal 17 (2024): sfae347. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 196. Granger C. B., Alexander J. H., McMurray J. J., et al., “Apixaban Versus Warfarin in Patients With Atrial Fibrillation,” New England Journal of Medicine 365 (2011): 981–992. [DOI] [PubMed] [Google Scholar]
  • 197. Patel M. R., Mahaffey K. W., Garg J., et al., “Rivaroxaban Versus Warfarin in Nonvalvular Atrial Fibrillation,” New England Journal of Medicine 365 (2011): 883–891. [DOI] [PubMed] [Google Scholar]
  • 198. Giugliano R. P., Ruff C. T., Braunwald E., et al., “Edoxaban Versus Warfarin in Patients With Atrial Fibrillation,” New England Journal of Medicine 369 (2013): 2093–2104. [DOI] [PubMed] [Google Scholar]
  • 199. Calderon Martinez E., Sanchez Cruz C., Diarte Acosta E. Y., et al., “Efficacy and Safety of Novel Anticoagulant Therapies in Patients With Chronic Kidney Disease‐a Systematic Review and Meta‐Analysis,” Journal of Nephrology 38 (2025): 111–126. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 200. De Vriese A. S., Caluwe R., Van Der Meersch H., De Boeck K., and De Bacquer D., “Safety and Efficacy of Vitamin K Antagonists Versus Rivaroxaban in Hemodialysis Patients With Atrial Fibrillation: A Multicenter Randomized Controlled Trial,” Journal of the American Society of Nephrology 32 (2021): 1474–1483. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 201. De Vriese A. S., Caluwe R., Pyfferoen L., et al., “Multicenter Randomized Controlled Trial of Vitamin K Antagonist Replacement by Rivaroxaban With or Without Vitamin K2 in Hemodialysis Patients With Atrial Fibrillation: the Valkyrie Study,” Journal of the American Society of Nephrology 31 (2020): 186–196. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 202. Pokorney S. D., Chertow G. M., Al‐Khalidi H. R., et al., “Apixaban for Patients With Atrial Fibrillation on Hemodialysis: A Multicenter Randomized Controlled Trial,” Circulation 146 (2022): 1735–1745. [DOI] [PubMed] [Google Scholar]
  • 203. Reinecke H., Engelbertz C., Bauersachs R., et al., “A Randomized Controlled Trial Comparing Apixaban With the Vitamin K Antagonist Phenprocoumon in Patients on Chronic Hemodialysis: The AXADIA‐AFNET 8 Study,” Circulation 147 (2023): 296–309. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 204. Mavrakanas T. A., Garlo K., and Charytan D. M., “Apixaban Versus no Anticoagulation in Patients Undergoing Long‐Term Dialysis With Incident Atrial Fibrillation,” Clinical Journal of the American Society of Nephrology 15 (2020): 1146–1154. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 205. Kaisaier W., Chen Y., Lip G. Y. H., Liu C., and Zhu W., “Safety and Efficacy of Factor Xa Inhibitors in Atrial Fibrillation Patients on Dialysis: Evidence From Four Randomized Controlled Trials,” Thrombosis and Haemostasis 126 (2026): 11–22. [DOI] [PubMed] [Google Scholar]
  • 206. Chang T. Y., Chan Y. H., Chao T. F., et al., “Efficacy and Safety of Non‐Vitamin K Antagonist Oral Anticoagulants Versus Warfarin in Atrial Fibrillation and Kidney Failure Under Hemodialysis: A Meta‐Analysis of Controlled Randomized Trials,” Journal of Arrhythmia 41 (2025): e70094. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 207. Kuno T., Takagi H., Ando T., et al., “Oral Anticoagulation for Patients With Atrial Fibrillation on Long‐Term Hemodialysis,” Journal of the American College of Cardiology 75 (2020): 273–285. [DOI] [PubMed] [Google Scholar]
  • 208. Elenjickal E. J., Travlos C. K., Marques P., and Mavrakanas T. A., “Anticoagulation in Patients With Chronic Kidney Disease,” American Journal of Nephrology 55 (2024): 146–164. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 209. Ballegaard E. L. F., Lindhard K., Lindhardt M., et al., “Protocol for a Randomised Controlled Trial Comparing Warfarin With no Oral Anticoagulation in Patients With Atrial Fibrillation on Chronic Dialysis: the Danish Warfarin‐Dialysis (DANWARD) Trial,” BMJ Open 14 (2024): e081961. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 210. See L. C., Lee H. F., Chao T. F., et al., “Effectiveness and Safety of Direct Oral Anticoagulants in an Asian Population With Atrial Fibrillation Undergoing Dialysis: A Population‐Based Cohort Study and Meta‐Analysis,” Cardiovascular Drugs and Therapy 35 (2021): 975–986. [DOI] [PubMed] [Google Scholar]
  • 211. Roh J. H., Kim Y. G., Kim D., et al., “Direct Oral Anticoagulants for Oral Anticoagulants‐Naive Asian Patients With Atrial Fibrillation and End‐Stage Renal Disease Undergoing Dialysis,” Scientific Reports 14 (2024): 14679. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 212. Kee Y. K., Jeon H. J., Oh J., et al., “Direct Oral Anti‐Xa Anticoagulants Versus Warfarin in Newly Diagnosed Atrial Fibrillation and CKD: the Korean National Health Insurance Data,” Frontiers in Medicine 10 (2023): 1212816. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 213. Dhar G., Phadnis M. A., Hunt S. L., et al., “Left Atrial Appendage Occlusion vs Anticoagulants in Dialysis With Atrial Fibrillation,” JAMA Network Open 8 (2025): e2530990. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 214. Chen J. J., Lin L. Y., Yang Y. H., Hwang J. J., Chen P. C., and Lin J. L., “Anti‐Platelet or Anti‐Coagulant Agent for the Prevention of Ischemic Stroke in Patients With End‐Stage Renal Disease and Atrial Fibrillation–a Nation‐Wide Database Analyses,” International Journal of Cardiology 177 (2014): 1008–1011. [DOI] [PubMed] [Google Scholar]
  • 215. Nochaiwong S., Ruengorn C., Awiphan R., Dandecha P., Noppakun K., and Phrommintikul A., “Efficacy and Safety of Warfarin in Dialysis Patients With Atrial Fibrillation: A Systematic Review and Meta‐Analysis,” Open Heart 3 (2016): e000441. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 216. Kao T. W., Chen Z. W., and Lin Y. H., “Anticoagulation for Patients With Concomitant Atrial Fibrillation and End‐Stage Renal Disease: A Systematic Review and Network Meta‐Analysis,” Journal of the American Heart Association 13 (2024): e034176. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 217. Kodani E., Atarashi H., Inoue H., et al., “Use of Warfarin in Elderly Patients With Non‐Valvular Atrial Fibrillation—Subanalysis of the J‐RHYTHM Registry,” Circulation Journal 79 (2015): 2345–2352. [DOI] [PubMed] [Google Scholar]
  • 218. Patti G., Lucerna M., Pecen L., et al., “Bleeding Outcomes and Effect of Different Antithrombotic Strategies in Very Elderly Patients With Atrial Fibrillation: A Sub‐Analysis From the PREFER in AF (PREvention oF Thromboembolic Events‐European Registry in Atrial Fibrillation),” Journal of the American Heart Association 6, no. 7 (2017): e005657, 10.1161/JAHA.117.005657. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 219. Kato E. T., Goto S., and Giugliano R. P., “Overview of Oral Antithrombotic Treatment in Elderly Patients With Atrial Fibrillation,” Ageing Research Reviews 49 (2019): 115–124. [DOI] [PubMed] [Google Scholar]
  • 220. Chao T. F., Chiang C. E., Liao J. N., Chen T. J., Lip G. Y. H., and Chen S. A., “Comparing the Effectiveness and Safety of Nonvitamin K Antagonist Oral Anticoagulants and Warfarin in Elderly Asian Patients With Atrial Fibrillation: A Nationwide Cohort Study,” Chest 157 (2020): 1266–1277. [DOI] [PubMed] [Google Scholar]
  • 221. Chao T. F., Liu C. J., Tuan T. C., et al., “Lifetime Risks, Projected Numbers, and Adverse Outcomes in Asian Patients With Atrial Fibrillation: A Report From the Taiwan Nationwide AF Cohort Study,” Chest 153 (2018): 453–466. [DOI] [PubMed] [Google Scholar]
  • 222. Di Carlo A., Bellino L., Consoli D., et al., “National Research Program: Progetto FAILFAiI. Prevalence of Atrial Fibrillation in the Italian Elderly Population and Projections From 2020 to 2060 for Italy and the European Union: the FAI Project,” Europace 21, no. 10 (2019): 1468–1475. [DOI] [PubMed] [Google Scholar]
  • 223. Zimerman A., Braunwald E., Steffel J., et al., “Dose Reduction of Edoxaban in Patients 80 Years and Older With Atrial Fibrillation: Post Hoc Analysis of the ENGAGE AF‐TIMI 48 Randomized Clinical Trial,” JAMA Cardiology 9 (2024): 817–825. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 224. Okumura K., Akao M., Fukuzawa M., Igawa Y., Hayashi T., and Yamashita T., “Association of Edoxaban Pharmacokinetics With Bleeding in Older Patients With Atrial Fibrillation Treated With Low‐Dose Edoxaban: A Post Hoc Analysis of a Randomized Controlled Trial,” Journal of the American Heart Association 15 (2026): e042950. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 225. Romiti G. F., Lip G. Y. H., and Proietti M., “Clinical Complexity in Atrial Fibrillation: A Call for a Multidimensional Framework,” JACC Advances 5 (2026): 102874. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 226. Guo Y., Romiti G. F., Proietti M., et al., “Mobile Health Technology Integrated Care in Older Atrial Fibrillation Patients: A Subgroup Analysis of the mAFA‐II Randomised Clinical Trial,” Age and Ageing 51, no. 11 (2022): afac245. [DOI] [PubMed] [Google Scholar]
  • 227. Li M., Chen Y., Chu M., et al., “Village Doctor‐Led Telemedicine for Rural Patients Aged 75 Years and Older With AF: A Prespecified Secondary Analysis of the MIRACLE‐AF Trial,” JAMA Network Open 9 (2026): e261385. [DOI] [PubMed] [Google Scholar]
  • 228. De Caterina R., Andersson U., Alexander J. H., et al., “History of Bleeding and Outcomes With Apixaban Versus Warfarin in Patients With Atrial Fibrillation in the Apixaban for Reduction in Stroke and Other Thromboembolic Events in Atrial Fibrillation Trial,” American Heart Journal 175 (2016): 175–183. [DOI] [PubMed] [Google Scholar]
  • 229. Okumura K., Yamashita T., Suzuki S., Akao M., and Investigators J. E. A., “A Multicenter Prospective Cohort Study to Investigate the Effectiveness and Safety of Apixaban in Japanese Elderly Atrial Fibrillation Patients (J‐ELD AF Registry),” Clinical Cardiology 43 (2020): 251–259. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 230. Okumura K., Yamashita T., Akao M., et al., “Oral Anticoagulants in Very Elderly Nonvalvular Atrial Fibrillation Patients With High Bleeding Risks: ANAFIE Registry,” JACC Asia 2 (2022): 720–733. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 231. Lee K. H., Chen Y. F., Yeh W. Y., et al., “Optimal Stroke Preventive Strategy for Patients Aged 80 Years or Older With Atrial Fibrillation: A Systematic Review With Traditional and Network Meta‐Analysis,” Age and Ageing 51, no. 12 (2022): afac292, 10.1093/ageing/afac292. [DOI] [PubMed] [Google Scholar]
  • 232. Lauw M. N., Eikelboom J. W., Coppens M., et al., “Effects of Dabigatran According to Age in Atrial Fibrillation,” Heart 103 (2017): 1015–1023. [DOI] [PubMed] [Google Scholar]
  • 233. Chao T. F., Chan Y. H., Chiang C. E., et al., “Stroke Prevention With Direct Oral Anticoagulants in High‐Risk Elderly Atrial Fibrillation Patients at Increased Bleeding Risk,” European Heart Journal—Quality of Care and Clinical Outcomes 8 (2022): 730–738. [DOI] [PubMed] [Google Scholar]
  • 234. Chao T. F., Chiang C. E., Chan Y. H., et al., “Oral Anticoagulants in Extremely‐High‐Risk, Very Elderly (>90 Years) Patients With Atrial Fibrillation,” Heart Rhythm 18 (2021): 871–877. [DOI] [PubMed] [Google Scholar]
  • 235. Kuroda M., Tamiya E., Nose T., et al., “Effect of 15‐Mg Edoxaban on Clinical Outcomes in 3 Age Strata in Older Patients With Atrial Fibrillation: A Prespecified Subanalysis of the ELDERCARE‐AF Randomized Clinical Trial,” JAMA Cardiology 7 (2022): 583–590. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 236. Akashi S., Oguri M., Ikeno E., et al., “Outcomes and Safety of Very‐Low‐Dose Edoxaban in Frail Patients With Atrial Fibrillation in the ELDERCARE‐AF Randomized Clinical Trial,” JAMA Network Open 5 (2022): e2228500. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 237. Akao M., Yamashita T., Fukuzawa M., Hayashi T., and Okumura K., “Efficacy and Safety of Low‐Dose Edoxaban by Body Weight in Very Elderly Patients With Atrial Fibrillation: A Subanalysis of the Randomized ELDERCARE‐AF Trial,” Journal of the American Heart Association 13 (2024): e031506. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 238. Yoshida T., Nakamura A., Funada J., et al., “Efficacy and Safety of Edoxaban 15 mg According to Renal Function in Very Elderly Patients With Atrial Fibrillation: A Subanalysis of the ELDERCARE‐AF Trial,” Circulation 145 (2022): 718–720. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 239. Chyou J. Y., Barkoudah E., Dukes J. W., et al., “Atrial Fibrillation Occurring During Acute Hospitalization: A Scientific Statement From the American Heart Association,” Circulation 147 (2023): e676–e698. [DOI] [PubMed] [Google Scholar]
  • 240. Lubitz S. A., Yin X., Rienstra M., et al., “Long‐Term Outcomes of Secondary Atrial Fibrillation in the Community: the Framingham Heart Study,” Circulation 131 (2015): 1648–1655. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 241. McIntyre W. F., Um K. J., Cheung C. C., et al., “Atrial Fibrillation Detected Initially During Acute Medical Illness: A Systematic Review,” European Heart Journal Acute Cardiovascular Care 8 (2019): 130–141. [DOI] [PubMed] [Google Scholar]
  • 242. Gundlund A., Olesen J. B., Butt J. H., et al., “One‐Year Outcomes in Atrial Fibrillation Presenting During Infections: A Nationwide Registry‐Based Study,” European Heart Journal 41 (2020): 1112–1119. [DOI] [PubMed] [Google Scholar]
  • 243. Walkey A. J., Hammill B. G., Curtis L. H., and Benjamin E. J., “Long‐Term Outcomes Following Development of New‐Onset Atrial Fibrillation During Sepsis,” Chest 146 (2014): 1187–1195. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 244. Walkey A. J., Wiener R. S., Ghobrial J. M., Curtis L. H., and Benjamin E. J., “Incident Stroke and Mortality Associated With New‐Onset Atrial Fibrillation in Patients Hospitalized With Severe sepsis,” JAMA: The Journal of the American Medical Association 306 (2011): 2248–2254. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 245. Butt J. H., Olesen J. B., Havers‐Borgersen E., et al., “Risk of Thromboembolism Associated With Atrial Fibrillation Following Noncardiac Surgery,” Journal of the American College of Cardiology 72 (2018): 2027–2036. [DOI] [PubMed] [Google Scholar]
  • 246. Lin M. H., Kamel H., Singer D. E., Wu Y. L., Lee M., and Ovbiagele B., “Perioperative/Postoperative Atrial Fibrillation and Risk of Subsequent Stroke and/or Mortality,” Stroke 50 (2019): 1364–1371. [DOI] [PubMed] [Google Scholar]
  • 247. Gundlund A., Kumler T., Bonde A. N., et al., “Comparative Thromboembolic Risk in Atrial Fibrillation With and Without a Secondary Precipitant‐Danish Nationwide Cohort Study,” BMJ Open 9 (2019): e028468. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 248. Kim K., Yang P. S., Jang E., et al., “Increased Risk of Ischemic Stroke and Systemic Embolism in Hyperthyroidism‐Related Atrial Fibrillation: A Nationwide Cohort Study,” American Heart Journal 242 (2021): 123–131. [DOI] [PubMed] [Google Scholar]
  • 249. Airaksinen K. E., Gronberg T., Nuotio I., et al., “Thromboembolic Complications After Cardioversion of Acute Atrial Fibrillation: the FinCV (Finnish CardioVersion) Study,” Journal of the American College of Cardiology 62 (2013): 1187–1192. [DOI] [PubMed] [Google Scholar]
  • 250. Fatkin D., Kuchar D. L., Thorburn C. W., and Feneley M. P., “Transesophageal Echocardiography Before and During Direct Current Cardioversion of Atrial Fibrillation: Evidence for “Atrial Stunning” as a Mechanism of Thromboembolic Complications,” Journal of the American College of Cardiology 23 (1994): 307–316. [DOI] [PubMed] [Google Scholar]
  • 251. Joglar J. A., Chung M. K., Armbruster A. L., et al., “ACC/AHA/ACCP/HRS Guideline for the Diagnosis and Management of Atrial Fibrillation: A Report of the American College of Cardiology/American Heart Association Joint Committee on Clinical Practice Guidelines,” Circulation 2024, no. 149 (2023): e1–e156. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 252. Darwish O. S., Strube S., Nguyen H. M., and Tanios M. A., “Challenges of Anticoagulation for Atrial Fibrillation in Patients With Severe sepsis,” Annals of Pharmacotherapy 47 (2013): 1266–1271. [DOI] [PubMed] [Google Scholar]
  • 253. Walkey A. J., Quinn E. K., Winter M. R., McManus D. D., and Benjamin E. J., “Practice Patterns and Outcomes Associated With Use of Anticoagulation Among Patients With Atrial Fibrillation During Sepsis,” JAMA Cardiology 1 (2016): 682–690. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 254. Stuijver D. J., van Zaane B., Romualdi E., Brandjes D. P., Gerdes V. E., and Squizzato A., “The Effect of Hyperthyroidism on Procoagulant, Anticoagulant and Fibrinolytic Factors: A Systematic Review and Meta‐Analysis,” Thrombosis and Haemostasis 108 (2012): 1077–1088. [DOI] [PubMed] [Google Scholar]
  • 255. Wang E. Y., Hulme O. L., Khurshid S., et al., “Initial Precipitants and Recurrence of Atrial Fibrillation,” Circulation. Arrhythmia and Electrophysiology 13 (2020): e007716. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 256. Lowres N., Hillis G. S., Gladman M. A., et al., “Self‐Monitoring for Recurrence of Secondary Atrial Fibrillation Following Non‐Cardiac Surgery or Acute Illness: A Pilot Study,” International Journal of Cardiology Heart & Vasculature 29 (2020): 100566. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 257. Corica B., Romiti G. F., Basili S., and Proietti M., “Prevalence of New‐Onset Atrial Fibrillation and Associated Outcomes in Patients With Sepsis: A Systematic Review and Meta‐Analysis,” Journal of Personalized Medicine 12, no. 4 (2022): 547, 10.3390/jpm12040547. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 258. Klein Klouwenberg P. M., Frencken J. F., Kuipers S., et al., “Incidence, Predictors, and Outcomes of New‐Onset Atrial Fibrillation in Critically Ill Patients With Sepsis. A Cohort Study,” American Journal of Respiratory and Critical Care Medicine 195 (2017): 205–211. [DOI] [PubMed] [Google Scholar]
  • 259. Induruwa I., Hennebry E., Hennebry J., Thakur M., Warburton E. A., and Khadjooi K., “Sepsis‐Driven Atrial Fibrillation and Ischaemic Stroke. Is There Enough Evidence to Recommend Anticoagulation?,” European Journal of Internal Medicine 98 (2022): 32–36. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 260. Neves I. A., Magalhaes A., Lima da Silva G., et al., “Anticoagulation Therapy in Patients With Post‐Operative Atrial Fibrillation: Systematic Review With Meta‐Analysis,” Vascular Pharmacology 142 (2022): 106929. [DOI] [PubMed] [Google Scholar]
  • 261. Huang M., Yang S., Ge G., Zhi H., and Wang L., “Effects of Thyroid Dysfunction and the Thyroid‐Stimulating Hormone Levels on the Risk of Atrial Fibrillation: A Systematic Review and Dose‐Response Meta‐Analysis From Cohort Studies,” Endocrine Practice 28 (2022): 822–831. [DOI] [PubMed] [Google Scholar]
  • 262. Zhang J., Bisson A., Fauchier G., et al., “Yearly Incidence of Stroke and Bleeding in Atrial Fibrillation With Concomitant Hyperthyroidism: A National Discharge Database Study,” Journal of Clinical Medicine 11, no. 5 (2022): 1342, 10.3390/jcm11051342. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 263. Krittayaphong R., Pumprueg S., Thongsri T., et al., “Impact of anemia on Clinical Outcomes of Patients With Atrial Fibrillation: The COOL‐AF Registry,” Clinical Cardiology 44 (2021): 415–423. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 264. Tu S. J., Hanna‐Rivero N., Elliott A. D., et al., “Associations of anemia With Stroke, Bleeding, and Mortality in Atrial Fibrillation: A Systematic Review and Meta‐Analysis,” Journal of Cardiovascular Electrophysiology 32 (2021): 686–694. [DOI] [PubMed] [Google Scholar]
  • 265. Westenbrink B. D., Alings M., Granger C. B., et al., “Anemia Is Associated With Bleeding and Mortality, but Not Stroke, in Patients With Atrial Fibrillation: Insights From the Apixaban for Reduction in Stroke and Other Thromboembolic Events in Atrial Fibrillation (ARISTOTLE) Trial,” American Heart Journal 185 (2017): 140–149. [DOI] [PubMed] [Google Scholar]
  • 266. Westenbrink B. D., Alings M., Connolly S. J., et al., “Anemia Predicts Thromboembolic Events, Bleeding Complications and Mortality in Patients With Atrial Fibrillation: Insights From the RE‐LY Trial,” Journal of Thrombosis and Haemostasis: JTH 13 (2015): 699–707. [DOI] [PubMed] [Google Scholar]
  • 267. Yeh Y. H., Chan Y. H., Chen S. W., et al., “Oral Anticoagulant Use for Patients With Atrial Fibrillation With Concomitant Anemia and/or Thrombocytopenia,” American Journal of Medicine 135 (2022): e248–e256. [DOI] [PubMed] [Google Scholar]
  • 268. Al‐Hussainy N., Kragholm K. H., Lundbye‐Christensen S., et al., “Gastrointestinal Bleeding With Direct Oral Anticoagulants in Patients With Atrial Fibrillation and Anaemia,” Thrombosis Research 232 (2023): 62–69. [DOI] [PubMed] [Google Scholar]
  • 269. Iyengar V., Patell R., Ren S., et al., “Influence of Thrombocytopenia on Bleeding and Vascular Events in Atrial Fibrillation,” Blood Advances 7 (2023): 7516–7524. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 270. Sabbag A., Yao X., Siontis K. C., and Noseworthy P. A., “Anticoagulation for Stroke Prevention in Older Adults With Atrial Fibrillation and Comorbidity: Current Evidence and Treatment Challenges,” Korean Circulation Journal 48 (2018): 873–889. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 271. Park J., Cha M. J., Choi Y. J., et al., “Prognostic Efficacy of Platelet Count in Patients With Nonvalvular Atrial Fibrillation,” Heart Rhythm 16 (2019): 197–203. [DOI] [PubMed] [Google Scholar]
  • 272. Tarniceriu C. C., Hurjui L. L., Florea I. D., et al., “Immune Thrombocytopenic Purpura as a Hemorrhagic Versus Thrombotic Disease: An Updated Insight Into Pathophysiological Mechanisms,” Medicina (Kaunas, Lithuania) 58, no. 2 (2022): 211, 10.3390/medicina58020211. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 273. Patell R. and Zwicker J. I., “Evidence‐Based Minireview: Full Dose, Modified Dose, or no Anticoagulation for Patients With cancer and Acute VTE and Thrombocytopenia,” Hematology. American Society of Hematology. Education Program 2022 (2022): 312–315. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 274. Wang C. L., Wu V. C., Lee C. H., et al., “Effectiveness and Safety of Non‐Vitamin‐K Antagonist Oral Anticoagulants Versus Warfarin in Atrial Fibrillation Patients With Thrombocytopenia,” Journal of Thrombosis and Thrombolysis 47 (2019): 512–519. [DOI] [PubMed] [Google Scholar]
  • 275. Falanga A., Leader A., Ambaglio C., et al., “EHA Guidelines on Management of Antithrombotic Treatments in Thrombocytopenic Patients With Cancer,” Hema 6 (2022): e750. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 276. Sharma R., Levine G. N., Spinler S. A., et al., “Management of Patients at Risk of Ischemic Stroke With Left Ventricular Systolic Dysfunction in the Absence of Intracardiac Thrombus: A Scientific Statement From the American Heart Association,” Stroke 57 (2026): e437–e454. [DOI] [PubMed] [Google Scholar]
  • 277. Levine G. N., McEvoy J. W., Fang J. C., et al., “Management of Patients at Risk for and With Left Ventricular Thrombus: A Scientific Statement From the American Heart Association,” Circulation 146 (2022): e205–e223. [DOI] [PubMed] [Google Scholar]
  • 278. Lurie A., Wang J., Hinnegan K. J., et al., “Prevalence of Left Atrial Thrombus in Anticoagulated Patients With Atrial Fibrillation,” Journal of the American College of Cardiology 77 (2021): 2875–2886. [DOI] [PubMed] [Google Scholar]
  • 279. Noubiap J. J., Agbaedeng T. A., Ndoadoumgue A. L., Nyaga U. F., and Kengne A. P., “Atrial thrombus Detection on Transoesophageal Echocardiography in Patients With Atrial Fibrillation Undergoing Cardioversion or Catheter Ablation: A Pooled Analysis of Rates and Predictors,” Journal of Cardiovascular Electrophysiology 32 (2021): 2179–2188. [DOI] [PubMed] [Google Scholar]
  • 280. Bertaglia E., Anselmino M., Zorzi A., et al., “NOACs and Atrial Fibrillation: Incidence and Predictors of Left Atrial thrombus in the Real World,” International Journal of Cardiology 249 (2017): 179–183. [DOI] [PubMed] [Google Scholar]
  • 281. Angelini F., Bocchino P. P., Peyracchia M., et al., “Prevalence and Predictors of Left Atrial Thrombosis in Atrial Fibrillation Patients Treated With Non‐Vitamin K Antagonist Oral Anticoagulants,” Acta Cardiologica 78 (2023): 290–297. [DOI] [PubMed] [Google Scholar]
  • 282. Farkowski M. M., Jubele K., Marin F., et al., “Diagnosis and Management of Left Atrial Appendage thrombus in Patients With Atrial Fibrillation Undergoing Cardioversion or Percutaneous Left Atrial Procedures: Results of the European Heart Rhythm Association Survey,” Europace 22 (2020): 162–169. [DOI] [PubMed] [Google Scholar]
  • 283. Kolakowski K., Farkowski M. M., Pytkowski M., et al., “The Comparative Effectiveness and Safety of Different Anticoagulation Strategies for Treatment of Left Atrial Appendage Thrombus in the Setting of Chronic Anticoagulation for Atrial Fibrillation or Flutter,” Cardiovascular Drugs and Therapy 37 (2023): 159–168. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 284. Dong S. J., Luo C. Y., Xiao C. L., et al., “Efficacy and Safety Profile of Novel Oral Anticoagulants in the Treatment of Left Atrial Thrombosis: A Systematic Review and Meta‐Analysis,” Current Therapeutic Research, Clinical and Experimental 96 (2022): 100670. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 285. Nelles D., Lambers M., Schafigh M., et al., “Clinical Outcomes and thrombus Resolution in Patients With Solid Left Atrial Appendage Thrombi: Results of a Single‐Center Real‐World Registry,” Clinical Research in Cardiology: Official Journal of the German Cardiac Society 110 (2021): 72–83. [DOI] [PubMed] [Google Scholar]
  • 286. Lip G. Y., Hammerstingl C., Marin F., et al., “Left Atrial thrombus Resolution in Atrial Fibrillation or Flutter: Results of a Prospective Study With Rivaroxaban (X‐TRA) and a Retrospective Observational Registry Providing Baseline Data (CLOT‐AF),” American Heart Journal 178 (2016): 126–134. [DOI] [PubMed] [Google Scholar]
  • 287. Mo G. L., Wen J., Ye Y. Y., et al., “Efficacy and Safety of New Oral Anticoagulants Versus Warfarin in the Resolution of Atrial Fibrillation With Left Atrial/Left Atrial Appendage Thrombus: A Systematic Review and Meta‐Analysis,” Reviews in Cardiovascular Medicine 26 (2025): 26055. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 288. Sunaga A., Nakatani D., Okada K., et al., “Comparison Between DOACs and Warfarin for Left Atrial thrombus in Atrial Fibrillation Patients,” International Journal of Cardiology Heart & Vasculature 59 (2025): 101745. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 289. Watanabe T., Shinoda Y., Ikeoka K., et al., “Dabigatran Therapy Resulting in the Resolution of Rivaroxaban‐Resistant Left Atrial Appendage Thrombi in Patients With Atrial Fibrillation,” Internal Medicine (Tokyo, Japan) 56 (2017): 1977–1980. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 290. Piotrowski R., Zaborska B., Pilichowska‐Paszkiet E., Sikora‐Frac M., Baran J., and Kulakowski P., “RIVAroxaban TWICE Daily for Lysis of thrombus in the Left Atrial Appendage in Patients With Non‐Valvular Atrial Fibrillation: the RIVA‐TWICE Study,” Archives of Medical Science 16 (2020): 289–296. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 291. Harada M., Koshikawa M., Motoike Y., et al., “Left Atrial Appendage Thrombus Prior to Atrial Fibrillation Ablation in the Era of Direct Oral Anticoagulants,” Circulation Journal 82 (2018): 2715–2721. [DOI] [PubMed] [Google Scholar]
  • 292. Hwang J., Han S., Park H. S., et al., “Resolution of Thrombi in Left Atrial Appendage With Edoxaban: Results of the ‘REFLEX’ Study,” JACC Asia 5 (2025): 695–698. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 293. Sharma S. P., Cheng J., Turagam M. K., et al., “Feasibility of Left Atrial Appendage Occlusion in Left Atrial Appendage Thrombus: A Systematic Review,” JACC: Clinical Electrophysiology 6 (2020): 414–424. [DOI] [PubMed] [Google Scholar]
  • 294. Tzeis S., Gerstenfeld E. P., Kalman J., et al., “2024 European Heart Rhythm Association/Heart Rhythm Society/Asia Pacific Heart Rhythm Society/Latin American Heart Rhythm Society Expert Consensus Statement on Catheter and Surgical Ablation of Atrial Fibrillation,” Journal of Arrhythmia 40 (2024): 1217–1354. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 295. Romero J., Cerrud‐Rodriguez R. C., Diaz J. C., et al., “Oral Anticoagulation After Catheter Ablation of Atrial Fibrillation and the Associated Risk of Thromboembolic Events and Intracranial Hemorrhage: A Systematic Review and Meta‐Analysis,” Journal of Cardiovascular Electrophysiology 30 (2019): 1250–1257. [DOI] [PubMed] [Google Scholar]
  • 296. Liu X. H., Xu Q., Luo T., Zhang L., and Liu H. J., “Discontinuation of Oral Anticoagulation Therapy After Successful Atrial Fibrillation Ablation: A Systematic Review and Meta‐Analysis of Prospective Studies,” PLoS One 16 (2021): e0253709. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 297. Proietti R., AlTurki A., Di Biase L., et al., “Anticoagulation After Catheter Ablation of Atrial Fibrillation: An Unnecessary Evil? A Systematic Review and Meta‐Analysis,” Journal of Cardiovascular Electrophysiology 30 (2019): 468–478. [DOI] [PubMed] [Google Scholar]
  • 298. Maduray K., Moneruzzaman M., Changwe G. J., and Zhong J., “Benefits and Risks Associated With Long‐Term Oral Anticoagulation After Successful Atrial Fibrillation Catheter Ablation: Systematic Review and Meta‐Analysis,” Clinical and Applied Thrombosis/Hemostasis 28 (2022): 10760296221118480. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 299. Kanaoka K., Nishida T., Iwanaga Y., et al., “Oral Anticoagulation After Atrial Fibrillation Catheter Ablation: Benefits and Risks,” European Heart Journal 45 (2024): 522–534. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 300. Noseworthy P. A., Yao X., Deshmukh A. J., et al., “Patterns of Anticoagulation Use and Cardioembolic Risk After Catheter Ablation for Atrial Fibrillation,” Journal of the American Heart Association 4, no. 11 (2015): e002597, 10.1161/jaha.115.002597. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 301. Verma A., Birnie D. H., Jiang C., et al., “Antithrombotic Therapy After Successful Catheter Ablation for Atrial Fibrillation,” New England Journal of Medicine 394 (2026): 323–332. [DOI] [PubMed] [Google Scholar]
  • 302. Kim D., Shim J., Choi E. K., et al., “Long‐Term Anticoagulation Discontinuation After Catheter Ablation for Atrial Fibrillation: The ALONE‐AF Randomized Clinical Trial,” JAMA 334 (2025): 1246–1254. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 303. Barbosa L. M., Oliveira V. M. R., Rivera A., et al., “Can Oral Anticoagulants Be Safely Discontinued After Atrial Fibrillation Ablation? A Systematic Review and Meta‐Analysis of Reconstructed Time‐To‐Event Data,” Heart Rhythm 23 (2026): e1329–e1346. [DOI] [PubMed] [Google Scholar]
  • 304. Hindricks G., Piorkowski C., Tanner H., et al., “Perception of Atrial Fibrillation Before and After Radiofrequency Catheter Ablation: Relevance of Asymptomatic Arrhythmia Recurrence,” Circulation 112 (2005): 307–313. [DOI] [PubMed] [Google Scholar]
  • 305. Cheng W. H., Chan Y. H., Kuo L., et al., “Antithrombotic Management After Successful Catheter Ablation for Atrial Fibrillation: Meta‐Analysis of the ALONE‐AF and OCEAN Trials,” TH Open 10 (2026): a29168912. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 306. Gonzalez‐Pacheco H., Marquez M. F., Arias‐Mendoza A., et al., “Clinical Features and In‐Hospital Mortality Associated With Different Types of Atrial Fibrillation in Patients With Acute Coronary Syndrome With and Without ST Elevation,” Journal of Cardiology 66 (2015): 148–154. [DOI] [PubMed] [Google Scholar]
  • 307. Krijthe B. P., Leening M. J., Heeringa J., et al., “Unrecognized Myocardial Infarction and Risk of Atrial Fibrillation: the Rotterdam Study,” International Journal of Cardiology 168 (2013): 1453–1457. [DOI] [PubMed] [Google Scholar]
  • 308. Coscia T., Nestelberger T., Boeddinghaus J., et al., “Characteristics and Outcomes of Type 2 Myocardial Infarction,” JAMA Cardiology 7 (2022): 427–434. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 309. Kralev S., Schneider K., Lang S., Suselbeck T., and Borggrefe M., “Incidence and Severity of Coronary Artery Disease in Patients With Atrial Fibrillation Undergoing First‐Time Coronary Angiography,” PLoS One 6 (2011): e24964. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 310. Guimaraes P. O., Zakroysky P., Goyal A., Lopes R. D., Kaltenbach L. A., and Wang T. Y., “Usefulness of Antithrombotic Therapy in Patients With Atrial Fibrillation and Acute Myocardial Infarction,” American Journal of Cardiology 123 (2019): 12–18. [DOI] [PubMed] [Google Scholar]
  • 311. Erez A., Goldenberg I., Sabbag A., et al., “Temporal Trends and Outcomes Associated With Atrial Fibrillation Observed During Acute Coronary Syndrome: Real‐World Data From the Acute Coronary Syndrome Israeli Survey (ACSIS), 2000–2013,” Clinical Cardiology 40 (2017): 275–280. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 312. Gibson C. M., Mehran R., Bode C., et al., “Prevention of Bleeding in Patients With Atrial Fibrillation Undergoing PCI,” New England Journal of Medicine 375 (2016): 2423–2434. [DOI] [PubMed] [Google Scholar]
  • 313. Cannon C. P., Bhatt D. L., Oldgren J., et al., “Dual Antithrombotic Therapy With Dabigatran After PCI in Atrial Fibrillation,” New England Journal of Medicine 377 (2017): 1513–1524. [DOI] [PubMed] [Google Scholar]
  • 314. Lopes R. D., Heizer G., Aronson R., et al., “Antithrombotic Therapy After Acute Coronary Syndrome or PCI in Atrial Fibrillation,” New England Journal of Medicine 380 (2019): 1509–1524. [DOI] [PubMed] [Google Scholar]
  • 315. Vranckx P., Valgimigli M., Eckardt L., et al., “Edoxaban‐Based Versus Vitamin K Antagonist‐Based Antithrombotic Regimen After Successful Coronary Stenting in Patients With Atrial Fibrillation (ENTRUST‐AF PCI): A Randomised, Open‐Label, Phase 3b Trial,” Lancet 394 (2019): 1335–1343. [DOI] [PubMed] [Google Scholar]
  • 316. Potpara T. S., Mujovic N., Proietti M., et al., “Revisiting the Effects of Omitting Aspirin in Combined Antithrombotic Therapies for Atrial Fibrillation and Acute Coronary Syndromes or Percutaneous Coronary Interventions: Meta‐Analysis of Pooled Data From the PIONEER AF‐PCI, RE‐DUAL PCI, and AUGUSTUS Trials,” Europace 22 (2020): 33–46. [DOI] [PubMed] [Google Scholar]
  • 317. Dewilde W. J., Oirbans T., Verheugt F. W., et al., “Use of Clopidogrel With or Without Aspirin in Patients Taking Oral Anticoagulant Therapy and Undergoing Percutaneous Coronary Intervention: An Open‐Label, Randomised, Controlled Trial,” Lancet 381 (2013): 1107–1115. [DOI] [PubMed] [Google Scholar]
  • 318. Lopes R. D., Hong H., Harskamp R. E., et al., “Safety and Efficacy of Antithrombotic Strategies in Patients With Atrial Fibrillation Undergoing Percutaneous Coronary Intervention: A Network Meta‐Analysis of Randomized Controlled Trials,” JAMA Cardiology 4 (2019): 747–755. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 319. Park D. Y., Wang P., An S., et al., “Shortening the Duration of Dual Antiplatelet Therapy After Percutaneous Coronary Intervention for Acute Coronary Syndrome: A Systematic Review and Meta‐Analysis,” American Heart Journal 251 (2022): 101–114. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 320. Gargiulo G., Goette A., Tijssen J., et al., “Safety and Efficacy Outcomes of Double vs. Triple Antithrombotic Therapy in Patients With Atrial Fibrillation Following Percutaneous Coronary Intervention: A Systematic Review and Meta‐Analysis of Non‐Vitamin K Antagonist Oral Anticoagulant‐Based Randomized Clinical Trials,” European Heart Journal 40 (2019): 3757–3767. [DOI] [PubMed] [Google Scholar]
  • 321. Haller P. M., Sulzgruber P., Kaufmann C., et al., “Bleeding and Ischaemic Outcomes in Patients Treated With Dual or Triple Antithrombotic Therapy: Systematic Review and Meta‐Analysis,” European Heart Journal—Cardiovascular Pharmacotherapy 5 (2019): 226–236. [DOI] [PubMed] [Google Scholar]
  • 322. Marx N., Federici M., Schütt K., et al., “2023 ESC Guidelines for the Management of Cardiovascular Disease in Patients With Diabetes,” European Heart Journal 44 (2023): 4043–4140. [DOI] [PubMed] [Google Scholar]
  • 323. Fauchier L., Guglieri M., Bisson A., Lenormand T., and Lip G. Y. H., “Antiplatelet Therapy in Patients With Stable Coronary Artery Disease Who Require Long‐Term Oral Anticoagulation,” European Journal of Internal Medicine 148 (2026): 106684. [DOI] [PubMed] [Google Scholar]
  • 324. Galli M., Vinciguerra M., Laudani C., et al., “Oral Anticoagulation With or Without Antiplatelet Therapy in Chronic Coronary Syndrome: A Meta‐Analysis of Randomized Trials,” JACC. Cardiovascular Interventions 19 (2026): 1294–1306. [DOI] [PubMed] [Google Scholar]
  • 325. Yasuda S., Kaikita K., Akao M., et al., “Antithrombotic Therapy for Atrial Fibrillation With Stable Coronary Disease,” New England Journal of Medicine 381 (2019): 1103–1113. [DOI] [PubMed] [Google Scholar]
  • 326. Cho M. S., Kang D. Y., Ahn J. M., et al., “Edoxaban Antithrombotic Therapy for Atrial Fibrillation and Stable Coronary Artery Disease,” New England Journal of Medicine 391 (2024): 2075–2086. [DOI] [PubMed] [Google Scholar]
  • 327. Lee S. J., Yu H. T., Lee Y. J., et al., “Therapy for Atrial Fibrillation in Patients With Drug‐Eluting Stents,” New England Journal of Medicine 394 (2026): 658–668. [DOI] [PubMed] [Google Scholar]
  • 328. Alexander J. H., Wojdyla D., Vora A. N., et al., “Risk/Benefit Tradeoff of Antithrombotic Therapy in Patients With Atrial Fibrillation Early and Late After an Acute Coronary Syndrome or Percutaneous Coronary Intervention: Insights From AUGUSTUS,” Circulation 141 (2020): 1618–1627. [DOI] [PubMed] [Google Scholar]
  • 329. Fiedler K. A., Maeng M., Mehilli J., et al., “Duration of Triple Therapy in Patients Requiring Oral Anticoagulation After Drug‐Eluting Stent Implantation: The ISAR‐TRIPLE Trial,” Journal of the American College of Cardiology 65 (2015): 1619–1629. [DOI] [PubMed] [Google Scholar]
  • 330. Douketis J. D., Spyropoulos A. C., Kaatz S., et al., “Perioperative Bridging Anticoagulation in Patients With Atrial Fibrillation,” New England Journal of Medicine 373 (2015): 823–833. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 331. Kovacs M. J., Wells P. S., Anderson D. R., et al., “Postoperative Low Molecular Weight Heparin Bridging Treatment for Patients at High Risk of Arterial Thromboembolism (PERIOP2): Double Blind Randomised Controlled Trial,” BMJ 373 (2021): n1205. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 332. Douketis J. D., Spyropoulos A. C., Duncan J., et al., “Perioperative Management of Patients With Atrial Fibrillation Receiving a Direct Oral Anticoagulant,” JAMA Internal Medicine 179 (2019): 1469–1478. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 333. Godier A., Martin A. C., Leblanc I., et al., “Peri‐Procedural Management of Dabigatran and Rivaroxaban: Duration of Anticoagulant Discontinuation and Drug Concentrations,” Thrombosis Research 136 (2015): 763–768. [DOI] [PubMed] [Google Scholar]
  • 334. Nazha B., Pandya B., Cohen J., et al., “Periprocedural Outcomes of Direct Oral Anticoagulants Versus Warfarin in Nonvalvular Atrial Fibrillation,” Circulation 138 (2018): 1402–1411. [DOI] [PubMed] [Google Scholar]
  • 335. Lee S. R., Lee K. Y., Park J. S., et al., “Perioperative Factor Xa Inhibitor Discontinuation for Patients Undergoing Procedures With Minimal or Low Bleeding Risk,” JAMA Network Open 8 (2025): e2458742. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 336. Siegal D., Yudin J., Kaatz S., Douketis J. D., Lim W., and Spyropoulos A. C., “Periprocedural Heparin Bridging in Patients Receiving Vitamin K Antagonists: Systematic Review and Meta‐Analysis of Bleeding and Thromboembolic Rates,” Circulation 126 (2012): 1630–1639. [DOI] [PubMed] [Google Scholar]
  • 337. Steinberg B. A., Peterson E. D., Kim S., et al., “Use and Outcomes Associated With Bridging During Anticoagulation Interruptions in Patients With Atrial Fibrillation: Findings From the Outcomes Registry for Better Informed Treatment of Atrial Fibrillation (ORBIT‐AF),” Circulation 131 (2015): 488–494. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 338. Chiang C. E., Chao T. F., Choi E. K., et al., “Stroke Prevention in Atrial Fibrillation: A Scientific Statement of JACC: Asia (Part 2),” JACC Asia 2 (2022): 519–537. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 339. Tomaselli G. F., Mahaffey K. W., Cuker A., et al., “2020 ACC Expert Consensus Decision Pathway on Management of Bleeding in Patients on Oral Anticoagulants: A Report of the American College of Cardiology Solution Set Oversight Committee,” Journal of the American College of Cardiology 76 (2020): 594–622. [DOI] [PubMed] [Google Scholar]
  • 340. Schulman S., Angeras U., Bergqvist D., Eriksson B., Lassen M. R., and Fisher W., “Subcommittee on Control of Anticoagulation of the S, Standardization Committee of the International Society on T, Haemostasis. Definition of Major Bleeding in Clinical Investigations of Antihemostatic Medicinal Products in Surgical Patients,” Journal of Thrombosis and Haemostasis 8 (2010): 202–204. [DOI] [PubMed] [Google Scholar]
  • 341. Kaatz S., Ahmad D., Spyropoulos A. C., Schulman S., and Subcommittee on Control of A , “Definition of Clinically Relevant Non‐Major Bleeding in Studies of Anticoagulants in Atrial Fibrillation and Venous Thromboembolic Disease in Non‐Surgical Patients: Communication From the SSC of the ISTH,” Journal of Thrombosis and Haemostasis 13 (2015): 2119–2126. [DOI] [PubMed] [Google Scholar]
  • 342. Cuker A., “Laboratory Measurement of the Non‐Vitamin K Antagonist Oral Anticoagulants: Selecting the Optimal Assay Based on Drug, Assay Availability, and Clinical Indication,” Journal of Thrombosis and Thrombolysis 41 (2016): 241–247. [DOI] [PubMed] [Google Scholar]
  • 343. Cuker A., Siegal D. M., Crowther M. A., and Garcia D. A., “Laboratory Measurement of the Anticoagulant Activity of the Non‐Vitamin K Oral Anticoagulants,” Journal of the American College of Cardiology 64 (2014): 1128–1139. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 344. Lewis S. R., Pritchard M. W., Evans D. J., et al., “Colloids Versus Crystalloids for Fluid Resuscitation in Critically Ill People,” Cochrane Database of Systematic Reviews 8 (2018): CD000567. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 345. Lee M. T., Park K. Y., Kim M. S., You S. H., Kang Y. J., and Jung S. Y., “Concomitant Use of NSAIDs or SSRIs With NOACs Requires Monitoring for Bleeding,” Yonsei Medical Journal 61 (2020): 741–749. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 346. Kubitza D., Becka M., Mueck W., et al., “Effects of Renal Impairment on the Pharmacokinetics, Pharmacodynamics and Safety of Rivaroxaban, an Oral, Direct Factor Xa Inhibitor,” British Journal of Clinical Pharmacology 70 (2010): 703–712. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 347. Qureshi W., Mittal C., Patsias I., et al., “Restarting Anticoagulation and Outcomes After Major Gastrointestinal Bleeding in Atrial Fibrillation,” American Journal of Cardiology 113 (2014): 662–668. [DOI] [PubMed] [Google Scholar]
  • 348. Murthy S. B., Gupta A., Merkler A. E., et al., “Restarting Anticoagulant Therapy After Intracranial Hemorrhage: A Systematic Review and Meta‐Analysis,” Stroke 48 (2017): 1594–1600. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 349. Nielsen P. B., Larsen T. B., Skjoth F., Gorst‐Rasmussen A., Rasmussen L. H., and Lip G. Y., “Restarting Anticoagulant Treatment After Intracranial Hemorrhage in Patients With Atrial Fibrillation and the Impact on Recurrent Stroke, Mortality, and Bleeding: A Nationwide Cohort Study,” Circulation 132 (2015): 517–525. [DOI] [PubMed] [Google Scholar]
  • 350. Nielsen P. B., Larsen T. B., Skjoth F., and Lip G. Y., “Outcomes Associated With Resuming Warfarin Treatment After Hemorrhagic Stroke or Traumatic Intracranial Hemorrhage in Patients With Atrial Fibrillation,” JAMA Internal Medicine 177 (2017): 563–570. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 351. Tapaskar N., Pang A., Werner D. A., and Sengupta N., “Resuming Anticoagulation Following Hospitalization for Gastrointestinal Bleeding Is Associated With Reduced Thromboembolic Events and Improved Mortality: Results From a Systematic Review and Meta‐Analysis,” Digestive Diseases and Sciences 66 (2021): 554–566. [DOI] [PubMed] [Google Scholar]
  • 352. Proietti M., Romiti G. F., Romanazzi I., et al., “Restarting Oral Anticoagulant Therapy After Major Bleeding in Atrial Fibrillation: A Systematic Review and Meta‐Analysis,” International Journal of Cardiology 261 (2018): 84–91. [DOI] [PubMed] [Google Scholar]
  • 353. Chai‐Adisaksopha C., Hillis C., Siegal D. M., et al., “Prothrombin Complex Concentrates Versus Fresh Frozen Plasma for Warfarin Reversal. A Systematic Review and Meta‐Analysis,” Thrombosis and Haemostasis 116 (2016): 879–890. [DOI] [PubMed] [Google Scholar]
  • 354. Sarode R., T. J. Milling, Jr. , Refaai M. A., et al., “Efficacy and Safety of a 4‐Factor Prothrombin Complex Concentrate in Patients on Vitamin K Antagonists Presenting With Major Bleeding: A Randomized, Plasma‐Controlled, Phase IIIb Study,” Circulation 128 (2013): 1234–1243. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 355. Goldstein J. N., Refaai M. A., T. J. Milling, Jr. , et al., “Four‐Factor Prothrombin Complex Concentrate Versus Plasma for Rapid Vitamin K Antagonist Reversal in Patients Needing Urgent Surgical or Invasive Interventions: A Phase 3b, Open‐Label, Non‐Inferiority, Randomised Trial,” Lancet 385 (2015): 2077–2087. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 356. C. V. Pollack, Jr. , Reilly P. A., van Ryn J., et al., “Idarucizumab for Dabigatran Reversal—Full Cohort Analysis,” New England Journal of Medicine 377 (2017): 431–441. [DOI] [PubMed] [Google Scholar]
  • 357. C. V. Pollack, Jr. , Reilly P. A., Eikelboom J., et al., “Idarucizumab for Dabigatran Reversal,” New England Journal of Medicine 373 (2015): 511–520. [DOI] [PubMed] [Google Scholar]
  • 358. Connolly S. J., Crowther M., Eikelboom J. W., et al., “Full Study Report of Andexanet Alfa for Bleeding Associated With Factor Xa Inhibitors,” New England Journal of Medicine 380 (2019): 1326–1335. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 359. Connolly S. J., T. J. Milling, Jr. , Eikelboom J. W., et al., “Andexanet Alfa for Acute Major Bleeding Associated With Factor Xa Inhibitors,” New England Journal of Medicine 375 (2016): 1131–1141. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 360. Majeed A., Agren A., Holmstrom M., et al., “Management of Rivaroxaban‐ Or Apixaban‐Associated Major Bleeding With Prothrombin Complex Concentrates: A Cohort Study,” Blood 130 (2017): 1706–1712. [DOI] [PubMed] [Google Scholar]
  • 361. Piran S., Khatib R., Schulman S., et al., “Management of Direct Factor Xa Inhibitor‐Related Major Bleeding With Prothrombin Complex Concentrate: A Meta‐Analysis,” Blood Advances 3 (2019): 158–167. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 362. Connolly S. J., Sharma M., Cohen A. T., et al., “Andexanet for Factor Xa Inhibitor‐Associated Acute Intracerebral Hemorrhage,” New England Journal of Medicine 390 (2024): 1745–1755. [DOI] [PubMed] [Google Scholar]
  • 363. Milioglou I., Farmakis I., Neudeker M., et al., “Prothrombin Complex Concentrate in Major Bleeding Associated With DOACs; an Updated Systematic Review and Meta‐Analysis,” Journal of Thrombosis and Thrombolysis 52 (2021): 1137–1150. [DOI] [PubMed] [Google Scholar]
  • 364. Wang K. L., Lip G. Y., Lin S. J., and Chiang C. E., “Non‐Vitamin K Antagonist Oral Anticoagulants for Stroke Prevention in Asian Patients With Nonvalvular Atrial Fibrillation: Meta‐Analysis,” Stroke 46 (2015): 2555–2561. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 365. Chao T. F., Liu C. J., Liao J. N., et al., “Use of Oral Anticoagulants for Stroke Prevention in Patients With Atrial Fibrillation Who Have a History of Intracranial Hemorrhage,” Circulation 133 (2016): 1540–1547. [DOI] [PubMed] [Google Scholar]
  • 366. Ray W. A., Chung C. P., Murray K. T., et al., “Association of Oral Anticoagulants and Proton Pump Inhibitor Cotherapy With Hospitalization for Upper Gastrointestinal Tract Bleeding,” JAMA 320 (2018): 2221–2230. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 367. Flack K. F., Desai J., Kolb J. M., et al., “Major Gastrointestinal Bleeding Often Is Caused by Occult Malignancy in Patients Receiving Warfarin or Dabigatran to Prevent Stroke and Systemic Embolism From Atrial Fibrillation,” Clinical Gastroenterology and Hepatology:The Official Clinical Practice Journal of the American Gastroenterological Association 15 (2017): 682–690. [DOI] [PubMed] [Google Scholar]
  • 368. Chang T. Y., Chan Y. H., Chiang C. E., et al., “Risks and Outcomes of Gastrointestinal Malignancies in Anticoagulated Atrial Fibrillation Patients Experiencing Gastrointestinal Bleeding: A Nationwide Cohort Study,” Heart Rhythm 17 (2020): 1745–1751. [DOI] [PubMed] [Google Scholar]
  • 369. Kuo L., Chan Y. H., Liao J. N., et al., “Risk of Incident Genitourinary cancer Following Hematuria in Patients With Atrial Fibrillation Receiving Oral Anticoagulants,” Heart Rhythm 22 (2025): 1915–1921. [DOI] [PubMed] [Google Scholar]
  • 370. Grewal K., Wang X., Austin P. C., et al., “Bleeding and New Malignancy Diagnoses After Anticoagulation for Atrial Fibrillation: A Population‐Based Cohort Study,” Circulation 151 (2025): 773–782. [DOI] [PubMed] [Google Scholar]
  • 371. Best J. G., Cardus B., Klijn C. J. M., et al., “Antithrombotic Dilemmas in Stroke Medicine: New Data, Unsolved Challenges,” Journal of Neurology, Neurosurgery, and Psychiatry (2022): jnnp‐2020‐325249, 10.1136/jnnp-2020-325249. [DOI] [PubMed] [Google Scholar]
  • 372. Lun R., Pensato U., Shaw J. R., et al., “Investigation and Management of Breakthrough Ischemic Stroke in Anticoagulated Patients With Atrial Fibrillation,” BMJ 394 (2026): e084905. [DOI] [PubMed] [Google Scholar]
  • 373. Hsieh M. T., Liu C. H., Lin S. H., et al., “Recurrent Ischemic Stroke and Cardiovascular Outcomes in Patients With Atrial Fibrillation With Ischemic Stroke Despite Direct Oral Anticoagulants,” Stroke: A Journal of Cerebral Circulation 54 (2023): e145–e146. [DOI] [PubMed] [Google Scholar]
  • 374. Ip Y. M. B., Lau K. K., Ko H., et al., “Association of Alternative Anticoagulation Strategies and Outcomes in Patients With Ischemic Stroke While Taking a Direct Oral Anticoagulant,” Neurology 101 (2023): e358–e369. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 375. Liao J. N., Chan Y. H., Kuo L., et al., “The Association Between Antithrombotic Drug Regimen Changes and Clinical Outcomes After Stroke in Atrial Fibrillation,” Heart Rhythm: The Official Journal of the Heart Rhythm Society 22 (2025): 486–494. [DOI] [PubMed] [Google Scholar]
  • 376. Tsai C. T., Chan Y. H., Liao J. N., et al., “The Optimal Antithrombotic Strategy for Post‐Stroke Patients With Atrial Fibrillation and Extracranial Artery Stenosis‐a Nationwide Cohort Study,” BMC Medicine 22 (2024): 113. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 377. Piccini J. P., Caso V., Connolly S. J., et al., “Safety of the Oral Factor XIa Inhibitor Asundexian Compared With Apixaban in Patients With Atrial Fibrillation (PACIFIC‐AF): A Multicentre, Randomised, Double‐Blind, Double‐Dummy, Dose‐Finding Phase 2 Study,” Lancet 399 (2022): 1383–1390. [DOI] [PubMed] [Google Scholar]
  • 378. Ruff C. T., Patel S. M., Giugliano R. P., et al., “Abelacimab Versus Rivaroxaban in Patients With Atrial Fibrillation,” New England Journal of Medicine 392 (2025): 361–371. [DOI] [PubMed] [Google Scholar]
  • 379. Piccini J. P., Patel M. R., Steffel J., et al., “Investigators. Asundexian Versus Apixaban in Patients With Atrial Fibrillation,” New England Journal of Medicine 392 (2025): 23–32. [DOI] [PubMed] [Google Scholar]
  • 380. Sobral M. V. S., Queiroz I., Amador W. F. O., et al., “Efficacy and Safety of Oral Factor XI/XIa Inhibitors in Atrial Fibrillation: A Systematic Review and Meta‐Analysis of Randomized Controlled Trials,” Heart Rhythm 22 (2025): 1452–1454. [DOI] [PubMed] [Google Scholar]
  • 381. Fan Y., Chen X., Jiang Y., et al., “Use of Factor XI/XIa Inhibitors in Patients With Atrial Fibrillation: Current Progress and Future Prospects,” Ageing Research Reviews 112 (2025): 102895. [DOI] [PubMed] [Google Scholar]
  • 382. Capodanno D., Alexander J. H., Bahit M. C., et al., “Factor XI Inhibitors for the Prevention and Treatment of Venous and Arterial Thromboembolism,” Nature Reviews Cardiology 22 (2025): 896–912. [DOI] [PubMed] [Google Scholar]

Associated Data

This section collects any data citations, data availability statements, or supplementary materials included in this article.

Data Availability Statement

The data that support the findings of this study are available on request from the corresponding author. The data are not publicly available due to privacy or ethical restrictions.


Articles from Journal of Arrhythmia are provided here courtesy of Japanese Heart Rhythm Society

RESOURCES